Hodgkin's Disease - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

HODGKIN’S DISEASE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES

J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS

ii

ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2003 by ICON Group International, Inc. Copyright ©2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1

Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Hodgkin’s Disease: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83927-1 1. Hodgkin’s Disease-Popular works. I. Title.

iii

Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.

Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail: [email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.

iv

Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on Hodgkin’s disease. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.

v

About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.

vi

About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health

vii

Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON HODGKIN’S DISEASE ................................................................................ 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Hodgkin’s Disease......................................................................... 4 E-Journals: PubMed Central ....................................................................................................... 64 The National Library of Medicine: PubMed ................................................................................ 64 CHAPTER 2. NUTRITION AND HODGKIN’S DISEASE..................................................................... 115 Overview.................................................................................................................................... 115 Finding Nutrition Studies on Hodgkin’s Disease...................................................................... 115 Federal Resources on Nutrition ................................................................................................. 127 Additional Web Resources ......................................................................................................... 128 CHAPTER 3. ALTERNATIVE MEDICINE AND HODGKIN’S DISEASE .............................................. 129 Overview.................................................................................................................................... 129 National Center for Complementary and Alternative Medicine................................................ 129 Additional Web Resources ......................................................................................................... 166 General References ..................................................................................................................... 167 CHAPTER 4. DISSERTATIONS ON HODGKIN’S DISEASE ................................................................ 169 Overview.................................................................................................................................... 169 Dissertations on Hodgkin’s Disease........................................................................................... 169 Keeping Current ........................................................................................................................ 170 CHAPTER 5. CLINICAL TRIALS AND HODGKIN’S DISEASE ........................................................... 171 Overview.................................................................................................................................... 171 Recent Trials on Hodgkin’s Disease........................................................................................... 171 Keeping Current on Clinical Trials ........................................................................................... 190 CHAPTER 6. BOOKS ON HODGKIN’S DISEASE ............................................................................... 193 Overview.................................................................................................................................... 193 Book Summaries: Online Booksellers......................................................................................... 193 The National Library of Medicine Book Index ........................................................................... 195 Chapters on Hodgkin’s Disease.................................................................................................. 197 CHAPTER 7. MULTIMEDIA ON HODGKIN’S DISEASE .................................................................... 199 Overview.................................................................................................................................... 199 Bibliography: Multimedia on Hodgkin’s Disease ...................................................................... 199 CHAPTER 8. PERIODICALS AND NEWS ON HODGKIN’S DISEASE ................................................. 201 Overview.................................................................................................................................... 201 News Services and Press Releases.............................................................................................. 201 Academic Periodicals covering Hodgkin’s Disease .................................................................... 206 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 207 Overview.................................................................................................................................... 207 U.S. Pharmacopeia..................................................................................................................... 207 Commercial Databases ............................................................................................................... 208 Researching Orphan Drugs ....................................................................................................... 209 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 213 Overview.................................................................................................................................... 213 NIH Guidelines.......................................................................................................................... 213 NIH Databases........................................................................................................................... 215 Other Commercial Databases..................................................................................................... 217 APPENDIX B. PATIENT RESOURCES ............................................................................................... 219 Overview.................................................................................................................................... 219 Patient Guideline Sources.......................................................................................................... 219 Finding Associations.................................................................................................................. 226

viii Contents

APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 229 Overview.................................................................................................................................... 229 Preparation................................................................................................................................. 229 Finding a Local Medical Library................................................................................................ 229 Medical Libraries in the U.S. and Canada ................................................................................. 229 ONLINE GLOSSARIES................................................................................................................ 235 Online Dictionary Directories ................................................................................................... 239 HODGKIN’S DISEASE DICTIONARY .................................................................................... 241 INDEX .............................................................................................................................................. 305

1

FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with Hodgkin’s disease is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about Hodgkin’s disease, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to Hodgkin’s disease, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on Hodgkin’s disease. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to Hodgkin’s disease, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on Hodgkin’s disease. The Editors

1

From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.

3

CHAPTER 1. STUDIES ON HODGKIN’S DISEASE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on Hodgkin’s disease.

The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and Hodgkin’s disease, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “Hodgkin’s disease” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •

Gingival Overgrowth as the Initial Paraneoplastic Manifestation of Hodgkin's Lymphoma in a Child. A Case Report Source: Journal of Periodontology. 72(1): 107-112. January 2001. Contact: Available from American Academy of Periodontology. 737 North Michigan Avenue, Suite 800, Chicago, IL 60611-2690. (312) 573-3220. Fax (312) 573-3225. Summary: This article presents a case of gingival (gum) overgrowth, premature root resorption, and alveolar bone loss, which preceded the diagnosis of a stage IV B Hodgkin's lymphoma (HL) in a 9 year old boy. The child presented complaining of gingival pain which first appeared 3 months prior. Clinical examination revealed inflamed, hyperplastic (overgrown) gingiva, while x ray shoed premature root

4

Hodgkin’s Disease

resorption and alveolar bone loss. Medical work up was significant for cervical (neck) lymphadenopathy. Gingival biopsy, followed by lymph node resection, was performed twice. Histological examination of both gingival biopsies disclosed a mixed inflammatory infiltrate, while classical Hodgkin's lymphoma of the nodular sclerosis type was diagnosed from the second lymph node biopsy. Chemotherapy was instituted. Remission of the lymphoma was observed with concomitant regression of the gingival overgrowth. 8 figures. 23 references.

Federally Funded Research on Hodgkin’s Disease The U.S. Government supports a variety of research studies relating to Hodgkin’s disease. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to Hodgkin’s disease. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore Hodgkin’s disease. The following is typical of the type of information found when searching the CRISP database for Hodgkin’s disease: •

Project Title: TREATMENT

"BEYOND

CANCER":

FOSTERING

TRANSITIONS

POST-

Principal Investigator & Institution: Dwyer, Kathleen A.; None; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2005 Summary: (provided by applicant): The relative 5-year survival rate for all cancer sites has increased over the past 20 years. More patients are completing treatment and entering the early post-treatment phase of coping with their illness. The end of treatment phase may be emotionally and physically crippling. These issues are typically not recognized and addressed by health care providers, and therefore, there are longterm survivors who never resume a 'normal' life. Most existing interventions use a faceto-face format, thus limiting their use to individuals who have the ability to 'get to' the intervention site. The proposed two-stage pilot study seeks to modify and then evaluate the acceptability and feasibility of the modified intervention strategy designed to enhance the return to a productive existence and improve quality of life. The proposed study addresses the previously identified gaps and limitations by: studying men and women cancer patients using two tumors that are gender neutral; incorporating the patient's and caregiver's perspectives; controlling for potential gender differences by blocking on gender; delivering the intervention during the first 3 months posttreatment; and using a format that makes the intervention widely accessible [videotapes, 2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).

Studies

5

a manual, telephone conference calls]. In particular, this proposal addresses the following questions: (1) How does an existing cognitive behavioral intervention program need to be adapted for use during the first 3 months following treatment with patients completing treatment for colorectal cancer, Hodgkin's disease, or NonHodgkin's lymphoma and their primary caregivers?; (2) How acceptable is the modified cognitive behavioral intervention program to patients and caregivers during the first 3 months after completing treatment?; and (3) What effects does the intervention have on the perceived control, coping, perceived social support, and quality of life reported by the participants? How sizable are the effects? In the first stage, we will conduct a descriptive study to elicit feedback about the existing intervention. Participants will be given the existing intervention videotapes and workbook along with evaluation questions. After reviewing the materials, a focus group to elicit specific feedback will be conducted. For Stage Two, a randomized clinical trial will be conducted to evaluate the acceptability/feasibility of the modified intervention as well as to determine the effects on quality of life and other related outcomes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: A COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKIN'S DISEASE Principal Investigator & Institution: Giardina, Patricia J.; Weill Medical College of Cornell Univ New York, Ny 10021 Timing: Fiscal Year 2001 Summary: This study will attempt to determine the role of low dose involved field radiotherapy (RT) in pediatric patients with Hodgkin's disease who attain a complete response following initial chemotherapy. Patients will receive 4-6 courses COPP/ABV hybrid chemotherapy and be randomized to receive RT. Stage IV patinets receive additional intensive chemotherapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: AIDS LYMPHOMA USING ANTISENSE TO EBV GENES Principal Investigator & Institution: Lacy, Jill; Internal Medicine; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2001; Project Start 01-MAY-1995; Project End 30-NOV-2003 Summary: (Applicant's Abstract) The long-term goal of this application is the development of antisense-based, tumor-specific therapies for the EBV-associated lymphomas. EBV has been implicated in the etiology of a variety of lymphoid malignancies, including AIDS- related, post-transplantation, Burkitt's and Hodgkin's lymphomas, and transformation by the virus may be mediated in part by latent viral gene products that impact on cell growth and death. Two latent viral proteins, EBNA-1 and LMP-1 appear to play a key role in transformation. EBNA-1 is required for episomal viral DNA replication and regulates transcription of other latent viral genes. LMP-1 alters growth properties and confers resistance to apoptosis through induction of antiapoptotic cellular genes. Given the key functions of EBNA-1 and LMP-1, they represent ideal targets for modulation by antisense strategies as a potential novel anti-tumor strategy. The applicant has demonstrated the feasibility and promise of this approach in in vitro studies using EBNA-1 and LMP-1 targeted antisense oligomers in lymphoblastoid cell lines (LCLs). These studies show that selected antisense oligomers specifically suppress the targeted viral proteins, and, importantly, elicit biological effects. Suppression of EBNA-1 is associated with inhibition of proliferation, decreased

6

Hodgkin’s Disease

viral DNA content, down-regulation of EBNA-2 and LMP-1, and enhanced sensitivity to cytotoxic drugs. Antisense-mediated suppression of LMP-1 not only inhibits proliferation but also down-regulates anti-apoptotic genes, stimulates apoptosis, enhances chemosensitivity, and reverses resistance to cell cycle arrest by TGF-beta. These findings provide the basis for further studies of the biological and anti-tumor effects of antisense- mediated suppression of EBNA-1 and LMP-1. She will extend her in vitro studies using EBNA-1 and LMP-1 targeted antisense to tumor derived cell lines and will explore the susceptibility of EBNA-2 to antisense modulation. To address the therapeutic potential of antisense strategies, she will undertake a detailed investigation of the anti- tumor and chemosensitizing effects of EBNA-1 and LMP-1 targeted antisense using a SCID mouse model of EBV-associated lymphoma. These studies may shed further light on our understanding of the functions of latent viral proteins in the establishment and maintenance of EBV- related lymphomas, and furthermore, may provide the basis for a tumor- specific, non-toxic therapy for EBV-associated lymphomas. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS MEMBER Principal Investigator & Institution: Von Roenn, Jamie H.; Medicine; Northwestern University 633 Clark St Evanston, Il 60208 Timing: Fiscal Year 2001; Project Start 30-SEP-1995; Project End 31-JUL-2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: PROGRAM

AIDS-ONCOLOGY

CLINICAL

SCIENTIST

DEVELOPMENT

Principal Investigator & Institution: Levine, Alexandra M.; Medical Director; Medicine; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2001; Project Start 11-AUG-1998; Project End 31-JUL-2004 Summary: (Applicant's Description) As survival has increased in patients with HIV infection, it is apparent that greater numbers of individuals are living long enough to eventually develop malignant disease. Further, with maturation of the AIDS epidemic, it appears that the spectrum of HIV associated diseases has expanded, with malignant diseases becoming more prominent as the cause of death in infected individuals. Aside from the current AIDS-defining malignancies, including Kaposi's sarcoma, lymphoma, and cervical cancer, additional types of cancers are now being reported in HIV infected individuals, with significantly increased standardized incidence ratios (SIRs) of anal cancer, Hodgkin's disease, lung cancer, multiple myeloma and others. In terms of public health policy, it is apparent from these data that the appropriate health care of our nation will require specific training of oncologist in the area of HIV disease. At the present time, there is no formalized mechanism to provide such cross-training, nor is there a mechanism to pay for such training. The goals of this Training Grant will be to train such individuals, who will then be prepared to treat HIV infected patients with malignant disease; to conduct research in this area; and, in time, to teach others these same skills. The specific aims of the proposal are: (1) To provide comprehensive, multidisciplinary clinical training in HIV disease to individuals who have recently completed one or more years of formal fellowship training in Hematology'/Oncology; (2) To provide a didactic core curriculum, which will give a broad understanding of the advances in HIV disease, per se, as well as the opportunistic cancers, infections, and

Studies

7

other illnesses which ensue; (3) To provide a didactic core curriculum, as well as practical, day-to-day training in the area of clinical research methods, to allow development of future clinical researchers in the area of AIDS-related malignancy; (4) To provide didactic training in the area of basic scientific research methods, to allow development of future clinical researchers who will understand the principles of translational research in the area of AIDS-malignancy; and (5) To provide close mentoring support from both clinical and basic scientific mentors, in order to assure that the candidates will engage in a specific translational research project related to the field of HIV-malignancies. We will offer a two-year Fellowship program. The first year will be spent in clinical work, with assignment of a specific clinical mentor to each Trainee. The year will consist of attendance at weekly general HIV/AIDS clinic; weekly AIDS/Lymphoma clinic; weekly AIDS/KS clinic; one month on in-patient HIV/AIDS ward; three months on inpatient AIDS malignancy ward; and attendance at didactic lectures and symposia. The second year will emphasize training in clinical and translational research in the area of AIDS-related malignancy, with assignment of specific scientific mentors, and development of research projects, as well as attendance at didactic lectures and symposia in the area of research methods and biologic principles. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: AMC OPERATIONS CENTER Principal Investigator & Institution: Lee, Jeannette Y.; Research Professor; Medicine; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2001; Project Start 30-SEP-1995; Project End 31-JUL-2004 Summary: This proposal is for the Comprehensive Cancer Center Biostatistics Unit at the University of Alabama at Birmingham (UAB) to serve as the Operations, Statistical and Data Management Center for the AIDS-Associated Malignancies Clinical Trials Consortium (AMC). To date, the AMC has enrolled 159 patients on five AMC protocols. Two protocols have recently opened to patient accrual. An additional 9 protocols are under development. The AMC Operations Center provides statistical expertise to the AMC in the areas to study design, sample size, and analyses; coordinates the development, submission, conduct and analysis of AMC; maintains the database for the clinical trials; performs statistical analyses on study data; manages the Discretionary Fund; and coordinates the acquisition of specimens from AMC participants for donation to the AIDS Malignancy Bank. During the upcoming funding period, the AMC Operations Center plans to increase the use of scanners in the data entry process; increase the level of biostatistical support; increase the use of the AMC WEB page for the dissemination of information; and add a fiscal associate to the staff to manage the discretionary fund. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: ANTI VIRAL THERAPEUTIC FOR EBV MALIGNANCIES Principal Investigator & Institution: Faller, Douglas V.; Professor and Director; None; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2001; Project Start 07-FEB-2001; Project End 31-JAN-2003 Summary: Epstein-Barr Virus is a common and worldwide pathogen. While exposure usually results in a self-limited lymphoproliferative syndrome, infectious mononucleosis, the virus is causative, or associated with, a number of malignancies. The latent virus is detected in 2 endemic tumors: 95% of African Burkitt's lymphoma, and

8

Hodgkin’s Disease

90-100% of nasopharyngeal carcinoma. Many B-lymphomas, some T-lymphomas, and approximately 50% of Hodgkin's lymphomas have also been found to contain latent EBV. 40% of lymphomas arising in AIDS, and nearly all lymphomas arising in transplant recipients (post-transplant-associated lymphoproliferative disease (PT-LPD) harbor EBV. PT-LPD is especially difficult to treat unless the immunosuppression can be reversed, and is typically refractory to radiation therapy and chemotherapy. Similar to herpes simplex virus and varicella-zoster virus, EBV encodes a thymidine kinase (TK) enzyme. In a rate-limiting step, the viral TK converts nucleoside analogues to their monophosphate form, eventually leading to premature termination of the nascent DNA and cell death. Latently-EBV-infected B-cells and epithelial cells, including tumor cells, do not express TK. We have found that exposure of these cells to the experimental drug Arginine Butyrate results in induction of TK expression. Preliminary in vitro studies demonstrated that induction of EBV-TK in patient-derived tumor cells by Arginine Butyrate is possible, and that these previously-resistant cells are rendered susceptible to Ganciclovir (GCV) therapy. We have years of clinical experience in the administration of Arginine Butyrate to adults and children in studies to induce fetal hemoglobin as therapy for sickle cell anemia and thalassemia. We hypothesized that treatment of patients with EBV- associated tumors with arginine butyrate (to induce the EBV-TK) and GCV (to eliminate EBV-TK expressing cells) might be an effective, nontoxic therapy. We have treated eight patients with Arginine Butyrate plus ganciclovir in an FDAregistered pilot study with documented responses in the majority of patients, and no adverse outcomes related to this regimen. Our Specific Aims are: (1) To determine if treatment with Arginine Butyrate plus Ganciclovir will result in clinical responses in a significant proportion of patients with EBV-associated lymphomas and lymphoproliferative disease (LPD); (2) To determine toxicity or side effects of the combination therapy; and (3) To determine if tumor specimens and cell lines derived from patients demonstrate the same response to Arginine Butyrate and Ganciclovir (with respect to TK gene induction and synergistic susceptibility) as the EBV(+) cell lines we have studied to date. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: ANTIVIRAL MEDIATED APOPTOSIS OF NON-HODGKIN'S LYMPHOMA Principal Investigator & Institution: Harrington, William; Medicine; University of Miami-Medical Box 248293 Coral Gables, Fl 33124 Timing: Fiscal Year 2003; Project Start 01-APR-2000; Project End 31-MAR-2008 Summary: (provided by applicant): Therapy for lymphoproliferative disease in immunocompromised patients is problematic. These patients often have a poor response to cytotoxic agents that also worsens their underlying immunosuppression. Nonetheless, there are distinct pathophysiologic features of these tumors that may be exploited as therapeutic targets. These lymphomas are often associated with gamma herpesviruses and dependent upon constitutive expression of NF-kappaB. We have identified a novel, pro-apoptotic therapy for Humanherpes Virus Type 8 (HHV-8), Primary Effusion Lymphoma (PEL) and Epstein Barr Virus (EBV) lymphomas. Azidothymidine (AZT) and Interferon alpha induce death receptor ligand mediated apoptosis in PEL. This occurs through a potent activation of the ligand TRAIL mediated by interferon alpha coupled with suppression of NF-kappaB by AZT. We hypothesize that death receptor signaling is potentiated upon suppression of NF-kappaB dependent anti-apoptotic factors. NF-kappaB blockade is effected by the monophosphate form of AZT which is preferentially generated in HHV-8 and EBV associated lymphomas. We

Studies

9

have demonstrated the effectiveness of antiviral therapy for gamma herpesvirus associated lymphomas in both animal models and patients. We propose to investigate the cellular and viral factors that mediate this apoptosis by 1) defining the signal transduction pathways induced by antivirals in herpesvirus lymphomas; 2) determining the role of cellular and viral proteins (such as vFlip) in NF-kappaB mediated blockade of death receptor mediated apoptosis; 3) investigating the role of viral thymidine kinase in the phosphorylation of antiviral thymidine analogues and the initiation of apoptosis and; 4) studying the anti-lymphoma effects of antivirals in a recently developed SCID mouse model. Development of a therapeutic strategy based on antiviral therapy would represent a targeted, biological approach to lymphomas in resource poor settings. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: BCL11 GENES IN NORMAL AND MALIGNANT B CELL DEVELOPMENT Principal Investigator & Institution: Tucker, Philip W.; Professor; Inst for Cell & Mol Biology; University of Texas Austin 101 E. 27Th/Po Box 7726 Austin, Tx 78712 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 30-APR-2006 Summary: (provided by applicant): Molecular cloning of chromosomal translocations targeted to the immunoglobulin (IG) loci allows the identification of genes of importance in the genesis of normal and malignant B-cells. We have cloned a highly conserved zinc finger gene locus BCL11A, from a chromosomal translocation, t(2;14)(p13;q32.3), that occurs as the sole cytogenetic abnormality in rare and clinically aggressive subset of CLL. All breakpoints involved IG gamma switch regions and clustered 5' of a CpG island associated with BCL11A. BCL11A maps closely telomeric to REL and also appears to be a target gene for amplifications and gains of 2p13 observed frequently in Hodgkin's disease and in extranodal B-NHL. Together the data implicate deregulated expression of BCL1 1A in the pathogenesis of divergent subtypes of aggressive human cancers. There are three common BCL11A isoforms; each is a transcriptional repressor and varies in the number of zinc fingers. BCL11A interacts physically with and shares several similarities with BCL6, a gene frequently translocated to both IG and non-IG associated sites. BCL1 1A shares high identity with a human family member, BCL11B, on chromosome 14q32.1 and with homologues across metazoan evolution. We propose to study the clinical significance of deregulation BCL11 expression in malignancies with abnormalities of chromosome 2p13 and to determine the function of BCL11 in normal and malignant B-cell development Specific approaches include screening for additional (BCL1 1A) and initial (BCL11B) cases containing breaks/amplifications a these loci; functional analysis of transcriptional mechanisms an downstream targets; assessing transforming activities using in vitro and transgenic models; and inactivating the gene by targeted disruption. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: LYMPHOMA

BIOLOGIC

THERAPY

FOR

BETA-CELL

NON-HODGKIN'S

Principal Investigator & Institution: Ansell, Stephen M.; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2002; Project Start 01-MAR-2002; Project End 28-FEB-2006 Summary: B-cell non-Hodgkin's lymphoma (NHL) is the sixth most common cause of cancer-related deaths in the United States and the incidence of this disease is increasing. While aggressive lymphomas may be cured with cytotoxic therapy, most indolent

10

Hodgkin’s Disease

lymphomas are incurable with current therapy. Novel effective therapies are therefore needed to treat these patients. We are investigating a biological combination therapy for patients with indolent lymphoma that incorporates an anti-CD20 monoclonal antibody, Rituximab, and Interleukin-12. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that binds specifically to CD20 on pre-B and mature B- lymphocytes. While binding of the Fab domain may induce apoptosis, the Fc domain recruits immune effector functions to mediate lysis of the B-cell. Interleukin-12 (IL-12) has been shown to facilitate cytolytic T-cell responses; promote the development of Th1-type helper T-cells; enhance the lytic activity of NK cells; and induce the secretion of interferon- gamma by both T and NK cells. Therefore, we hypothesized that combining IL-12 with Rituximab would augment the immune mediated cell lysis induced by Rituximab. We have shown in a recently completed Phase I trial of this combination that the optimal immunological dose of IL-12 to give with standard doses of Rituximab is 300ng/kg. A substantial increase in the serum levels of downstream molecules such as interferon-gamma and Inducible Protein-10 (IP-10) was seen in response to this dose of IL-12. We also observed a 69 percent response rate to this therapy, with many of the responses seen in heavily pretreated patients. In this application, we are proposing to further evaluate the efficacy and toxicity of the combination of IL-12 and Rituximab through two different treatment regimens in patients with indolent B-cell non-Hodgkin's lymphoma and to determine if either one is promising enough to explore further in a phase III setting. We plan to do a randomized Phase II study to evaluate the efficacy of IL-12 and Rituximab given concurrently, as in the Phase I study, and to also evaluate the efficacy of Rituximab alone with IL-12 given only if there is a suboptimal response to Rituximab or disease progression. As shown in the Phase I trial, IL-12 induces the expression of cytokines such as gamma-interferon and chemokines such as IP-10. These molecules have been shown to upregulate T-cell function and inhibit angiogenesis. A further goal of the study is therefore to evaluate, in correlative studies, whether the combination of IL-12 plus Rituximab can alter gene expression in the malignant B-cells, restore the potentially deficient T-cell repertoire and inhibit angiogenesis leading to an improve clinical outcome for patients with indolent lymphoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: BLEOMYCIN STRUCTURE & FUNCTION: NMR SPECTROSCOPY Principal Investigator & Institution: Stubbe, Joanne; Professor; Massachusetts Institute of Technology Cambridge, Ma 02139 Timing: Fiscal Year 2001 Summary: The bleomycins (BLM's) are a family of antitumor antibiotics presently used clinically in the treatment of testicular cancer, head and neck carcinoma as well as Hodgkin's disease. Establishing the major intracellular target(s) and the mechanism(s) responsible for BLM's observed cytotoxicity and therapeutic efficacy is thus of great interest. BLM has been known for some time to effect both single strand (ss) and double strand (ds) breaks of DNA in vitro and in vivo. These ds breaks have been proposed to be the major contributing factor in BLM's cytotoxicity. A model for the way in which a single molecule of BLM can effect cleavage on two strands of DNA without dissociating has been proposed based on recent structural data acquired at CM[R. In this model, the bithiazole unit of the BLM molecule is thought to undergo a trans to cis flip that repositions the metal binding region of the molecule at the second strand. The hydroperoxide form of iron BLM (activated BLM) has been shown in mechanistic studies to abstract the 4'-H of the DNA ribose moiety. Once the 4'-H has been removed,

Studies

11

two major DNA lesions are formed. A phosphoglycolate lesion can be formed in an oxygen dependent manner, and a 4'-keto abasic site can be formed by an oxygen independent pathway. The structure of the phosphoglycolate lesion may present the key to understanding the ds cleavage of the DNA by BLM. Previously, a phosphoglycolate lesion containing the GTAC sequence had been synthesized in our lab. The GTAC sequence was chosen since it is a hot spot for ds cleavage with a ratio of ds : ss cleavage of I : 3. The key to acquiring good data for this piece had been to synthesize the oligonucleotide as a double hairpin connected with hexaethyleneglycol spacers. The proton chemical shift assignments have been completed and modeling of the 2D NMR data collected on a 750 MHz NMR is currently underway. The oligonucleotide had also been titrated with a cobalt hydroperoxy form of BLM, which is a proposed analog of activated iron BLM. This titration will be repeated with a more concentrated sample in the near future. Preparation of this sample is underway. The complex of cobalt BLM and DNA may hold the key to understanding the mechanism of ds cleavage. It may be possible to cont rast the data from the phosphoglycolate lesion with the data from an intact piece of DNA and detect a trans to cis isomerization in the bithiazole region. Another oligonucleotide sample containing the phosphoglycolate lesion has been prepared as well. This oligonucleotide is also a double hairpin linked by hexaethyleneglycol spacers. However, this piece contains the GGCC sequence. Interestingly, this sequence cannot undergo ds cleavage via the BLM molecule. This sequence thus functions as a control experiment. Data for this DNA has been collected in D20 and 90%H20/10%D20. The assignments of the chemical shifts are in progress. This oligonucleotide will also be titrated with a cobalt hydroperoxy BLM. If this oligonucleotide yields a one to one complex with the BLM, it will be interesting to contrast this data with the data from the GTAC piece. The synthesis of the 4'-keto abasic site is also in progress in the lab. This lesion is a synthetic challenge and efforts to make this lesion have thus far been unsuccessful. However, a new approach to this problem has been taken. A 4'-azido-2'-deoxyuridine moiety has been synthesized that will be incorporated into DNA using a polymerase and a kinase. Subsequent reduction will yield the 4'-keto abasic site. Since the 4'-keto abasic site is currently unavailable for structure determination, a close relative, a 4'-OH abasic site is being studied by 2D NMR. Again, this data was acquired on the 750 MHz instrument at CMR. This abasic site is being studied in the GTAC sequence context for comparison with the phosphoglycolate lesion. The modeling of this duplex 13-mer containing the abasic site is in the final stages of refinement. Interestingly, two distinct conformations of this abasic site in the GTAC region are present in equal amounts. This leads to the question of recognition of this damage site by DNA repair enzymes. It is reasonable to postulate that one of these conformations is recognized preferentially by DNA repair enzymes such as human apurinic/apyrimidinic endonuclease (APEI). In summary, modeling of 2D NMR data acquired on the 750 MHz instrument are at various stages of refinement for the abasic site and the phosphoglycolate lesions. Assignments of the 2D NMR data are in progress for additional phosphoglycolate lesions with and without Co-BLM bound. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: BONE MARROW GRAFTING FOR LEUKEMIA AND LYMPHOMA Principal Investigator & Institution: Negrin, Robert S.; Associate Professor; Medicine; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001; Project Start 15-APR-1989; Project End 30-JUN-2002

12

Hodgkin’s Disease

Summary: This program project grant application seeks support for experimental and clinical studies concerning the major obstacles to successful allogeneic and autologous bone marrow or peripheral blood progenitor cell transplantation (BMT) for the hematologic malignancies: leukemia, Hodgkin's disease, non-Hodgkin's lymphoma and multiple myeloma. The relevant problems after BMT include recurrence of the underlying disease, graft-versus-host disease (GVHD) and opportunistic infections with fungi, cytomegalovirus (CMV) and/or varicella zoster virus (VZV). The program consists of nine research projects and three supporting cores. The clinical projects deal with attempts to eradicate the underlying malignancies and to explore new drugs or drug combinations intended to prevent transplant-related complications such as acute or chronic GVHD, fungal infections and clinical VZV disease. Novel hematopoietic progenitor cell preparations (allogeneic and autologous) will be explored for their capacity to successfully restore hematopoiesis and lymphopoiesis in patients with hematologic malignancies. Dendritic cells will be employed to enhance the immunological anti-tumor effect of idiotype vaccination. The clinical projects will also serve as a resource for the experimental projects of the program. The experimental projects address the following biologically important transplant-related problems and topics: development of cytokine- induced killer cells for the prevention and therapy of post-transplant relapse; identification and enrichment of T-lymphocytes from murine marrow or peripheral blood with the intent to reduce GVHD and to preserve graftversus-leukemia activity; definition of barriers to allogeneic hematopoietic stem cell grafting; prevention of experimental GVHD; protection of immunity to VZV after allogeneic and autologous BMT; conditions for latency and reactivation of CMV. The nine interrelated projects of this application are supported by three cores, one for administration and research coordination, one providing biostatistical and data management expertise, and one for molecular and cytogenetic evaluations of transplant patients before and after BMT. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: BREAST CANCER PREVENTION IN HODGKINS DISEASE Principal Investigator & Institution: Garber, Judy E.; Assistant Professor of Medicine; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 29-JUN-2001; Project End 31-MAY-2003 Summary: (Applicant's Description) Hodgkin's Disease carries an excellent prognosis, with the majority of patients cured of their primary tumor. However, late complications of therapy in these patients are of increasing concern, especially new primary cancers of particular importance in this group is the increased risk of breast cancer among female Hodgkin's disease survivors who received mantle or chest radiation (RR approximate 20 by 15 yrs after treatment). Tamoxifen has been shown to reduce the risk of breast cancer by nearly 50percents in women at increased risk on the basis factors considered in the Gail model, DCIS or prior breast cancer II. It has not yet been evaluated in radiogenic breast cancer. HD survivors may also experience early menopause if their HD treatment included chemotherapy 12, and early atherosclerotic heart disease l3,14 and other second cancer risk from radiation or combined modalities I. These concerns may affect the risk/benefit considerations of tamoxifen in this high risk population whose risk becomes manifest at young ages. Because of these issues, it seems important to prove, rather than assume, that tamoxifen ireduces breast cancer risk in this population. However, since there are a limited number of women available for a study of sufficient size to address the question with sufficient power, demonstration of feasibility seems critical. In the proposed study, we will address aspects of feasibility ,

Studies

13

including recruitment/acceptance, adherence, toxicities and quality of life, and reproductive hormone status. We propose to recruit 50 female Hodgkin's Disease survivors whose treatment included radiation therapy (mantle or other chest), diagnosed before age 30, current age greater than 30 years, greater than 8 years from radiation to participate in a pilot study in which they will receive tamoxifen for 2 years on study, and 5 years in total. We will estimate recruitment rates, evaluate adherence, and assess quality of life and toxicities using measures employed in the BCPT, as well as questions developed for this population. Our advisory board will consider the one year data and assist us in deciding whether or not to proceed to attempt the larger study. A definitive randomized trial would be feasible with available HD survivors if adherence were 90 percents, based upon an estimated absolute risk of 8 percents over a 5 year period in women without tamoxifen. This is a risk much greater than the average risk in the BCPT cohort, permitting the smaller sample size. We will also evaluate mammographic density as a potential intermediate endpoint that might permit more rapid completion of a randomized study. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: CANCER AND LEUKEMIA GROUP B Principal Investigator & Institution: Taplin, Mary E.; Assistant Professor; Medicine; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655 Timing: Fiscal Year 2001; Project Start 09-JUL-1998; Project End 31-MAR-2003 Summary: (adapted from the applicant's abstract): Since its inception in 1993, the University of Massachusetts Cancer Center has sought to elucidate new insights into normal and cancer cell biology. Investigators based at U Mass are beginning to translate this knowledge into clinical correlative studies and therapeutic approaches through the CALGB. For example, Dr. Mary-Ellen Taplin has described specific androgen receptor gene mutations that may target more effective treatments for hormone independent prostate cancer. These initial studies constitute one of the funded Correlative Science Studies through the CALGB and comprises one of the CALGB Core Labs. Based on our experience and substantial base in hematopoietic cell biology, a major focus of the U Mass Cancer Center has been in transplantion biology. Efforts have centered on (1) determining factors that enhance engraftment, (2) the development of entirely new transplant models using minimal myeloablation, (3) cord blood transplantation, (4) NOD-SCID preclinical transplant models to detect minimal residual disease, and (5) gene therapy approaches such as MDR1 transfer into normal hematopoietic stem cells. Many principles of hematopoietic stem cell biology "are now being applied to solid organ systems, with investigators at U Mass evaluating growth characteristics of both normal and neoplastic cells by defining the malignant stem cell" in solid tumor systems and defining autocrine and paracrine loop pathways of growth control. Stem cell "studies in breast cancer, prostate cancer, and glioblastoma" are ongoing and may provide important clinical correlative studies as companion studies to CALGB treatment protocols. Our Group Activities and Scientific contributions have increased significantly in the past four years. U Mass investigators in CALGB have contributed substantially to activities in Transplant, Breast Cancer, Prostate Cancer, Surgery, and Gastrointestinal Cancer. Administrative contributions through the Audit committee and other ad hoc committees have been substantial. Major efforts have led to improvement in accrual to Group Studies and improvement in the quality of data submitted on CALGB clinical trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

14

Hodgkin’s Disease

•

Project Title: CANCER IN CHILDREN Principal Investigator & Institution: Whitlock, James A.; Pediatrics; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2001; Project Start 01-JAN-1981; Project End 30-NOV-2002 Summary: The long-range objective of this proposal is further improvement in the treatment of cancer in children through the participation of investigators at the Vanderbilt University School of Medicine in Children Cancer Group (CCS). The multidisciplinary team of investigators from Vanderbilt are pooling resources with comparable teams from other institutions to investigate the biology, treatment, and epidemiology of the childhood cancers. Specific aims can be summarized in terms of Vanderbilt's contributions to the Group's scientific endeavors and administrative leadership. These include the following: 1. Through participation in disease-specific Strategy Groups, establish research priorities and develop new strategies for therapeutic studies of acute lymphocytic leukemia (ALL), Hodgkin's disease, neuroblastoma, bone sarcomas, and brain tumors. 2. Through Study Committee chairmanships, provide leadership in the development, conduct, analysis, and reporting of investigation dealing with the treatment of ALL, neuroblastoma, and brain tumors. 3. Through participation as Study Committee members, assist in the conduct of studies concerned with the treatment of ALL, Hodgkin's disease, astrocytoma, and brain stem tumors. 4. Provide leadership in the development and interpretation of studies that assess the developmental and neuropsychologic sequelae of curative therapy for ALL. 5. Through committee participation, contribute to the development and analyses of investigational drugs. 6. Provide administrative leadership through participation on the Executive Committee, the Officers Committee, and the Affiliate Activities Steering Committee. In addition, investigators will continue to enlist the participation of Vanderbilt patients in CCG research protocols so as to facilitate the expeditious conduct and timely conclusion of Group studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: CASE-CONTROL STUDY OF HODGKIN'S DISEASE IN CHILDREN Principal Investigator & Institution: Grufferman, Seymour; Professor; Family Med/Clin Epidemiology; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2001; Project Start 01-SEP-1987; Project End 30-JUN-2004 Summary: (Adapted from the Investigator's Abstract) This is a competing renewal application for a case-control study of childhood Hodgkin's disease (HD) with epidemiologic, genetic and virologic components. Cases are from the Children's Cancer and Pediatric Oncology Groups with individually matched controls selected by random digit dialing (RDD). Epidemiologic data for 480 cases and 726 matching controls have been collected by telephone interviews of parents. Tumor specimens have been collected for 321 cases and blood samples for 234 cases for Epstein-Barr virus (EBV) studies. In the new phase of this study, emphasis will be placed on genetic factors in the etiology of HD. Thus far, 186 case and 79 control families have been re-interviewed. Complex segregation analyses of the family data have been performed and the best fit is with an environmental rather than a Mendelian inheritance model of HD using two approaches. DNA microsatellite markers will be used to test for the association between HD and candidate HLA regions and non-HLA regions. The second approach will perform high resolution molecular typing HLA Class I (HLA-A,B,C) and II (HLA-DR, DQA1, D1B1 and DP) alleles. The proposed HLA studies will allow for analyses of the relationship

Studies

15

between EBV-status and subject's HLA type. The proposed new studies will also include statistical assessment of time-space clustering of cases and controls, an evaluation of the introduction of socioeconomic status bias by RDD and the performance of a second follow-up interview of subjects' families. The study will focus on Hispanic cases since they differ significantly from other cases in EBV-positivity of their tumors and other epidemiologic features. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: CCSG RESEARCH BASE FOR CCOP Principal Investigator & Institution: Robison, Leslie L.; Professor; National Childhood Cancer Foundation Box 60012, 440 E Huntington Dr, Ste 402 Arcadia, Ca 910063777 Timing: Fiscal Year 2001; Project Start 15-SEP-1983; Project End 31-MAY-2002 Summary: (Applicant's narrative) The Childrens Cancer Group (CCG) is an NCI-funded clinical trials cooperative oncology group, which has acted as a research base for the Community Clinical Oncology Program (CCOP) since the program's inception. CCG has a network of university-associated, tertiary care, pediatric cancer centers, which sponsor smaller community institutions, thereby providing them the resources to carry out clinical trial protocols at the local site. Membership currently includes 35 tertiary centers with 79 affiliated community institutions, 18 of which are CCOP affiliates. The catchment area includes thirty-six states, the District of Columbia, four Canadian provinces, and Perth, Western Australia. Through this broad geographic distribution, CCG has the opportunity to influence the diagnostic, treatment and management practices in a large portion of North America. CCG has established goals for its CCOP project which are consistent with the CCOP's stated goals, but which reflect the unique nature of childhood cancer and the practitioners who treat it. CCG will continue to bring state-of-the-art protocols to the community by continuing to involve CCOP investigators in the development and execution of clinical trials. Workshops, scientific and educational sessions are regularly conducted to assure that investigators and clinical data managers have current knowledge and understand the processes for participation in clinical trials. Since most pediatric cancer patients are enrolled on clinical trials, a modest outreach program is proposed to continue and improve on the record. CCG has recently appointed a new Epidemiology and Cancer Control Strategy Group to further the involvement of CCG and the CCOP institutions in cancer control and prevention studies. Studies in development are related to evaluating both short-term and long term quality of life in cancer patients, to improving supportive care measures, to studying cancer etiology and prevention, and to identifying long-term health-related outcomes and defining intervention strategies to reduce negative effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: CHILDRENS CANCER GROUP Principal Investigator & Institution: Steinherz, Peter G.; Member/ Attending Pediatrician and Prof; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2001; Project Start 30-SEP-1986; Project End 30-NOV-2002 Summary: This grant application requests support the continued participation of the Memorial Sloan-Kettering Cancer Center and its affiliate hospitals in the research protocols of the Childrens Cancer Group. The clinical studies are designed to improve the survival of children with cancer through multidisciplinary randomized, collaborative treatment protocols that are stratified to the patients' stages of disease and their prognostic groups. Whenever possible the treatments are reduced to minimize

16

Hodgkin’s Disease

both short and long-term toxicity. Epidemiologic studies are conducted to study the incidence, natural history and possible causes of childhood malignancies. Laboratory studies will be conducted to study the biology of cancer cells and correlate these with the clinical variables. The aims of our participation and those of CCG are a) to provide large numbers of patients for groupwide studies in order to make multiarm, randomized, prospective studies possible, b) to utilize the scientific leadership, expertise and clinical experience of Pediatric Oncologists and other experts at MSKCC to help design and implement new studies, and c) to contribute scientific and administrative expertise and experience to Standing Committees of CCG. Clinical studies at MSKCC will continue in the evaluation and development of new chemotherapeutic agents for patients who become refractory to conventional therapy. Pharmacologic studies will evaluate drug metabolism and correlate it with therapeutic response. Studies will be conducted in the role of bone marrow transplantation in hematopoietic disorders and refractory solid tumors. The extensive clinical facilities of MSKCC with its well developed intensive supportive care program and its research laboratories will make it possible to develop novel treatment protocols. They will be piloted and made available for groupwide randomized prospective trials. The clinical personnel of MSKCC have extensive and proven experience in the design and implementation of innovative treatment protocols that have been adopted worldwide. They will continue to provide leadership for CCG in study committees and strategy groups. Current pilot studies at MSKCC that will become available for CCG use during this grant period include protocol for high-risk ALL, a retrieval protocol for refractory Hodgkin's disease, a new CNS leukemia therapy, a new osteogenic sarcoma protocol and a monoclonal antibody treatment for neuroblastoma. Members of the affiliate hospitals have been participating in CCG studies and have proven their ability to conduct the clinical studies and provide material for laboratory evaluation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: CHILDRENS CANCER GROUP (CCG) Principal Investigator & Institution: Rogers, Paul C.; University of British Columbia 2075 Wesbrook Pl Vancouver, Timing: Fiscal Year 2001; Project Start 01-JUL-1981; Project End 30-NOV-2002 Summary: The Pediatric Oncology Division of the University of British Columbia, Department of Pediatrics, has a long established record of commitment to CCG. The Division has enjoyed full membership since 1974 and NCI funding support since 1980. The Division actively participates in CCG Trials as well as being involved in strategic planning, trial design, lab-based research, outcome analysis and administrative responsibilities within the CCG network. During the next 5 year grant cycle, the Division will continue to participate in all aspects of CCG activities. Specific aims: Commitment to continue to enter as many patients as possible into CCG Trials; Actively participate in new proposals specifically in the field of high risk acute lymphatic leukemia (Dr. K. Schultz), Hodgkin's Disease (Dr. C. Fryer), radionucleotide imaging studies- Thallium (Dr. H. Nadel), radiotherapy aspects of CCG (Dr. C. Fryer); Investigate prognostic markers specifically the significance of molecular abnormalities in sarcomas (Dr. P. Sorensen); Continue to develop new therapies for poor prognostic patients, specifically to continue Phase II Pilot work on marrow ablative therapy and PBSC rescue in patients presenting with metastatic disease utilizing molecular genetic techniques to detect minimal residual disease and contamination of PBSC; To continue our laboratory research into understanding mechanisms of graft-versus-host disease and graft-versus-leukemia effect to gain further understanding of the host response to

Studies

17

malignant disease; To expand our molecular biology research into the genetic changes associated with childhood cancers; and to investigate the cytolytic T-cell therapy for Hodgkin's Disease directed against EB viral antigens (Dr. K. Schultz and Dr. Ru Tan). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: CLINICAL INVESTIGATIONS IN HODGKINS DISEASE Principal Investigator & Institution: Horning, Sandra J.; Professor of Medicine; Medicine; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001; Project Start 07-FEB-1992; Project End 31-MAR-2002 Summary: It is the objective of these studies to improve the treatment outcomes for patients with newly diagnosed Hodgkin's disease and to continue to monitor the late effects of treatment on adults and children participating in past and present clinical trials. We intend to accomplish these goals through the conduct of novel therapeutic studies and the maintenance of a database on over 2500 Hodgkin's disease patients. The proposed clinical studies build upon our previous research efforts in Hodgkin's disease. A novel treatment for adults with early stage disease has been designed to maintain high cure rates, limit staging, and reduce late effects. This treatment, which consists of just eight weeks of chemotherapy followed by lower dose, modified involved field irradiation, is based on the success of abbreviated chemotherapy and limited irradiation in advanced stage disease. We plan to continue to study the abbreviated chemotherapy program, Stanford U, alone or in combination with irradiation in unfavorable and advanced stage Hodgkin's disease. Preliminary data indicate that this treatment approach is highly effective and, to date, has not been associated with serious morbidity. In the adult studies we plan to incorporate potentially more sensitive nuclear imaging for the identification of Hodgkin's disease and assessing the risk for relapse following the described treatments. Similar to adults, children with Hodgkin's disease will be treated according to risk group on clinical trials conducted at Stanford University, St. Jude Children's Research Hospital and the Dana Farber Cancer Center. Those patients with favorable, limited disease will receive four cycles of chemotherapy and low dose irradiation while an alternating chemotherapy program and low dose irradiation will be used for patients with unfavorable or advanced disease. Follow-on studies are planned for each of the clinical trials in progress in adults and children. An integral part of this application is the continued follow up of patients enrolled on prospective clinical trials at Stanford University since 1962. This includes the description of relapses, subsequent therapies, late morbidity, fatal treatment complications, causes of death and survival in over 2500 treated patients. These data, which have allowed Stanford investigators to make seminal observations on late effects such as second malignancy and cardiac disease, are maintained in a sophisticated database, representing a national resource for the efficacy and complications of the treatment of Hodgkin's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: COMMUNITY CLINICAL ONCOLOGY PROGRAM Principal Investigator & Institution: Locker, Gershon Y.; Chief; Evanston Northwestern Healthcare 2650 Ridge Ave Evanston, Il 60201 Timing: Fiscal Year 2003; Project Start 01-SEP-1983; Project End 31-MAY-2008 Summary: (provided by applicant): Evanston Northwestern Healthcare has over 20 years of successful participation as an NCI-designated CCOP. Over these years we have met or exceeded clinical trial accrual goals, held leadership positions in our research bases, directed national cooperative group studies and brought to the cooperative

18

Hodgkin’s Disease

groups our experience and expertise in many areas such as quality-of-life research, thoracic and breast oncology, neuro-oncology and recently cancer genetics. Evanston Northwestern Healthcare has the only tertiary care oncology program in our area (population >1.2 million) with consistent participation in NCI-approved cancer treatment, prevention and control studies. We are the major supplier of oncologic healthcare in our area, and a major force for health education and promotion. The specific aims of this renewal proposal are: 1. To continue to offer the populations of the North suburbs of Chicago state-of-the-art clinical research trials covering cancer treatment, control, and prevention. 2. To extend our efforts into Lake County, Illinois (population 661,000), one of the fastest growing communities in the Midwest and until now not served by any medical institution with consistent participation in NIHapproved clinical trials in oncology. 3. To disseminate within our catchment area stateof-the-art clinical practice in oncology as an outgrowth of our participation in the CCOP programs. 4. To bring to our national research bases expertise and proposals based on the ongoing research programs and clinical strengths of Evanston Northwestern Healthcare, and reflecting the needs of our community. 5. To expand our cancer treatment, prevention and control efforts to underserved and minority populations. 6. To continue our leadership positions in our established national research bases and to offer leadership in our new research base. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE Principal Investigator & Institution: Puccetti, Diane M.; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: CONTROL OF T LYMPHOPOIESIS AND GROWTH BY MAD GENES Principal Investigator & Institution: Iritani, Brian M.; Comparative Medicine; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-DEC-2007 Summary: (provided by applicant): Antigen-activated lymphocytes, or transformed lymphocytes in leukemias, must double their size and contents (termed cell growth) before they can divide into equal sized daughter cells. Despite the importance of cell growth in normal cell proliferation and cancer, the molecular events that control cell growth in dividing lymphocytes or other mammalian cells remain an enigma. Our preliminary studies in mice suggest that the Mad family of basic helix-loop-helix transcription factors (Mad1, Mxi1, Mad3, Mad4), considered to be antagonists of the Myc oncoprotein, inhibit T cell proliferation and development in part by inhibiting cell growth. Furthermore, human mad1 and mxi1 genes each localize to separate chromosome regions associated with lymphocytic leukemias, Hodgkin's disease, and prostatic carcinomas suggesting the importance of mad genes in lymphocyte biology and cancer. The broad objective of this proposal is to determine the normal roles and mechanism of action of Mad family members in the development and expansion of T Iymphocytes Specifically, we intend to: (1) Test the hypothesis that Mad family members modulate the maturation of T lymphocytes. We will examine the role(s) of Mad family members in T lymphocyte development by employing targeted deletion,

Studies

19

and transgenic overexpression, of selected Mad family members in mice. (2) Test the hypothesis that Mad family members control the proliferation and cell growth (cell size, protein synthesis) of T Iymphocytes during T cell activation. We will examine the functional consequences of Mad overexpression or loss on cell division, cell size, RNA processing, and protein synthesis in primary lymphocytes immediately following activation. (3) Test the hypothesis that Mad directly binds and modulates the expression of essential genes involved in cell growth control. We will determine if Mad1 inhibits the expression of several essential genes involved in cell growth control. We will then use chromatin immunoprecipitation assays to determine if the regulatory regions of these genes are directly bound by Mad proteins. Together, these aims will test the overall hypothesis that Mad-Max complexes normally modulate lymphocyte proliferation and development in part by controlling the expression of growthregulating genes. Results of these studies will identify target genes that could be manipulated to regulate the balance between Myc and Mad in order to inhibit lymphocyte proliferation in lymphomas or autoimmune disease, or to enhance clonal expansion of antigen-specific lymphocytes in a primary immune response, or following bone marrow transplantation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: DNA METHYLATION IN NON-HODGKIN'S LYMPHOMAS Principal Investigator & Institution: Caldwell, Charles W.; Professor of Pathology and Anatomical Sc; Pathology; University of Missouri Columbia 310 Jesse Hall Columbia, Mo 65211 Timing: Fiscal Year 2003; Project Start 16-APR-2003; Project End 31-MAR-2007 Summary: The major activity in our laboratory is studies of DNA methylation in tumorigenesis, a process commonly observed in GC-rich sequences called CpG islands in many types of human cancers and is often associated with transcriptional silencing. Using non-Hodgkin's lymphoma (NHL) as a model system, our discovery-driven preliminary studies demonstrate that DNA hypermethylation is not a random event; many CpG island loci are susceptible to methylation alteration. As a result of this epigenetic mutation, the expression of genes that govern key functions of the cell may become silent, leading to clonal proliferation of tumor cells. Differential susceptibility of critical CpG island loci to DNA hypermethylation may therefore influence the development of different NHL subtypes and may help explain differences in tumor growth and treatment outcomes. We have identified several loci that are differentially methylated and may be involved in lymphomagenesis. Our Central Hypothesis: B-cell differentiation is affected by methylation of CpG islands and this frequently leads to silencing of gene transcription. We further hypothesize that 1) Histological classes of NHL actually contain more than one clinical disease; 2) Hypermethylation of CpG island loci in NHL cells can generate unique molecular signatures that are associated with clinical subtypes and; 3) Dissecting these complex epigenetic profiles requires an understanding of gene methylation in normal, as well as neoplastic, B-cell differentiation. This application will expand a current version of our MethylationSpecific Oligonucleotide (MSO) microarray, an invention that combines the power of the bisulfite treatment protocol with the versatility of oligonucleotide microarrays, and apply this innovative technique to study DNA methylation in cases of B-cell NHL and normal B-cells at similar stages of differentiation, and relate these changes to gene silencing and classification. We plan to test our hypotheses by pursuing 4 specific aims; 1. Generate an MSO microarray for analysis of promoter hypermethylation at about 4,000 loci in 80 genes; 2. Determine patterns of CpG island methylation that characterize

20

Hodgkin’s Disease

subsets of NHL classes and their putative normal stage of B-cell differentiation; 3. Correlate the status of promoter hypermethylation defined by MSO with gene expression; 4. Develop and apply data management, analysis and visualization tools to decipher methylation profiles of NHL classes. The proposed studies are expected to yield important insights into potential mechanisms of DNA methylation-driven gene silencing related to B-cell differentiation and development of clinical subtypes of NHL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: EBNA1-SPECIFIC CD4+T HELPER 1 CELLS Principal Investigator & Institution: Bickham, Kara; Lab/Cell Physiol & Immunology; Rockefeller University New York, Ny 100216399 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2004 Summary: Epstein Barr virus (EBV) is a gamma herpes virus that latently infects greater than 90% of the adult population. Despite a relatively benign course in most carriers, EBV has growth transforming potential and is associated with a number of malignancies, including nasopharyngeal carcinoma, Hodgkin's lymphoma and Burkitt's lymphoma. EBNA1 is a vital EBV latency antigen that maintains the viral episome and is found in all EBV-associated tumors. EBNA1-specific CD8+ T cell immunity is blocked by its glycine-alanine repeat domain, which prevents proteosomal processing for MHC class I. However, our laboratory recently showed that the normal host response to EBNA1 lies in the CD4+ TH1 T cell compartment. TH1 CD4+ T cells are known to be critical for resistance to tumors and viruses in mice. This project will characterize EBNA1-specific CD4+ lymphocytes in several ways. First, we will optimize techniques to detect EBNA1 - specific responses using intracellular cytokine staining and real time PCR and thereby have methods to follow this immune response in patients with EBVassociated malignancies. Second, we will investigate the role of the antigen-presenting cell in the polarization of the CD4+ T cells to TH1 in vivo. We will describe the phenotype of the EBNA1- specific response in blood and tumor infiltrating lymphocytes from patients with EBV-associated Hodgkin's lymphoma and nasopharyngeal carcinoma to determine if EBNA1 immunity is reduced or changed to a TH2 response. Finally, we will learn to expand EBNA1 immunity in T cells from patients with EBVassociated malignancy, including if need be redirect established TH2 responses to TH1. These experiments will set the stage for clinical studies, most likely with dendritic cells pulsed with EBNA1, to manipulate the immune response in patients with EBVassociated malignancy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: EBV BZLF1 GENE PRODUCT Principal Investigator & Institution: Flemington, Erik K.; Associate Professor; Pathology and Laboratory Medicine; Tulane University of Louisiana New Orleans, La New Orleans, La 70112 Timing: Fiscal Year 2001; Project Start 01-JAN-1993; Project End 10-APR-2003 Summary: EBV is the casual agent of infectious mononucleosis and is associated with the development of both B-cell and epithelial cell malignancies including the endemic form of Burkitt's lymphoma, post-transplantation lympho-proliferative diseases, AIDSassociated lymphomas, Hodgkin's disease and undifferentiated nasopharyngeal carcinoma. Viral genes expressed during the latent phase of the EBV life cycle are growth promoting and are responsible for EBV's link to these human cancers. However, it has been known for some time that the lytic phase of the EBV life cycle occurs in

Studies

21

differentiated and/or growth arrested tissues. We have recently found that the lytic switch gene, Zta, has potent cell growth inhibitory activity suggesting that EBV can actively promote this cell growth arrested status. Therefore, Zta may represent an evolutionary counterpart to the latency associated EBV gene products. The objectives of this proposal are to identify how Zta integrates into cell-cycle control pathways and to learn how interactions with key cell- cycle control proteins influences progression through the EBV lytic replication cycle. Our specific aims are: 1) Genetic analysis of Zta mediated cellular growth arrest. a) Generation of Zta mutants (rationale) b) Preliminary characterization of Zta mutants - analysis of dimerization/DNA binding, nuclear localization, transactivation. c) Genetic analysis of Zta mediated growth arrest, p21, p27, and p53 induction, and inhibition of c-Myc expression. 2) Yeast two -hybrid for screening Zta interacting factors. a)Library screening. b) Clone selection - rationale. c) Interaction studies. d) Functional analysis of Zta:Zta-targeting factor interactions. 3) Genetic analysis of Zta mediated latency disruption. a) Development of model system. b) Analysis of latency disruption by Zta mutants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: EBV GENOME EXPRESSION--LOCALIZATION OF SPECIFIC FUNCTION Principal Investigator & Institution: Hayward, S D.; Professor; Pharmacology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 30-SEP-1981; Project End 31-MAR-2005 Summary: Epstein-Barr virus (EBV) immortalizes B cells and is associated with human malignancies including Burkitt's lymphoma, nasopharyngeal carcinoma, gastric carcinoma, Hodgkin's disease and lymphoproliferative disease in immunosuppressed patients such as AIDS patients and organ and bone marrow transplant patients. Primary infection by EBV may cause infectious mononucleosis in young adults. Primary infection leads to a proliferative expansion of the infected B cells. This is followed by the establishment of life-long persistence in which the EBV genome resides in resting B cells. Lytic viral replication occurs in the oropharynx and results in virus shedding into the saliva. Different patterns of EBV latency gene expression are seen in latently infected resting B cells and in EBV associated tumors. This application addresses factors that may regulate these expression patterns and contribute to the different aspects of EBV pathogenesis. EBV replication is necessary for virus spread and Zta is a key regulator of the EBV lytic cycle. Zta not only regulates EBV lytic DNA replication but may also influence the maintainance of latent infection. The Specific Aims are: (Aim 1). To characterize the role of Zta in replication of the EBV origin of lytic replication, orilyt. Transfection assays will be used to analyse the role of Zta in the formation of replication compartments, to analyze the relative contributions of Zta's transcriptional and replication activities to orilyt activation and to relate Zta mediated regulation of the cell cycle to Zta replication function. (Aim 2). To evaluate the contribution of the JAK-STAT signaling pathway to the regulation of EBV latency gene expression in in vivo latency and tumorigenesis. STAT regulation of individual EBV latency promoters will be examined in transient assays. The role of activated STATs and Zta expression in the maintainance of EBV positive epithelial tumor cell lines in culture will be pursued and negative regulation of the EBV lytic cycle by STATs will be examined. (Aim 3). A role for EBNA-1 in the regulation of EBV latency gene expression will be evaluated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

22

Hodgkin’s Disease

•

Project Title: REGULATION

EBV

TRANSFORMATION

OF

B

LYMPHOCYTES--EBNA

Principal Investigator & Institution: Gutsch, David E.; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 17-JUN-1997; Project End 02-JUN-2001 Summary: Epstein-Barr virus is strongly associated with Burkitt lymphoma and nasopharyngeal carcinoma and is responsible for lymphoproliferative disease in immunocompromised individuals. The long-term objectives of the studies proposed are to determine the mechanisms of cellular transformation by EBV. When this virus infects B cells in vitro, the lymphocytes become immortalized. Activation of the EBV W promoter (Wp) is the first viral transcriptional event detected during infection. Wp directs the early expression of Epstein-Barr virus nuclear antigens (EBNA). The EBNA proteins are involved in cellular and viral gene regulation and the maintenance of chronic EBV latency. Later in infection, there is a switch to usage of the other EBNA promoters, Cp, then Qp. While Cp and Qp have been studied extensively, almost no information exists regarding the specific cis and trans constituents of Wp regulation. Our preliminary studies have demonstrated the presence of at least three cis elements within the W promoter, so these elements have been selected for detailed study in this proposal. In the first specific aim, the particular cellular transcription factors which interact with critical cis elements in Wp will be characterized. Extensive promoter mutagenesis, gel shift assays, promoter footprinting and southwestern gels of bound factors will be employed. The second specific aim will explore the functional importance of Wp cis elements. This will be accomplished with transfection studies using expression vectors for pertinent transactivators and using various Wp deletional and mutational constructs. In the third aim, in vivo footprinting of Wp, and the use of whole EBV mutants with disruption of key cis elements will be used to demonstrate the in vivo significance of Wp domains. Finally, these studies will ascertain the in vivo role of factors acting upon Wp in trans during the time course of EBNA promoter switching. Knowledge gained from these studies might ultimately produce means of exploiting the control of EBV gene expression to augment immune destruction of EBV-infected malignant cells in such catastrophic diseases as Burkitt lymphoma or Hodgkin's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: EPIDEMIOLOGIC ANALYSIS OF EPSTEIN BARR VIRUS AND HODGKINS DISEASE Principal Investigator & Institution: Muller, Nancy E.; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2001 Summary: The epidemiology of Hodgkin's disease (HD) is consistent with a viral etiology. The Epstein-Barr virus (EBV) is closely related to HD on the basis of both serologic and molecular evidence, with 30- 50% of the cases' biopsies being EBV-genome positive. Several risk factors have been consistently identified which point to age of infection as an important modifier of risk in parallel with age at diagnosis. Following the paralytic polio paradigm, both very early and late EBV infections may be more severe. How these risk factor, serologic, and molecular data fit together is unknown. We propose to address this issue in a population-based case-control study conducted in the greater Boston area and the state of Connecticut, involving 600 incident cases and 600 population controls. Risk factor data will be obtained by telephone interview; blood

Studies

23

specimens will be drawn from the cases, and tissue blocks tested for EBV- genome. These data will be evaluated for consistency with three models of HD pathogenesis: 1. The EBV is solely related to EBV- genome positive HD with EBV-genome negative disease due to non-viral causes; 2. HD is a virally induced malignancy with the EBV responsible for EBV-genome positive disease and another unidentified virus(es) linked to EBV-genome negative disease; 3. The EBV plays a crucial early role in the pathogenesis of essentially all HD cases but the genome is selectively lost in some patients. Both case-case and case-control comparisons will be done. By integrating the risk factor profile in relation to EBV-genome status of a large series of cases, we should be able to distinguish between these alternative hypotheses. This will be complimented by the serologic comparisons between the two sets of case, and in concert with data from Project 2. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: EPSTEIN BARR VIRUS LATENCY AND ONCOGENESIS Principal Investigator & Institution: Kieff, Elliott; Princeton University 4 New South Building Princeton, Nj 085440036 Timing: Fiscal Year 2001 Summary: The objective of these experiments is to understand the mechanisms by which Epstein-Barr Virus (EBV) establishes latent infection, persists, and causes neoplasia. The specific aims are (i) To complete the identification of EBV reading frames and proteins that are expressed at various stages of experimental latent or lytic infection of cells, in vitro. (ii) To identify cellular genes whose expression is specifically altered during the course of latent or lytic EBV infection, in vitro. (iii) To further identify viral and cellular genes expressed in cell lines and tumor tissue from patents with EBV associated Lymphoproliferative Disease, Burkitt's Lymphoma, Hodgkin's Disease, Nasopharyngeal Carcinoma, and Gastric Cancer and to further explore the association of EBV with testicular cancers. (iv) To further identify EBV and cellular gene expression in latently infected lymphocytes in the peripheral blood and lymphoid organs of normal people undergoing phlebotomy, biopsy, or surgical resection. (v) To establish and maintain databases of the effects of EBV on cell gene expression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: FUNCTIONAL DIFFERENTIATION IN B LYMPHOCYTES Principal Investigator & Institution: Rittenberg, Marvin B.; Professor; Molecular Microbiology and Immunology; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2001; Project Start 01-JUL-1988; Project End 31-MAR-2003 Summary: (Adapted from the Investigator's abstract): The ability of somatic mutation to modify the course of a humoral immune response is well documented. However, the focus has been almost exclusively on the ability of this process to improve the functional characteristics of representative antibodies; the harmful effects have not been well characterized. Yet in terms of cell numbers, all evidence suggests that B-cell wastage caused by harmful somatic mutations probably far exceeds the number of cells whose antibodies are improved through mutation. The purpose of this project is to gain quantitative insight into the contribution of mutation to B-cell wastage and secondly to exploit the well-known power of harmful mutations, to illuminate function. The investigators have previously made and characterized in vitro the binding of a large number of mutants of the T15 antibody to the hapten, phosphocholine (PC). The

24

Hodgkin’s Disease

hypothesis is that mutant Abs displaying defective Ag binding or secretion in vitro would lead to apoptosis and B-cell wastage if they were to occur in vivo. This hypothesis will be tested in three ways: 1) by examining the ability of mutant antibodies to recognize PC which is displayed in different structural contexts on the surfaces of the pathogenic organisms, Streptococcus pneumoniae, Ascaris suum and Trichinella spiralis as well as Proteus morganii; 2) by testing the ability of mutant antibodies to transmit antigen-induced signals to transfected B lymphoma cells, and 3) by examining apoptotic GC B-cells for mutations in the VH1 gene of T15 shown to be harmful in vitro. These studies bear on B-cell wastage and homeostasis and the causes of apoptosis in germinal centers where recent evidence has suggested some lymphoid tumors such as Hodgkin's disease may originate. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: FUNCTIONAL STUDIES OF GP42 AND HLA CLASS 11 IN EBV Principal Investigator & Institution: Longnecker, Richard M.; Associate Professor; Microbiology and Immunology; Northwestern University Office of Sponsored Programs Chicago, Il 60611 Timing: Fiscal Year 2002; Project Start 22-FEB-2002; Project End 30-NOV-2006 Summary: This proposal represents a collaborative project between Dr. Longnecker and Dr. Jardetzky to define the molecular mechanisms involved in Epstein-Barr virus (EBV) entry into B lymphocytes, the major target cell of EBV in human hosts. EBV is associated with a variety of hematopoietic, epithelial, and lymphoproliferative diseases. EBV causes infectious mononucleosis in adolescents and is known to play an etiological role in human malignancies. EBV is a causative agent in endemic Burkitts lymphoma and undifferentiated nasopharyngeal carcinoma (NPC). EBV is also recognized as an important pathogen in immunosuppressed individuals, causing a variety of proliferative disorders including immunoblastic lymphomas, oral hairy leukoplakia, and an unusual tumor of muscle origin in immunosuppressed children. EBV may also be a factor in a variety of other human malignancies including some T-cell lymphomas, Hodgkin's Disease, and breast cancer. These disorders suggest a wide variety of tissue tropism for EBV in vivo. In vitro and in vivo, the cells that are most susceptible to EBV infection and most permissive for viral replication are of B cell origin. The major viral envelope glycoprotein 350 (gp350) binds to the complement receptor type two (CD21) which is abundantly expressed on B cells. Fusion of the virion membrane with the cell membrane minimally requires a complex of viral proteins that includes gp85, gp25, and gp42. Gp42 has been specifically found to bind to human leukocyte antigen (HLA) class II and this interaction is required for EBV entry into B lymphocytes. To date, little is known about the mechanism that EBV uses to bind and penetrate B cells. This proposal will analyze the role of gp42 and its interaction with HLA for viral entry by structurefunction studies. Clarifying the interactions between cellular receptors and viral glycoproteins is essential for understanding the tropisms behind EBV associated diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: GEMCITABINE IN RELAPSED HODGKIN'S DIS/ NONHODGKINS LYMPH Principal Investigator & Institution: Yuen, Alan R.; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001

Studies

25

Summary: We are testing the activity of the chemotherapy agent gemcitabine in patients with recurrent or refractory Hodgkin's disease or non-Hodgkin's lymphoma. Patients may have either disease and must have recurred or progressed after standard treatments. Patients will receive treatment until the maximum benefit is achieved, usually around six months of treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: GENETIC STUDY OF HODGKIN'S DISEASE Principal Investigator & Institution: Yao, Yin Y.; Pediatrics; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 16-JUL-1999; Project End 30-JUN-2003 Summary: This is a pilot study grant application for a genetic study of Hodgkin's disease (HD). The grant includes two parts. Part I is to collect blood samples from 200 sib pairs affected with HD and their parents through national and international collaborations, and to use DNA microsatellites in candidate regions to identify genes contributing to HD, and to examine gene-environment interaction in etiology of HD. Approximately 20 DNA markers, including HLA and non-HLA regions which were documented to have an association with HD will be tested. Part II is a meta analysis for pre-existing familial HD data with HLA haplotype information pooled from the literature. The main focus in Part I is 1) to test the hypothesis of a major gene factor to estimate age specific penetrance using complex segregation analysis and 2) to test the hypothesis of linkage and quantify the proportion of HLA linked or non- linked families using lod score approach and non-parametric linkage analysis and 3) to estimate relative risk in sibs based on HLA haplotype information. preliminary study for the purpose of Part I has been carried out on 63 HD patients. We tested one DNA marker named DQCARIII in the HLA class 11 region. The results support a weak association between HD and the marker DNA (P value =0.06). This naturally provides a candidate gene for our study. For the purpose of Part II, 60 multiple families from the published literature have been identified. That data is being entered and verified at the current time. In summary, we believe that this is a feasible approach and can serve as a first step towards future breakthroughs in our understanding of HD by addressing the association between DNA markers and HD, and by thoroughly examining the genetic mode of inheritance of HD through sophisticated statistical tools. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: GRAFT REJECTION Principal Investigator & Institution: Mcniece, Ian K.; Professor; Oncology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 08-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): Non-myeloablative transplants are being used increasingly for a number of diseases, including Non Hodgkins lymphoma, Hodgkin's disease, myeloma, acute leukemia, chronic lymphoytic leukemia (CLL) and chronic myelogenous leukemia (CML). A reduction in toxicity compared to fully myeloabative allogeneic stem cell transplantation is stimulating the use of this strategy particularly for older patients. Donor engraftment is achieved in the majority of patients, however, a significant number of patients, particularly those with myelodisplastic syndrome (MDS) experience secondary loss of donor engraftment. This can be fatal for some patients due to the prolonged pancytopenia that follows. There are several possibilities for the loss of donor engraftment; 1) donor graft rejection by recipient T cells, 2) late donor graft failure

26

Hodgkin’s Disease

due to insufficient stem cells in the graft, or 3) dominance of recipient stem cells due to competitive repopulation. In allogeneic transplants to support high dose chemotherapy, graft failure/graft rejection occurs early after transplant within the first month, however, for patients that achieve early donor engraftment secondary graft failure/graft rejection is rare and only occurs in less than 5% of patients [1,2]. In contrast, nearly a 100% of patients receiving mini-allogeneic transplants achieve donor engraftment within 2 months of transplant. Graft failure/graft rejection occurs at 2 to 4 months post transplant in approximately 15% of mini-allogeneic recipients. We hypothesize that loss of donor grafts in non-myeloablative stem cell transplant (NST) recipients can occur due to rejection of the donor cells by recipient T cells and/or low numbers of donor stem cells in the graft resulting in secondary graft failure. The aim of this proposal is to develop methods to evaluate graft rejection and determine the mechanisms responsible for late donor graft failure in recipients of NST. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: HEART FUNCTION FOLLOWING TREATMENT OF HODGKIN'S DISEASE AND RADIATION Principal Investigator & Institution: Chen, Ming Hui.; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: HEMATOLOGIC MALIGNANCY PROGRAM Principal Investigator & Institution: Forman, Stephen J.; Director; Beckman Research Inst of City of Hope Helford Building Duarte, Ca 910103000 Timing: Fiscal Year 2003; Project Start 07-FEB-2003; Project End 30-NOV-2007 Summary: The purposeof the Hematologic Malignancy Program is to develop laboratory-based treatment programs that will lead to improvements in long-term, disease-free survival following allogeneic or autologous bone marrow transplantation and widen the applicability of the therapy. This progress is dependent upon the development of novel therapeutic programs to decrease relapse and to prevent complications of the therapy. During the previous funding periods, we completed a series of Phase I, II and III trials in both allogeneic and autologous transplantation which have led to improvements in the outcome for patients with hematologic malignancy. These include allogeneic transplant trials in leukemia; graft-versus-host disease and CMV infection; and autologous transplant in Hodgkin's disease, multiple myeloma, AML and lymphoma. During this time, progress in our understanding the immunology of CMV has facilitated the development of peptide-based immunization trials to control CMV infection after transplantation. The first trials utilizing retroviral-mediated gene transfer of ribozymes that convey resistance to HIV were performed for patients undergoing autologous BMTfor HIV lymphoma. In addition, programs in hematopoiesis and tumor immunology focused on leukemia and lymphoma were also developed. Importantly, the construction of the Center for Biomedicine and Genetics was planned and completed. This biologic production facility enables us to perform novel clinical studies utilizing radioimmunotherapy for treatment of leukemia and lymphoma, genetic modification of T cells targeted to leukemia and lymphoma andgene therapy trials in HIV lymphomautilizing AAV and lentivirus. The work accomplished in the previous funding period, the clinical expansion of the program and the introduction

Studies

27

of new investigators will allow us to achieve our goals for the next funding cycle which include: 1. To improve the longterm, disease-free survival of patients with hematologic malignancy undergoing allogeneic or autologous hematopoietic stem cell transplantation. 2. To use novel interventions for genetic manipulation of hematopoietic cells, radioimmunotherapy,antigen specific T-cell immunotherapy and peptide immunizations to accomplish these goals. 3. To develop Phase I and Phase II clinical trials that can be tested in larger patient populations or in comparative trials in the cooperative group setting. The 48 members of the Hematologic Malignancies program have published 403 articles, book chapters, etc., since the last competitive grant review. Of these, 209 are intraprogrammatic and 173 are interprogrammatic publications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: HOST IMMUNITY TO EBV INFECTION IN VITRO AND IN VIVO Principal Investigator & Institution: Thorley-Lawson, David A.; Professor of Pathology; Pathology; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2003; Project Start 01-SEP-1981; Project End 31-JAN-2008 Summary: (provided by applicant): The long term objective of this study is to develop a deeper understanding of persistent infection with Epstein-Barr virus (EBV). EBV has the capacity to drive the proliferation of resting B lymphocytes and this makes it a risk factor for human cancers such as Hodgkin's disease, Burkitt's lymphoma, immunoblastic lymphoma and nasopharyngeal carcinoma. However, the virus is able to persist in a quiescent state in vivo where it specifically targets resting memory B cells. By understanding how EBV can persist in most individuals without causing disease we hope to gain insight into what goes wrong when the virus does cause neoplastic disease. This study wilt employ sophisticated cell fractionation techniques and quantitative RealTime DNA and RT PCR assays to address four unresolved issues around EBV persistence. 1. Does acute EBV infection, infectious mononucleosis (AIM), represent a disordered state of EBV infection or simply an amplified version of the stable, long term carrier state? 2. Does EBV, like other herpesviruses, shut off the expression of all protein coding genes when it reaches its final site of persistence - long lived memory B cells in the peripheral blood? 3. What is the nature and origin of the latently infected memory cells proposed as the site of EBV persistence? Are they bona fide memory cells? Does antigen play a role in the production and/or maintenance of these memory cells or do latent proteins perform these functions? How rapidly do the infected cells turn over? 4. Are epithelial cells of the nasopharyngeal lymphoid system e.g. tonsils infected with EBV in vivo or infectable in vitro? Previous studies have analyzed EBV infection of epithelial cell lines and tissues from sites other than the site of persistent infection - the nasopharyngeal lymphoid tissue. However, epithelial tissues are biologically diverse so we will focus our studies on the biologically relevant epithelium from the tonsil. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: HUMAN GAMMA HERPES VIRUS DNA VACCINES Principal Investigator & Institution: Dittmer, Dirk; Oklahoma Medical Research Foundation Oklahoma City, Ok 73104 Timing: Fiscal Year 2001 Summary: Human gamma herpesviruses include Epstein-Barr virus (EBV or HHV- 4) and Kaposi's Sarcoma herpesvirus (KSHV or HHV-8). Both are oncogenic and have a chronic latent phase of infection, which leaves humans hosts infected for life. We hope to adapt the current knowledge of these viruses to develop DNA vaccines. Our purpose

28

Hodgkin’s Disease

is to facilitate the elimination or relative suppression of Kaposi's sarcoma (especially in AIDS patients), as caused by KSHV, and of the latent EBV infection found in normals or expressed in some lymphomas, Hodgkin's disease, nasopharyngeal carcinomas, posttransplant lymphoproliferative disease, and infectious mononucleosis. These are over 150 gene products from which to select the targets for a DNA vaccine, as measured by the number of open reading frames in EBV and KSHV. We plan to begin this project (Specific Aim 1) by constructing DNA vaccines directed against four viral gene products, the TSAs ("tumor specific antigens"): LANA (latency associated nuclear antigen) and v-cyclin form KSHV and LMP-1 ((latent membrane protein) and LMP-2A from EBV. The immunogenicity and optimal vaccination strategy will be evaluated and developed in Balb/c mice (Specific Aim 2), where suppression of the transformed phenotype is expected using appropriately engineered vectors with, the 10(3) cell line. (Additional modifications may be needed for LMP-2A, which is the only one of the four TSAs not known to be oncogenic.) Finally, in preparation for future human studies we will test the DNA vaccines in non-human primates (Specific Aim 3). The suppression of EBV-induced lymphomas by the DNA vaccines will be assessed in Cotton top tamarins. Similarly, the acceleration of KSHV elimination will be assessed in DNA vaccine immunized Rhesus macaques. This experience and the immunologic evaluations performed will hopefully be preparatory for a successful trial of one or more of these gamma herpes virus vaccines in man. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: IMMUNE CONTROL OF EPISTEIN BARR VIRUS IN HODGKINS DISEASE Principal Investigator & Institution: Ambinder, Richard F.; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2001 Summary: EBV nucleic acids and antigens are commonly detected in association with the tumor cells of Hodgkin's disease. Abnormal immune function has long been recognized in patients with Hodgkin's disease but there has not yet been any systematic attempt to study EBV infection and the immune response to EBV in patients with Hodgkin's disease. We will study patients with newly diagnosed EBV(+) and EBV(-) Hodgkin's disease seen at the Joint Center for Radiation Therapy in Boston to determine: (i) the EBV load in peripheral blood lymphocytes, (ii) the CD8 cytotoxic immune response to a panel of EBV latency antigens expressed in Hodgkin's disease, (iii) the CD4 proliferative and cytokine responses to a panel of EBV latency antigens. This study will be the first comprehensive study of EBV and Hodgkin's disease, and will provide information crucial to characterizing the interplay between the viral infection, the immune system and tumorigenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: INFECTION

IMMUNE

CONTROL

OF

LATENT

GAMMAHERPESVIRUS

Principal Investigator & Institution: Blackman, Marcia A.; Associate Member; Trudeau Institute, Inc. Saranac Lake, Ny 12983 Timing: Fiscal Year 2003; Project Start 01-DEC-2002; Project End 30-NOV-2007 Summary: (provided by applicant): Gammaherpesviruses, such as Epstein Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus are important human pathogens, associated with lymphoproliferative disorders and various maligancies, including

Studies

29

Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma and Kaposi's sarcoma. The initial lytic infection is efficiently cleared, but the virus establishes life-long latency, effectively hiding from the immune system. Periodic viral reactivation occurs sporadically, but is kept in check by host mechanisms of immune control. CD8+ T cells have been shown to be important for control of EBV, but the mechanisms are poorly understood. In the current proposal, we will exploit a new mouse model, murine gammaherpesvirus-68, MHV-68, to study basic mechanisms of immune control of this important class of viruses. Accumulating data from our laboratory and others show that MHV-68 latency is harbored in multiple cell types and anatomical sites. Therefore, an essential first step in characterizing immune control is to characterize reservoirs of latency, and determine mechanisms for maintaining the latent load, which will be addressed in Aims 1 and 2 of the current proposal. Taking this information into account, we will then examine immune mechanisms for controlling latency and preventing viral recrudescence in Aim 3. This is important for human health, as loss of immune control as a consequence of AIDS or post-transplant immunosuppression is associated with increased latent load and the onset of disease. The availability of an easily manipulated experimental mouse model is a major advance in the field, and allows fundamental mechanisms to be addressed. It is anticipated that the basic information gathered in this proposal will provide insight into the mechanisms of immune control of the clinicallyrelevant human gammaherpesviruses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: IMMUNOTHERAPY FOR EBV POSITIVE HODGKIN'S DISEASE Principal Investigator & Institution: Lucas, Kenneth G.; Assistant Professor; Pediatrics; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2003 Summary: (Provided by applicant): Patients with chemotherapy-refractory Hodgkin's disease (HD) have few treatment options. Approximately 40 percent of all cases of HD have been shown to be associated with Epstein Barr virus (EBV), characterized by a type II Latency pattern of infection and expression of fewer EBV antigens than in Latency III tumors. Previous studies have established that adoptive immunotherapy for EBVinduced lymphoproliferations in stem cell transplant and organ transplant patients (Latency III infections) with EBV-specific cytotoxic T lymphocytes (CTL) can lead to remission of disease. It is possible that similar strategies would be successful for Latency type II disorders. The objective of this study is to examine the clinical and immunologic effects of infusing donor-derived, EBVspecific CTL from HLA identical or haploidentical donors for patients with relapsed/refractory, EBV-positive HD. The spectrum of the EBV antigens recognized by the CTL preparation and from patient T cells postinfusion will be determined, as well as levels of EBV specific CTL precursors (CTLp) by limiting dilution analysis (LDA). The therapeutic outcome will be assessed with clinical and radiographic endpoints and will be correlated with the level of donor/host HLA disparity, CTL reactivity against Latency II antigens, and levels of EBV CTLp postinfusion. We will track the infused CTL using PCR assays for short tandem repeats (STR). While the initial group of patients will receive EBV CTL without prior immunosuppression, subsequent cohorts of patients will receive a single CTL infusion following fludarabine, which will be used as an immunosuppressive agent to facilitate lymphoid engraftment. Since immunosuppression may increase the risk of graft vs. host disease, the CTL infusates and patient blood specimens will be examined for the presence of donor-derived, recipient specific T cells by LDA. To assess risk for CTL rejection, LDA will also be performed on post-infusion blood specimens to detect host-

30

Hodgkin’s Disease

derived CD4 and CD8 cells with reactivity against donor antigens. This study will provide information on 1) whether therapy with allogeneic EBV specific CTL has clinical efficacy against EBV-positive HD; 2) if effective, whether this is correlated with effector cells specific to EBV latency type II antigens, and 3) if not effective, whether the failure is associated with a short half-life of the infused CTL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-ASSOCIATED MALIGNAN Principal Investigator & Institution: Yang, Yiping; Medicine; Duke University Durham, Nc 27706 Timing: Fiscal Year 2002; Project Start 12-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): Dr. Yang?s long-term career goal is to pursue translational research in the development of novel therapies for the malignancies. His immediate term career objective is to explore antigendefined immunotherapeutic approaches for Epstein Barr virus (EBV)-associated malignancies. EBV(+) tumors offer a unique opportunity to develop antigendefined immunotherapeutic strategies because specific EBV antigens expressed in tumor cells can serve as validated targets for T cell mediated specific tumor killing. The overall objective of this proposal is to study methods of immune manipulation targeting EBV-associated tumors, specifically nasopharyngeal carcinoma (NPC) and Hodgkin?s disease (HD). Strategies to be pursued include: 1) an antigen-specific cell vaccine to induce or enhance specific T cell responses in patients with NPC; 2) ex vivo expansion of antigen-specific T cells from patients with HD or NPC using dendritic cells transduced with self-inactivating recombinant lentiviral vectors of interest; and 3) combination of in vivo vaccination and ex vivo expansion strategies in NPC patients. Success in ex vivo expansion will lead to an adoptive immunotherapeutic trial. These EBV-associated tumors are seen as models for other tumors in which tumor specific antigens have been identified and the development of novel therapeutic approaches. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: IMPROVED RETROVIRAL GENE THERAPY IN AIDS LYMPHOMA Principal Investigator & Institution: Zaia, John A.; Director, Virology and Infectious Diseas; City of Hope National Medical Center Duarte, Ca 91010 Timing: Fiscal Year 2001 Summary: Project V will evaluate HIV vector-mediated delivery of anti-HIV ribozyme genes into stem cells, followed by autologous stem cell transplantation (ASCT) for the treatment of AIDS lymphoma. This project will specifically address the issue of safety in HIV-vector application using novel methods for vector modification and production. In addition, improved assays for detecting helper-virus contamination in vector preparations will be established. For gene therapy-based ASCT in AIDS lymphoma patients, this project will develop anti-HIV-1 ribozymes designed for use not only for the improvement of safe vector production, but also for eventual anti-viral effect in the clinical study. The study of the HIV vector and the efficacy of the anti-HIV ribozymes delivered by the vector will be evaluated in transduced CD34+ cells derived from AIDS lymphoma patients in preclinical studies. Finally, a clinical trial of HIV-vector transduced ASCT will be completed in a study of AIDS- related non-Hodgkin's lymphoma and Hodgkin's disease. Methods for the production of helper free HIV vectors will utilize ribozymes that target HIV sequences that are not included in the

Studies

31

vector and sequences of VSV-G that are crucial to vector packaging. The candidate HIVvector chosen for clinical trial will have been exhaustively analyzed for absence of helper virus. In addition to protection of the production lot from contamination with helper virus, this vector will also encode anti-HIV ribozymes that could potentially have activities in vivo against HIV-1 infection and influence long-term survival This project will advance the theme of the Program by seeking to improve the outcome of transplantation for hematologic malignancy. In addition, interactions of Project II, Project IV, and Project V, in which HIV-vectors and AAV- vectors are evaluated for stem cell gene delivery, will permit a comparison of these vectors within a similar patients groups for transduction efficiency, cell engraftment, and duration of transgene expression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: IN VIVO SOMATIC MUTATIONS IN CHILDREN WITH CANCER Principal Investigator & Institution: Finette, Barry A.; Pediatrics; University of Vermont & St Agric College 340 Waterman Building Burlington, Vt 05405 Timing: Fiscal Year 2001; Project Start 30-SEP-1998; Project End 29-SEP-2002 Summary: (Applicant's Description): The primary objective of this proposal is to complete a 3 component career development plan that will result in the applicant's acquiring the necessary skills and experience to develop an independent translational research program investigating the genetic mechanisms responsible for malignant transformation in children. The 3 components of this plan are: 1) a one-year comentorship with two senior cancer researcher scientists who will provide him with the guidance and expertise required to complete the academic and research portion of his training: 2) a didactic program that focuses on specific areas of cancer biology; and 3) a transition segment from colleague/mentor to independent research scientist and collaborator during the independent research portion of his proposal. The principal research objectives of this proposal are to investigate the molecular mechanisms and biologic consequences of in vivo somatic genetic events responsible for pediatric malignancies. The hypothesis of the applicants is that somatic mutational events in children with cancer will occur at a higher frequency and with a unique mutational spectra compared to a normal population. The specific aims which will test the proposed hypotheses are: 1) to determine the frequency and mutational spectra of background and t h erapy induced in vivo somatic mutations in children with specific malignancies (acute lymphocytic leukemia [ALL], Hodgkin's disease, neuroblastoma, and sarcomas) and where possible, to correlate these molecular events with subsequent diseases: 2) to determine if "illegitimate" V(D)J recombinase mediated mutations occur at a known cancer gene, p53; and 3) to isolate and identify T-lymphocyte imitator phenotype clones from children with relapsed ALL who have an extremely high frequency of background somatic mutations. The frequency of somatic mutational events will be determined by the hprt T-cell cloning assay. Mutational spectra of hprt and p53 mutations will be determined by a variety of methods including multiplex PCR, RT-PCR, IPCR, Southern blotting and DNA sequencing. Clonality of hypermutable clones will be determined by RFLP analysis of TCR gamma and CDR3 region DNA sequence analysis of TCR-beta. These studies will provide the first data on the frequency and mutational spectrum of in vivo spontaneous or treatment induced somatic mutations in children with specific malignancies. The investigators will also begin to determine the potential mutagenic effects associated [with] background "illegitimate" V(D)J recombinase mediated events in a known cancer gene, p53. In addition, the isolation of mutator phenotype clones will allow for future m e chanistic studies

32

Hodgkin’s Disease

characterizing the genetic and biologic defect(s) associated with leukemogenesis in children. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: MENTORED DEVELOPMENT AW

PATIENT

ORIENTED

RESEARCH

CAREER

Principal Investigator & Institution: Sampson, John H.; Medicine; Duke University Durham, Nc 27706 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2005 Summary: (Adapted from the applicant's abstract): The brain is the most frequent site of crippling and incurable human disease, and malignant primary brain tumors alone are more common than Hodgkin's disease, and cause more deaths than cancer of the bladder or kidney, leukemia, or melanoma. Conventional therapy for malignant brain tumors is ineffective and incapacitating, and represents the most expensive medical therapy per quality- adjusted life-year saved currently provided in the U.S. At the investigators institution, direct injection of (131)I-labeled, operationally-specific, monoclonal antibodies (MAbs) into brain tumor resection cavities delivers extremely high radiation doses to tumor cells around the resection cavity and has produced promising results in Phase II clinical trials. However, these MAbs diffuse only short distances beyond the cavity. Therefore, most of the radiation extending beyond the cavity is not specifically targeted to tumor cells and the radiation dose delivered beyond the cavity declines exponentially from the cavity interface. As a result, tumor cells that are known to infiltrate the brain for significant distances beyond the cavity are subopitimally treated and lethal tumors always recur within 2cm of the radiated resection cavity. Continuous microinfusion is a promising technique that allows homogeneous delivery of even large molecular weight molecules at high concentrations throughout large areas of the brain. Although this technique may enhance the delivery of (131)I-labeled MAbs and other therapeutic agents to diffusely infiltrating malignant brain tumors and reduce recurrence rates, the parameters that govern this technique and its limitations have not been defined. One of the major goals of this proposal is to define these parameters. In addition, this proposal is designed to investigate whether targeted radiotherapy might be improved through the use of human chimeric MAbs with increased biostability and the use of high linear energy transfer radioisotopes, such as (211)At, with greater relative biological effectiveness. The hypothesis to be tested in this proposal is that continuous microinfusion will widely deliver operationally tumorspecific MAbs conjugated to (131)I or the alpha-emitter (211)At such that they will be specific and potent therapeutic agents against malignant brain tumors with major reductions in toxicity to normal brain over conventional whole brain radiotherapies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: MHC CLASS II RESTRICTED EBV PEPTIDES AND CD4 T CELLS IN CANCER IMMUNOTHERAPY Principal Investigator & Institution: Wang, Rongfu; Associate Professor; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Weak cytotoxic T lymphocyte (CTL) responses against the EBV antigens EBNA1, LMP1 and LMP2 have been observed in Hodgkin disease, Burkitt lymphoma and nasopharyngeal cancer, but have been insufficient to eradicate tumor cells. Thus, a broadly effective anti-EBV-tumor immunotherapy, based

Studies

33

on MHC class I-restricted peptides, is lacking. The central hypothesis to be tested in Project 2 is that immunogenic MHC class Il-restricted peptides from EBNA1, LMP1 and LMP2 (especially) are present in EBV-positive tumor cells and can be used to improve the priming and activation of CD8+ T cells, leading to more potent antitumor immunity. This prediction will be tested by direct stimulation of human PBMCs with computerpredicted peptides or, alternatively, in HLA-DR or DP transgenic mice deficient in MHC class II molecules (Aim 1), followed by efforts to improve the immunogenicity of the most promising peptides (Aim 2) and then by clinical evaluation in Hodgkin disease and neuroblastoma patients (Aim 3), in collaboration with the leaders of Projects 1 and 3.This combination of strategies is designed to detect the majority of immunogenic MHC class II-restricted peptides (or their variants) with enhanced potency for eliciting T cell responses. With these characterized epitopes in hand, it will be possible to consider novel ways to enhance immune responses against EBV-associated tumors and perhaps against other malignant diseases as well. Frequent interactions with other investigators in the program will be essential to a successful conclusion of this project, and will be particularly evident during years 4 and 5, during clinical evaluation of promising peptide vaccines. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: MOLECULAR BIOMARKERS AS PREDICTORS OF HODGKIN'S DISEASE Principal Investigator & Institution: El-Zein, Randa; Epidemiology; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): A major concern for Hodgkin's Disease (HD) survivors is the development of recurrence or second primary tumors. Although factors responsible for the unfavorable outcomes and poor survival of HD patients remain incompletely understood, the population at highest risk seems to be genetically predisposed. In this proposal we propose to evaluate a panel of susceptibility biomarkers as predictors of disease outcome in an existing cohort of 254 HD patients for whom demographic, epidemiological, clinical data and pretreatment blood samples are available. We will test the hypothesis that unfavorable outcomes occur more frequently in patients with poor DNA repair capacity (measures by increase chromosome instability) and with adverse genotypes (polymorphisms in DNA repair and cell cycle control) as compared with patients with favorable outcome. Specifically we propose: 1) To collect follow-up information on health and vital status data to ascertain endpoints (recurrence or second primary tumors) for all the HD patients in the cohort; 2) To phenotypically characterize the role of background chromosomal instability (measured by chromosome aberrations and sister chromatid exchanges) in disease recurrence or development of SPTs. We hypothesize that patients with poor outcomes exhibit higher levels of baseline chromosomal damage than patients with favorable outcome. 3) To elucidate the role that specific polymorphisms in DNA repair capacity genes (XRCC1, XPD and XRCC3) and cell cycle control (p53 gene) play in the modulation of HD outcome. We hypothesize that individuals with DNA repair allelic variants have altered DNA repair capacity and increased risk of developing recurrence or SPT. Similarly, the allelic variants of p53 gene are associated with variant proteins that may alter cell cycle control encouraging progression either by inducing genomic instability and DNA misrepair or by permitting survival of mutants which will in turn have a negative impact on outcome; and 4) To analyze epidemiological and biomarker data independently and jointly as predictors of recurrence and development of SPTs.

34

Hodgkin’s Disease

Identification of subgroups of HD patients who are at increased risk for recurrence or second primary tumor development has both clinical and prognostic relevance. The high risk population can be targeted for intensive preventive and early detection strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: MOUSE MODELS FOR HUMAN CANCER Principal Investigator & Institution: Dove, William F.; Professor of Oncology and Medical Geneti; Oncology; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-MAR-2004 Summary: A group of experienced investigators in cancer genetics and human cancer virology at the University of Wisconsin have organized a set of projects that would synergize with the MMHCC. These projects include de novo derivations of mouse models for ductal pancreatic carcinoma, cervical carcinoma, uveal melanoma, and Hodgkin's Disease. Further, these investigators propose the further development of extant mouse models for intestinal neoplasia and retinoblastoma leading to validation against the corresponding human disease. More globally, it is proposed to broaden the range of mouse models displaying genetic instability, including deficiencies in doublestrand break repair and G-T mismatch repair. These deficiencies will be studied within the set of tissue-specific mouse models for cancer, seeking acceleration of the pathogenetic process within the one-year lifespan of the mouse. Finally, two initiatives of technology development are proposed. One seeks high-resolution MRI imaging at 9.4 Tesla in order to follow directly the regression of mouse tumors whose sizes are often in the mm range. The second seeks a way to develop fluorigenic markers by which to characterize the distinct cell types of the normal intestinal epithelium, document the source of tumors under different genetic and environmental conditions, and crossreference between mouse and human tumors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: MUTATIONS W/ SECONDARY LEUKEMIA FOR HODGKINS OR CHILDHOOD BRAIN TUMOR Principal Investigator & Institution: Halperin, Edward C.; Duke University Durham, Nc 27706 Timing: Fiscal Year 2001 Summary: In this protocol, we seek to determine the frequency of chromosome aberrations in peripheral blood lymphocytes specifically associated with iatrogenic acute myelogenous leukemia using chromosome painting techniques following radiotherapy and/or chemotherapy used in the treatment of Hodgkin's disease and childhood brain tumors. We are also using blood samples from these patients to study toxicological response to carcinogen, exposure and gene rearrangements associated with deregulation of a growth promoting oncogene. Through these techniques, we hope to develop predictive assays for treatment-induced second malignant neoplasms which may lead to an improved understanding of this complication of cancer treatment and, perhaps, preventive and therapeutic strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

Studies

•

35

Project Title: NEOMYCIN RESISTANT GENE CTLS IN PTS WITH EBV+ HODGKIN'S Principal Investigator & Institution: Heslop, Helen E.; Professor; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2001 Summary: The primary objective of the study is to determine the safety of 2 IV injections of autogously derived EBV specific cytotoxic T-lymphocytes that have been marked with the Neomycin resistnace gene introduce by a retroviral vector. The two injections will be given at day 0 and day 14 and the three dose levels of interest are discussed in Section 6.1 of the protocol. Buring the coused of the study, the survival, immunological efficacy and anti-tumor activity of neomycin resistance gene marked EBV specific cytotoxic T-lymphocyte lines will also be studied. This is a classical phase I study to obtain the optimal dose level in a dose escalation trial. The results of this study will not be definitive but only suggestive and a Phase II trial will be undertaken to study the efficacy of the treatment after determining the safe dose level. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: NEUROLOGICAL PARANEOPLASTIC SYNDROMES Principal Investigator & Institution: Posner, Jerome B.; Professor of Neurology; SloanKettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2001; Project Start 01-APR-1990; Project End 30-JUN-2005 Summary: (Adapted from the Investigator's Abstract): Paraneoplastic syndromes are believed to be immune-mediated disorders caused by the ectopic expression of a neuronal antigen in a non-neuronal cancer e.g. Lung or ovarian cancer. The immune system identifies the ectopically expressed neuronal antigen as "foreign" and mounts an immune attack that affects both the cancer and the nervous system. Although rare, paraneoplastic syndromes are important neuroimmunologically, in that unlike multiple sclerosis, the causal antigens are known. The goal of this application is to understand the pathogenesis of paraneoplastic syndromes because such understanding may lead to more effective therapy of the neurologic disorder and the cancer that causes them. Understanding paraneoplastic syndromes may also help us better understand the pathogenesis of other neurologic autoimmune disorders such as multiple sclerosis. To achieve these goals, both clinical and laboratory investigations are planned. The investigators will continue to probe serum (and when available cerebrospinal fluid and tumor tissue) of patients suspected of suffering from paraneoplastic syndromes. To search for novel autoantibodies, they will continue to probe their serum bank, which contains over 3500 specimens of patients with cancer and/or putative paraneoplastic syndromes. The goal is to find new autoantibodies, discover if they are associated with a particular neurologic picture and with a particular underlying cancer. They will attempt to characterize the antigen(s) recognized by these antibodies by cloning their genes from central nervous system libraries. To compliment the antibody studies, patients suffering from paraneoplastic syndromes will be assayed for cytotoxic T-cells whose receptors recognize the paraneoplastic antigens. They will continue to search tumor and when available neural tissue to characterize the T-cell response in paraneoplastic disorders. In the clinic, they want to expand prospective analysis of patients with small cell lung cancer and add patients with Hodgkin's disease, testicular and ovarian cancer to discover how many harbor paraneoplastic autoantibodies and how that affects their neurologic status as well as the clinical course of their cancer. In addition to routine

36

Hodgkin’s Disease

evaluation, antibody studies and haplotyping will be performed and the patients will be followed serially during treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: NEW ENGLAND PEDIATRIC ONCOLOGY CONSORTIUM Principal Investigator & Institution: Ferguson, William S.; Rhode Island Hospital (Providence, Ri) Providence, Ri 02903 Timing: Fiscal Year 2002; Project Start 01-JAN-1981; Project End 31-DEC-2002 Summary: The specific aims of the New England Pediatric Oncology Consortium (NEPOC) are: Development and enhanced productivity of a consortium of regional pediatric cancer centers (Brown University/Rhode Island Hospital; Dartmouth University/Dartmouth-Hitchcock Medical Center; Harvard University/Massachusetts General Hospital; SUNY at Stony Brook/Children's Medical Center at Stony Brook; University of Vermont/Medical Center Hospital-Vermont Regional Cancer Center) for the purposes of: A. Contributing to the understanding and treatment of children and adolescents with malignancies through: 1. Input into national cooperative studies through membership in the Pediatric Oncology Group (POG): a. Patient accrual: Achieve significant number and quality of patient entries on protocols; b. Study development and evaluation: Assist in the development of new protocols through committee memberships, institutional reviews of proposed protocol designs, analysis of study results, and proposal of new protocols for POG implementation based on NEPOC studies; c. Administration: Accept responsibilities for POG administrative functions. 2. Cooperative efforts within NEPOC (New England Pediatric Oncology Consortium) in studies of joint interest in the areas of childhood malignancies, particularly toward developing potential pilot studies for POG. B. Enhancement of the care of children and adolescents with cancer in the geographical areas served by the member institutions through: 1. Assuring comprehensive and modern management of children and adolescents with malignancies as a benefit of membership in POG; 2. Sharing staff expertise and investigative facilities at each of the member institutions; 3. Joint efforts in promotion of education of the local community in the area of cancer in children and adolescents. Through a centralized administration, this Consortium integrates the activities and resources (staff, facilities, patients) at each institution into a single program aimed at achieving these goals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: NYUMC-AIDS-RELATED MALIGNANCY CONSORTIUM Principal Investigator & Institution: Takeshita, Kenichi; Dermatology; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2001; Project Start 30-SEP-1995; Project End 31-JUL-2002 Summary: This proposal is for New York University Medical Center (NYUMC) to continue to participate as a member of the NCI-sponsored AIDS- associated Malignancies Clinical Trials Consortium (AMC). The specific aims of this proposal are: 1) To help design, develop and participate in multicenter Phase I and II clinical trials using novel agents and/or innovative approaches for the treatment of patients with AIDS-associated malignancies; 2) To provide well characterized tissue specimens to the recently established AIDS Malignancies Bank (AMB) including: cryopreserved tumor tissue, sera, peripheral blood mononuclear cells (PBMC), bone marrow, and other body fluids from individuals with AIDS-related Neoplasms such as Kaposi's sarcoma (AIDSKS), non- Hodgkin's lymphoma (NHL), Hodgkin's Disease (HD), multicentric angio-

Studies

37

lymphoproliferative hyperplasia (Castleman's Disease), anogenital or cervical dysplasia and carcinomas. These permanently stored specimens would be made available to other members of the AMC and other investigators in the research community at large for future clinical, epidemiologic, virologic and molecular biological research. NYUMC is an NCI-designed Cancer Center. NIAID supported AIDS- Treatment Evaluation Unit (ATEU), and an NIH sponsored Center for AIDS Research (CFAR) to which patients from the greater New York area are referred. NYUMC has served as a major referral center for HIV-infected individuals from the greater New York area. We continue to see a substantial number of patients with AIDS- related malignancies. Investigators at our institution have an established track record for patient accrual and the performance of clinical treatment trials in a well supported setting. Because of the decrease in patients with AIDS-related malignancies seen in the USA, attributed in part to the use of combination, highly active, antiretroviral therapy (HAART), we have recently enlisted the referral of appropriate patients from investigators at Beth Israel and Northshore Hospitals to participate in the AMC trials performed at the NYUMC. A newly formed health management organization (HMO) which will care for more than 10,000 HIV/AIDS clients on Medicaid in NYC has also agreed to refer suitable patients to our AMC clinical trials. Scientists and physicians at NYUMC are dedicated to basic and clinical research on the etiology, pathogenesis and treatment of HIV-disease, especially AIDS-KS, AIDS-NHL and anogenital neoplasia during the past 17 years including participation in the AMC trials since its inception in 1995. These studies have contributed to the development of potentially innovative approaches for the treatment of these neoplastic disorders, which tend to be more aggressive and difficult to manage in AIDS patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: OVERCOMING TUMOR IMMUNE EVASION STRATEGIES IN HODGKIN'S LYMPHOMA Principal Investigator & Institution: Rooney, Cliona M.; Associate Professor; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): The malignant B-lineage Reed-Sternberg (H-RS) cells in about half of all cases of Hodgkin lymphoma express Epstein-Barr virus (EBV) antigens, rendering this tumor highly attractive for cytotoxic T-lymphocyte (CTL) immunotherapy. However, these tumor-associated viral antigens are either subdominant (LMP1 and LMP2) or not presented to the immune system (EBNAI and BARFO). The H-RS cells also express molecules that are inhibitory to CTL, such as TGFbeta, the chemoattractant TARC and Fas-ligand that can comprise immunotherapy even when immune epitopes are effectively presented to CTLs. The studies proposed here seek to overcome these immune evasion tactics by redirecting immune responses to the LMP2 viral antigen, using LMP2a-transduced dendritic cells, and by genetically modifying CTLs in vitro so that they will resist the inhibitory effects of TGF-beta and Fas ligand. The latter aim will rely on a transgenic dominant-negative TGF-beta type 2 receptor expressed on CTLs and the adenoviral RID protein, which should render CTLs resistant to inhibition by TGF-beta and killing through Fas ligand-receptor interactions. Our preliminary studies suggest that there may be few T helper epitopes in LMP2. Since persistence in vivo is dependent on the availability of help, we will also explore the possibility that EBNA1, expressed as a retrogen in dendritic cells (using technology developed in project 4) will reactivate EBNA1-specific CD4+ T cells that can provide cognate help for LMP2-specific CTL as well as broaden the cytotoxic repertoire of the

38

Hodgkin’s Disease

tumor specific CTL by reactivating CD4+ EBNA1-specific CTL. The hypotheses underlying these aims will be tested both in vitro and in vivo (Phase l/ll trials in patients with post-transplant or relapsed EBV-positive Hodgkin Lymphoma). Upon successful completion of the project, we will have learned whether our experimental modifications are safe in patients and whether they will render CTLs resistant to several of the immune evasion strategies commonly used by tumor cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Grier, Holcombe E.; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-1986; Project End 31-DEC-2002 Summary: The principal activity of this grant is to improve the care and treatment of children with cancer by participating in the Pediatric Oncology Group (POG). The three specific goals of the participation of the Dana-Farber Cancer Institute/Children's Hospital (DFCI/CH) and Maine Children's Cancer Program (MCCP) are to 1) enter and follow children with malignancies on appropriate Pediatric Oncology Group (POG) protocols 2) provide leadership in planning and executing POG protocols and 3) provide pilot clinical studies and scientific leadership to POG. 1) Patient entry: the referral patterns at the two institutions has not changed and the commitment to POG protocols remains high. Therefore, patients accrual will continue at the high level previously noted over the last grant period. 2) Leadership within POG: Drs. Weinstein and Grier respectively are the disease chairs for the Myeloid and Sarcoma Committees. The disease committee chairs have primary responsibility for all scientific and clinical activities within POG. Investigators from these institutions are currently or were in the last cycle chairs for 7 separate POG protocols and co chairs of 35 more. They also have 18 positions on disease or discipline committees within POG. Enthusiasm remains strong, and involvement at the current level will continue. 3) Pilot POG protocols and scientific leadership: Scientific leadership is detailed in part above. Dr. Arceci provided scientific leadership for and analyzed the samples of the MEC protocol (#9222) that piloted the use of multidrug resistance reversal agents (cyclosporine) in relapsed AML. This protocol provided the background for the about to open group wide AML up-front protocol (#9394) that will randomize whether or not patients will receive cyclosporine during maintenance therapy. DFCI ALL protocols have provided the background for one of the arms of the proposed new T- cell protocol (#9404). In addition, the background for the current stereotactic protocol (#9373) was in part developed at the Joint Center for Radiation Therapy and the DFCI. Finally, POG has embarked on a major effort to study the autologous transplant protocols for ALL (#9421) developed at the DFCl. Finally Dr. Lipshultz ran at DFCI/CH the pilot studies of late cardiac toxicity from anthracyclines that provides the background data for the randomized trial of enalapril for patients with elevated after load. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Luchtman-Jones, Lori; Pediatrics; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2001; Project Start 01-JAN-1978; Project End 31-DEC-2002 Summary: The Washington University Medical Center in St. Louis is one of the 39 full member institutions, 48 affiliate, 12 consortia and 9 CCOP institutions of the Pediatric

Studies

39

Oncology Group who has pooled their patient resources and scientific expertise to study the natural history of childhood cancer, develop and compare effective therapeutic regimens and investigate the toxicity and effectiveness of new anticancer agents in the treatment of children with cancer. Additionally tumor specimens and occasionally normal tissue and blood samples are collected to determine more about the basic cancer biology and pathology of the disease. Group studies are ongoing in epidemiology, cancer control, pharmacology and pharmacokinetics. The investigators at the Washington University Medical Center include pediatric oncologists, radiologists, radiation oncologists, cytogenetists, neurologists, surgeons, and pathologists. All children with malignant disease are placed on cooperative group protocols if they are eligible and if informed consent is obtained. Data accessioned at the time the patient is placed on study protocol, during the study, and when off therapy is submitted to the Group Statistical Office for data analysis, interpretation and eventual publication. The investigators at Washington University Medical Center serve in multiple administrative and research capacities for the Group. The diagnostic studies, pathological findings, surgical procedure and therapeutic plan for all new patients and patients who relapse are discussed at the weekly Tumor Board Conference. The Principal Investigator has a phase I contract and works with 16 other POG institutions to establish the maximum tolerated dose of a new agent along with the pharmacology and, if indicated, the biologic response of the agent. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Ravindranath, Yaddanapudi; Pediatrics; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2001; Project Start 01-JUN-1981; Project End 31-DEC-2002 Summary: This proposal is a request for funding for our continued involvement in the Pediatric Oncology Group (POG). The aims and objectives are to find better means of management for malignant diseases in children and adolescents, and thus increase disease-free survival rates. The Children's Hospital of Michigan (CHM) provides diagnostic evaluation and multimodal therapy for children throughout the State of Michigan. While there is one other Pediatric Oncology facility in the State, the Hematology/Oncology service sees almost all children and adolescents with malignant disease who live in the greater metropolitan Detroit area, and also sees large numbers of such children referred from other parts of the State (and from Canada) regardless of their ability to pay. Until 1979, the oncology service at CHM remained "independent". In September 1979, the CHM oncology team joined the pediatric division of the Southwest Oncology Group and in January 1981 joined the Pediatric Oncology Group, which appears to have even a greater potential for development of better treatment regimens for childhood malignant disease. At the time of referral and/or admission to CHM for possible malignancy, each child is seen and evaluated by the appropriate oncology team members. Following appropriate diagnostic evaluation, each child is presented and discussed at the Tumor Board, which meets weekly and is attended by pediatric oncologists, pathologists, radiologists, surgeons, surgical subspecialities, and radiotherapists. A plan of action is outlined for each child's management. All such children are registered with POG, and whenever judged appropriate, children are entered on POG treatment protocols. By our participation in such a cooperative children's cancer group, our investigators are able to share new information and ideas and gain access to new multimodal therapy regimens and investigational drugs which hopefully provide the best available care to these children. Our objectives in the coming

40

Hodgkin’s Disease

years are: 1) increased participation in POG cancer biology and epidemiology studies; 2) to continue our leukemia biology studies particularly pharmacology studies in AML/T ALL, and 3) to develop new strategies for treatment of brain tumors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Kung, Faith H.; Associate Professor; Pediatrics; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 92093 Timing: Fiscal Year 2001; Project Start 01-JUL-1980; Project End 31-DEC-2002 Summary: This proposal represents a request to support continued participation in the pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic, immunological and molecular biological approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant disease free survival has been achieved and contributions have been made in clinical pharmacology, tumor immunology and biology of cancer. However the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG led in the investigation in the immunophenotyping of acute lymphoblastic leukemia, NTX polyglutamates accumulation in leukemic cells, and N-myc gene amplication in neuroblastoma, correlated the findings with patient outcome, and then incorporated them in new treatment protocols designed to improve the survival of children with cancer. The Division of pediatric Hematology/Oncology at the University of California, San Diego has 24 years experience (10 years in CALGB and 14 in POG) in cooperative clinical trials. In the past 5 years the 4 consortium member institutions had entered 332 patients on both therapeutic and non- therapeutic studies and the satellites, 211 patients. Our investigators served on 12 committees, designed/coordinated 16 group protocol studies. We also contributed to 15 group publications/presentations. Our investigators will continue to design and chair therapeutic protocols,and serve on committees. Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Steuber, C P.; Pediatrics; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2001; Project Start 01-JAN-1978; Project End 31-DEC-2002 Summary: The concept of the pediatric cooperative cancer group was introduced over 30 years ago because of the rarity of pediatric malignant diseases and the vital importance of controlled trials to improve the outcome for such patients. For such a group to succeed, the collaborative contributions of individuals from a large variety of specialties and fields of research are absolutely essential. This multimodal organized approach to the treatment of childhood cancer through the cooperative group has welldemonstrated its value. The Section of Pediatric Hematology-Oncology at Baylor College of Medicine has been involved in the genesis of this kind of clinical research and

Studies

41

has participated in the activities at even level. The current goals of the Section regarding cancer prevention, treatment, and research have lead to the recent development of the Texas Children's Cancer Center. The Center is a joint effort of Texas Children's Hospital and Baylor College of Medicine and is committed to providing the finest possible patient care, education and research in the areas of pediatric and adolescent cancer and hematological disorders. Major expansion of the clinic and research lab facility is underway. New faculty are being recruited to expand the current research program in the areas of gene therapy, bone marrow transplantation, molecular biology, clinical pharmacology, and experimental therapeutics. Additional personnel including data managers, pediatric nurse practitioners, and research personnel have been recruited to support the new faculty members and the expanded programs. In addition, outreach efforts are making the Center known to communities in Texas that would benefit from a service dedicated to the treatment of children with cancer. The development of the Texas Children's Cancer Center will enhance Baylor's contributions to the Pediatric Oncology Group (POG) by expanding the research and treatment programs that have so successfully contributed to POG throughout the years, by developing new and innovative treatment and research programs, and by increasing study populations for those programs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Breitfeld, Philip P.; Pediatrics; Duke University Durham, Nc 27706 Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The goal of the proposed research is to determine optimum care for children with all types of cancer. The research mechanism involves participation by pediatric investigators in a consortium of medical institutions in North Carolina and West Virginia in collaborative multidisciplinary clinical cancer research protocols generated through the Pediatric Oncology Group. The proposed research grant will allow for the continued participation of Duke University Medical Center, Charlotte Memorial Hospital, East Carolina University School of Medicine and West Virginia University School of Medicine in Pediatric Oncology Group activities. These activities involve studies of the epidemiology and tumor biology of selected neoplasms and the natural history and optimum multimodal therapy of all childhood malignancies. Cooperative studies among physicians from a group of medical centers allow for rapid accrual of a statistically significant number of children with cancer in order to define quickly both those avenues of biologic research which have immediate clinical relevance and those therapeutic approaches which provide prolonged disease-free survival. Through participation in cooperative studies, the entire medical community engaged in the care of children with cancer has a focal point to provide not only improved patient care but also improved multidisciplinary teaching and research. Our objectives for the coming years are: 1) to develop new protocols for the immunologic stratification and chemotherapeutic management of patients with malignant lymphoproliferative and myeloproliferative disorders; 2) to develop protocols for specific brain tumor therapy which take advantage of our expanding knowledge of the biology and pharmacologic sensitivity of human brain tumors in vitro and in vivo; 3) to expand our studies of the pharmacologic agents which influence intermediary metabolism, using our in vitro data as the basis for drug scheduling in clinical trials; 4) to expand our innovative groupwide epidemiology studies to include studies of neuroblastoma and T-cell malignancies which include laboratory investigation (immunologic, biochemical and cytogenetic)

42

Hodgkin’s Disease

where relevant; 5) to expand our multidisciplinary therapeutic research efforts in other pediatric malignancies; and 6) to expand our outreach programs for patient care and education through our regional consortium. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Cohn, Susan L.; Associate Professor of Pediatrics; Children's Memorial Hospital (Chicago) Chicago, Il 606143394 Timing: Fiscal Year 2001; Project Start 01-DEC-1978; Project End 31-DEC-2002 Summary: The objectives of this project are to enroll children with cancer in clinical trials, to develop clinical trials and study the biologic behaviors of childhood cancer, and to improve and evaluate the disease- free survival of patients enrolled in these clinical trials. In order to achieve these goals, the member institutions of the Pediatric Oncology Group (POG) meet biannually to discuss, develop, and implement clinical trials for the most common childhood malignancies and to supply the reference research laboratories of the proper material or tissue necessary for the research. Since 1989, CMH has been one of the member institutions of POG who is actually involved in the accrual of children with cancer to clinical trials. CMH's faculty is also involved in the coordination of studies either as the Principal Investigator or co-Investigator. These protocols are POG 9443, POG 9240/41/42, POG 9135/6, POG 9410, NTWS #5. Participation in administrative activities within POG include the POG Chairperson, the POG Executive Officer, the Head of the Neuroblastoma Biology Committee, the Head of the Neuroblastoma Bone Marrow Transplant Working Group, along with members of the following committees: Non- Hodgkin's Lymphoma, Neuroblastoma, Bone Marrow Transplantation, Hodgkin's Disease, New ALL, Wilms' Tumor, Nursing, and Surgery, Radiotherapy, and Pathology Disciplines. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Link, Michael P.; Professor; Pediatrics; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The overall goal of this research proposal is for Stanford University, the University of Arizona, and the Kaiser Permanente Medical Centers of the South San Francisco Bay Area to continue their active involvement in Pediatric Oncology Group research activities. Stanford faculty and the University of Arizona faculty have already assumed key leadership positions in POG and have or have had major roles in the scientific and administrative aspects of the Group. Further, Stanford, the University of Arizona, and Kaiser have maintained excellent performance ratings in their participation in POG studies and have received commendations for the large numbers of evaluable patients placed on therapeutic protocols. Specifically: l) We plan to continue to enter patients on appropriate POG studies where they exist. The number of patient entries from Stanford has increased each year as appropriate POG studies become available. We anticipate that between 65 and 80 patients will be entered on front-line therapeutic studies each year from Stanford in addition to patients who will be entered from the affiliates; in addition, 40-50 patients or more will be entered on POG non-therapeutic studies. 2) We anticipate that the activities of individual investigators from Stanford and the University of Arizona will continue and increase during the period of this research proposal. Currently, our faculty serve as study coordinators for

Studies

43

front- line therapeutic studies in lymphoma and leukemia, and they have coordinated and analyzed data from recently closed protocols in osteosarcoma, lymphoma, leukemia, and Ewing's sarcoma. Our faculty also serve key scientific and administrative roles as Group Vice Chair, Disease and Discipline Committee Chairmen and CoChairmen, as members of Disease and Discipline Core Committees, and as members of the Executive Committee. Thus, our faculty are in position to influence the future direction of the scientific activities of POG. 3) We anticipate that involvement of Stanford faculty in the laboratory scientific activities of POG will continue. The laboratories of Drs. Link and Cleary have served as immunology reference laboratories and molecular biologic reference laboratories for leukemia studies of POG. 4) We anticipate that non-POG related laboratory and clinical research conducted at Stanford University and its affiliates will become increasingly relevant to POG activities. Some of these activities have already been incorporated into POG laboratory and therapeutic studies and others are targeted for incorporation into future POG studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Lauer, Stephen J.; Professor of Pediatrics; Pediatrics; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 01-JAN-1978; Project End 31-DEC-2002 Summary: The Pediatric Oncology Program at Emory University is the only comprehensive children's cancer center in Georgia and one of the largest of its kind in the Southeast. It serves a racially, ethnically, and socioeconomically diverse population from metropolitan Atlanta, the State of Georgia, and other states including Alabama, Arkansas, the Carolinas, Florida, and Mississippi. Since the inception of the Pediatric Oncology Group (POG), Emory is consistently one of the largest single-institution contributors to POG clinical and laboratory studies. Emory is a center for Phase I and pilot POG trials and has initiated numerous protocols that have subsequently been implemented by POG. The specific aims of the Emory POG Program are: l) to continue as a major source of patients for POG-sponsored Phase I, pilot, groupwide, and intergroup studies; 2) to provide leadership by its investigators as POG Study Coordinators, Co- coordinators, and Core Committee members; 3) to develop innovative institutional clinical trials on which to base future POG investigations; and 4) to maintain strong basic and translational research programs in pediatric oncology. To address these aims, Emory investigators are Coordinators for several major POG studies, including standard-risk new ALL (#9405), high-risk new ALL (#9006), salvage chemotherapy in relapsed neuroblastoma (#9140), and chemotherapy vs. autologous bone marrow transplantation (ABMT) in AML (#8821). Emory POG members actively participate in POG Core Committees, Subcommittees, and new protocol development. Institutional pilot studies include therapy of relapsed AML with idarubicin and chlordeoxyadenosine, treatment of relapsed solid tumors with high-dose busulfan/melphalan and ABMT, transplantation of haploidentical CD34+ cells for relapsed ALL or AML, and vincristine plus dose-escalated cyclophosphamide and infusions of peripheral blood-derived progenitor cells in refractory solid tumors. Complementary laboratory research activities include molecular biology of ALL (mechanisms of IL-6- mediated autocrine growth and aberrations in tumor-suppressor genes); in vitro sensitivity of leukemia cells to antineoplastic agents mid biological response modifiers; mechanisms of resistance of AML cells to alkylating agents; molecular neuro-oncology; and xenogeneic models to evaluate normal and neoplastic human hematopoiesis. Investigators at Emory are participating in the POG laboratory

44

Hodgkin’s Disease

study of methotrexate metabolism by ALL cells (ALinC #16) and coordinate the study of alterations in p53 tumor-suppressor gene pathways in relapsed ALL (SIMAL #l0). Taken together, these activities of the Emory POG Program will continue to contribute to our knowledge of the biology, therapy, and prevention of neoplastic diseases in infancy, childhood and adolescence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Meyer, William H.; Pediatrics; University of Oklahoma Hlth Sciences Ctr Health Sciences Center Oklahoma City, Ok 73126 Timing: Fiscal Year 2001; Project Start 01-JAN-1978; Project End 31-DEC-2002 Summary: Children's Hospital of Oklahoma (CHO) at the University of Oklahoma is a member institution of the Pediatric Oncology Group. One of our primary goals is the enrollment of the majority of pediatric patients with cancer in the state of Oklahoma in a cooperative cancer program (POG). Participation in group studies guarantees optimal care for these patients and the opportunity to study in depth the natural history of childhood cancer, develop effective therapeutic regimens, and evaluate the toxicity. and effectiveness of new anti-cancer agents in the treatment of childhood cancer. In addition to the POG studies, institutional non- therapeutic protocols have been developed, i.e., evaluation of leukemic therapy on the central nervous system of newly diagnosed leukemic patients and longitudinal evaluation of coping mechanisms with stress among patients and parents of children with cancer. For all these programs, patient resources and scientific expertise are available in Children's Hospital of Oklahoma. The team at the University of Oklahoma is multidisciplinary. It consists of pediatric hematologistsoncologists, radiation therapists, radiologists, pediatric surgeons, immunologists, pathologists and psychologists. All protocols are reviewed by the Institutional Review Board and informed consent is obtained on all patients entered into these protocols. Protocol compliance remains a high priority. The evaluability rate for the last four years averaged 92.5%. St. Francis Hospital of Tulsa was previously considered a branch of CHO. At the request of the POG Operations Office, Tulsa has applied to become an affiliate institution. The University of New Mexico is also affiliated with the University of Oklahoma. It serves an economically disadvantaged population (native American Indians) which needs to be included in the population studied by cooperative cancer groups. The Pathology Department at the University of New Mexico has special expertise in molecular diagnostic hematopathology and in solid tumors which can benefit the research efforts of the Pediatric Oncology Group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Castleberry, Robert P.; Professor of Pediatrics; Pediatrics; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2001; Project Start 01-MAR-1979; Project End 31-DEC-2002 Summary: The University of Alabama at Birmingham (UAB) is a leading contributor to the ongoing clinical and basic research activities of the Pediatric Oncology Group (POG) which are focused upon improving the care and cure for children with cancer. Current results of these trials are in some cases already published and are available in the Progress Report. The leadership from UAB in POG is evident in several areas: l) through enrollment of substantial numbers of assessable patients on Phase I, II and III therapeutic trials, including multidiscipline (surgery, chemotherapy, and radiotherapy)

Studies

45

management studies; through participation in and development of Group-wide biological studies of selected hematopoietic and solid malignancies; through evolving, coordinating and reporting data from POG therapeutic trials; and by providing discipline and disease committee, and administrative leadership within the group. UAB will continue to enroll all eligible patients on active POG therapeutic and biological studies, including phase I investigations, and maintain high evaluability. UAB investigators will continue to coordinate clinical trials for children with neuroblastoma, bone tumors, and juvenile chronic myelogenous leukemia (JCML) and to assess the therapeutic utility of IL6. Further, UAB investigators will be principal to the development of new studies in neuroblastoma, brain tumors, JCML and acute myelogenous leukemia. UAB will continue to supervise laboratories for POG in the following areas: 1) Banded chromosomal analysis in newly diagnosed patients with lymphoid leukemia; 2) A required reference laboratory for children with JCML (POG #9265) studying the pathogenesis of myeloproliferation; 3) A required serum/plasma repository (POG #9047) with clinical and demographic data referenced on a computer data base; and 4) A non- mandatory reference laboratory to evaluate the biological and clinical significance of rnicrotubular associated protein (MAP) and tubulin isotype expression in neuroblastoma. UAB investigators will continue their scientific and administrative leadership roles on the Neuroblastoma and Other Embryonal Tumors, Myeloid Disease Core, Biologic Response Modifier Core, Executive, Principal Investigator Core, Clinical Research Associate Core, and Diagnostic Imaging Core Committees. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Kavan, Petr; Montreal Children's Hospital 2300 Tupper St Montreal, Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The Pediatric Oncology Group (POG) is a multi-disciplinary, multiinstitutional research community which collaborates to increase knowledge of and improve treatment for cancer and leukemia in children and adolescents. The Montreal Children's Hospital/McGill University (MCH), a founding member, requests funding for itself and its two affiliates, the Children's Hospital of Eastern Ontario (CHEO) and the University of Sherbrooke Medical Center (USMC) to continue to participate fully in administrative and scientific activities of the POG during the next 5 years. We expect to enroll a total of 70 patients a year on therapeutic protocols for childhood leukemias, lymphomas, solid tumors and brain tumors, with continued emphasis on Phase I and II studies of new agents and coordination or co-coordination of a minimum of 13 protocols. We expect to enroll 110 patients per year on non-therapeutic studies of cancer etiology, epidemiology, biology, psychologic impact and late effects of therapy with particular emphasis on the pharmacology and molecular pharmacology of methotrexate in acute lymphoblastic leukemia (ALL). We will comply with all requirements of the POG constitution, with MR regulations governing ethical conduct of clinical research and with OPRR and IRB requirements for informed consent and protection of subjects from research risks. In addition to an anticipated doubling of patient accruals since 5 years ago, our major contributions to POG research will include: confirmation that the extent of accumulation of methotrexate polyglutamates by lymphoblasts in B-progenitor cell ALL correlates with event-free survival (EFS) and characterization of the mechanisms regulating this metabolism (Whitehead); promotion of new agent drug development through New Agents and Pharmacology Committee leadership

46

Hodgkin’s Disease

(Whitehead and Bernstein) and protocol coordination (Bernstein, Baruchel); introduction of stereotactic and fractionated stereotactic radiation therapy in brain tumors (Freeman); coordination of treatment protocols of newly-diagnosed and relapsed B-progenitor cell ALL (Abish, Bernstein); introduction of new agents and combinations in recurrent lymphoid disease as Sub-committee Chair, Lymphoid Relapse (Bernstein); chemotherapy and surgery of brain tumors (Baruchel, Ventureyra); and study of the biology, including p53 gene mutations, and treatment of HIV-related lymphomas (Baruchel, Whitehead). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP ACTIVITIES Principal Investigator & Institution: Buchanan, George R.; Pediatrics; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2001; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: This grant application seeks continued support for the Pediatric Oncology Group (POG) activities of The University of Texas Southwestern Medical Center (UT Southwestern) Consortium, which consists of UT Southwestern (Dallas), Cook-Ft. Worth Children's Medical Center (Ft. Worth), and Scott & White Clinic (Temple). Since joining POG in 1981, this partnership of children's cancer treatment and research centers in North Texas has grown to become POG's largest contributing member with regard to patients enrolled on therapeutic studies (over 100 annually). During the current grant cycle, consortium investigators have held administrative and scientific leadership positions on major Group committees, including Executive Committee, Principal Investigator's Committee, New ALL Committee, T-cell Committee, and Lymphoid Relapse Committee. UT Southwestern Consortium investigators have also served or are serving as study coordinators on multiple POG treatment protocols studying ALL (newly diagnosed patients with B-lineage and T-cell disease as well as following relapse), non-Hodgkin's lymphoma, bone marrow transplantation and new agents being explored in Phase I-II trials. UT Southwestern Consortium investigators have also had prominent roles in the arenas of data management, protocol development, molecular and pharmacologic monitoring in authorized POG reference laboratories, and supportive care. Results of pilot projects conducted at UT Southwestern have been instrumental in the construct of group-wide treatment strategies, especially involving use of methotrexate for B-lineage ALL. To support the UT Southwestern Consortium's continued commitment to POG research during the next 5 years, this new grant proposal describes personnel and facilities in the 3 consortium centers. Specifically, during 1996-2000 the Consortium aims to advance POG research by: (l) enrolling as many patients as possible on POG treatment, biological classification, and epidemiology protocols; (2) collecting, recording, and submitting research data in an accurate and timely fashion; (3) providing administrative and scientific expertise to the Group through continued active participation on major committees, including service as disease committee chairs and protocol coordinators; and (4) continuing to conduct innovative in-house pilot studies for subsequent use by the Group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: PEDIATRIC ONCOLOGY GROUP MEMBERSHIP Principal Investigator & Institution: Schwartz, Cindy L.; Associate Professor; Oncology Center; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 01-JUL-1980; Project End 31-DEC-2002

Studies

47

Summary: The aim of this research is to improve the treatment of childhood cancer through participation in organized clinical trials with fellow members of the Pediatric Oncology Group. In addition, we intend to expand our understanding of these diseases by collaborative laboratory investigations. Multiple projects are described which reflect the intense commitment of our faculty to work within the Pediatric Oncology Group. Our faculty are leaders of the POG commitments in ALL phenotyping, Neuropathology, Bone Tumors, Hodgkins disease, Rhabdomyosarcoma, Radiation Oncology, Bone Marrow Transplantation, Myeloid disease, Germ Cell Tumors, Late Effects of Childhood Cancer Therapy, and Multiple Drug Resistance. Pediatrics is the program that describes patient accrual and protocol activity within the division of Pediatric Oncology at Johns Hopkins under the supervision of Dr. Cindy Schwartz as POG PI. The disciplines of Radiation Oncology, Pathology, Pediatric Surgery, Orthopedic Surgery, Neurosurgery and Nursing also play a major role in patient accrual and protocol activity. In addition, Fairfax Hospital under the direction of Dr. Jay Greenberg is an active affiliate of our institution. With the limited numbers of children admitted with any single oncologic diagnosis to an individual institution, it is clear that cooperative clinical research is required if significant advances are to be made. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP PARTICIPATION Principal Investigator & Institution: Pui, Ching-Hon; Acting Chairman; St. Jude Children's Research Hospital Memphis, Tn 381052794 Timing: Fiscal Year 2001; Project Start 01-JAN-1982; Project End 31-DEC-2002 Summary: We propose continued participation in the Pediatric Oncology Group (POG). Our goals are as follows: (1) to improve cure rates for children with cancer through participation in Phase I, II, and III clinical trials designed to test new agents or concepts; and (2) to participate in laboratory-based research aimed at clarifying the basis of drug resistance and pathogenetic mechanisms of childhood cancers. We are committed to Group participation because we believe: (1) that collaborative efforts are both desirable and necessary for study of childhood cancers, since all are relatively rare; and (2) that well-designed randomized clinical trials provide the most definitive test of efficacy and general applicability of new therapies and that pooled intellectual resources are advantageous as well. Our contribution to the Group can be categorized as follows: (1) contribution of selected patients (those with rare tumors or less common stages of other cancers, n approximately 80-100/year) to Group studies; (2) administrative and scientific leadership (e.g., disease or discipline committee chairs, and protocol coordinators); (3) provision of multiple reference laboratories (flow cytometry analyses of leukemia and solid tumors, cell bank, AML cytogenetics, pharmacokinetics/pharmacodynamics, molecular genetics of leukemia and solid tumor); (4) regular presentation of results of in-house research to the group. Since our center has an unusually large number of patients and staff (both clinical and basic), the latter contribution assumes unusual importance. We have an extensive in-house developmental therapeutics program which is independent of, but complementary to, the Group's clinical research programs. We also have extensive programs in basic research. The aim of these programs, to determine the pathogenesis of pediatric neoplasia, is expected to positively influence the Group's central goal -- curing children with cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

48

Hodgkin’s Disease

•

Project Title: PEDIATRIC ONCOLOGY GROUP STUDIES Principal Investigator & Institution: Chauvenet, Allen R.; Pediatrics; Wake Forest University Health Sciences Winston-Salem, Nc 27157 Timing: Fiscal Year 2001; Project Start 01-APR-1991; Project End 31-DEC-2002 Summary: The overall objective of the proposed research effort is to continue work towards determining the optimum care for children with all types of cancer. The research mechanism involves participation by pediatric investigators at the Bowman Gray School of Medicine in the development and execution of collaborative multidisciplinary clinical protocols of the pediatric Oncology Group. The proposed research grant will support the continued participation of the Bowman Gray School of Medicine as a full member of the pediatric Oncology Group. Our accomplishments in the past grant period are described in detail in the proposal. Our institutional goals for the five year period of this grant include: (1) continuing our high level of patient accrual and excellent clinical contributions to the POG including our outstanding patient evaluability and protocol compliance which has merited a letter of commendation from the operations office at every 6-month analysis in the past (2) maintaining our institutional involvement in POG leukemia studies and our representation on the new ALL core committee (3) continuation and further development of our multi-disciplinary institutional commitment to POG Hodgkin's disease activities (4) a major role on the POG cytogenetics committee including optimal use of our new reference laboratory status (5) increased institutional development of late effects studies in collaboration with the POG late effects efforts (6) expansion of our efforts in neuro-oncology including increased enrollment on brain tumor studies and investigator roles on the POG brain tumor committee (7) use of in situ studies of tumor cell ploidy in collaboration with POG and other investigators (8) continued contributions to the administrative aspects of the POG. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: CANCER CTR

PEDIATRIC

ONCOLOGY

GROUP--MIDWEST

CHILDREN'S

Principal Investigator & Institution: Camitta, Bruce M.; Pediatrics; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532264801 Timing: Fiscal Year 2001; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The primary objective of the Midwest Children's Cancer Center is to reduce the incidence of and mortality from childhood cancers. This is approached by: 1) providing the best possible patient care (diagnostic and therapeutic; 2) education of medical and nonmedical groups as to the types of, treatments for, and availability of care for different childhood cancers; and 3) clinical and laboratory research. Investigators at the Cancer Center include specialists in pediatric oncology, surgery, orthopedic surgery, neurosurgery, radiology, radiation therapy, pathology, neurology, psychology and nursing. All new patients are discussed at a multidisciplinary Tumor Board. The children are then treated on Pediatric Oncology Group (POG) or institutional protocols. Results are analyzed and reported regularly. The purpose for the Midwest Children's Cancer Center's participation in POG are: l) to enhance the probability of achieving the above objectives by collaboration with other institutions in the design and execution of clinical protocols; and 2) to evaluate, through laboratory investigations, aspects of tumor biology which result in successful and unsuccessful therapy. Pediatric tumors are relatively rare. The POG is composed of more than 50 member institutions. By pooling resources, biologic and therapeutic studies on these uncommon tumors are

Studies

49

facilitated. Similar collaboration permits more rapid development of new drugs. In addition, participation in a common milieu promotes dissemination of information between institutions and investigators. If all children with cancer receive the best possible care, morbidity and mortality will be minimized. The Midwest Children's Cancer Center has been a major contributor to POG by: 1) patient accrual; 2) coordination of POG protocols; 3) institutional pilot studies that were advanced to POG studies; and 4) participation in POG disease and administrative committees. In the next grant period we will continue each of these activities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM Principal Investigator & Institution: Barredo, Julio C.; Professor; Pediatrics; Medical University of South Carolina 171 Ashley Ave Charleston, Sc 29425 Timing: Fiscal Year 2001; Project Start 15-JUN-1996; Project End 31-DEC-2002 Summary: (Adapted from the applicant's description): The institutions included in this proposal have been part of the Pediatric Oncology Group (POG) and received good performance scores during the past five years. There are two primary goals of this proposed research; the first is to accrue patients to the Group clinical trials in order to determine the optimal care of children with all types of cancers. The second is to contribute scientific expertise to the Group in areas of both patient care and tumor biology. This proposed research will allow participation in POG activities through a consortium effort of East Carolina University (ECU) School of Medicine, Carolinas Medical Center, Medical University of South Carolina (MUSC), Greenville Hospital, Presbyterian Hospital, and Memorial Mission Hospital (The Carolinas' Consortium). In addition to these clinical activities, their scientific efforts in next five years will include: (1) development of new protocols for the treatment of children with cancer focusing mainly on pediatric lymphomas; (2) expansion of studies of minimal marrow residual disease (using RT-PCR analysis) and assessment of new purging techniques in neuroblastoma; (3) participation in the laboratory evaluation of folylpolyglutamate synthetase (FPGS) in lymphoblasts of newly diagnosed patients; and (4) evaluation of the role hematopoietic growth factors in the treatment of pediatric malignancies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: PREDIAGNOSIS EBV--EBV GENOME STATUS OF TUMOR BIOPSY IN HODGKINS DISEASE Principal Investigator & Institution: Levin, Lynn I.; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2001 Summary: The focus of Project 2 is to integrate the pre-diagnosis Epstein- Barr virus (EBV) serology in relation to the molecular status of Hodgkin's disease (HD) cases in order to elucidate the interplay of host and viral factors in the pathogenesis of this disease. We will conduct a nested case-control study of incident cases and matched controls from the Army-Navy Serum Repository (ANSR) which contains specimens from over 3 million men and women from the United States uniformed services. We expect a total of 200 cases and 200 controls. Tissue blocks from all cases will be tested for EBV genome status. These data will be evaluated for consistency with three models of HD pathogenesis: 1. The EBV is solely related to EBV-genome positive HD with EBVgenome negative disease due to non-viral causes; 2. HD is a virally induced malignancy with the EBV responsible for EBV- genome positive disease and another unidentified

50

Hodgkin’s Disease

virus(es) linked to EBV-genome negative disease; 3. The EBV plays a crucial early role in the pathogenesis of essentially all HD cases but the genome is selectively lost in some patients. Both case-case and case- control serologic comparisons will be done. We will also evaluate the consistency of pre-diagnosis and post-diagnosis serum samples frog cases. By integrating the, EBV serologic profile preceding diagnosis and molecular data of a large series of cases, we should move forward in describing the natural history of this disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: PROTEOMICS SOFTWARE PACKAGE FOR THE DETECTION OF CANCER Principal Investigator & Institution: Sasinowski, Maciek; Incogen, Inc. 263 Mclaws Cir, Ste 200 Williamsburg, Va 23185 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 30-SEP-2003 Summary: (provided by applicant): This SBIR project proposes the development of a software package containing bio-computational tools to facilitate accurate diagnosis of cancer based on classification of proteomics data obtained through mass spectrometry (MS). The software will accept MS data produced from a wide range of instruments but is specifically targeted toward MALDI/SELDI TOF analysis (Applied Biosystems, Ciphergen). The Phase I work will focus on exploring the applicability of various existing and modified statistical approaches for signal conditioning (Wiener filters) and classification (linear discriminant analysis, principal components analysis, support vector machines, Bayes method) of SELDI data derived from analysis of sera from individuals with pediatric Hodgkin's disease and acute myeloid leukemia. A software package to perform this task does not currently exist; therefore, the proposed research has significant potential for technical innovation. Cross-validation will be used to obtain an unbiased estimate of the performances of the classifiers. The TRIFT II equipment at the ARC (W&M) will be used to provide high-resolution MS TOF SIMS data to calibrate the SELDI equipment at EVMS. The Phase II project will leverage the research and proof-of-concept tools developed in Phase I to produce a commercial software package that will be licensed to researchers, as well as equipment manufacturers for inclusion with their instruments. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: SURVIVORS

PSYCHOSOCIAL

OUTCOMES

IN

CHILDHOOD

CANCER

Principal Investigator & Institution: Zebrack, Brad J.; Assistant Professor; Pediatrics; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 08-FEB-2001 Summary: The purpose of this proposal is to further understanding of the prevalence, characteristics and predictors of the psychosocial health status, health risk behaviors and neurological sequelae of long-term survivors of childhood cancer. The research proposed in this application will make use of the Childhood Cancer Survivor Study, a multi-institutional collaborative project that has established and followed a retrospectively-ascertained cohort of long-term survivors of childhood cancer and 6,000 sibling controls. This is the largest sample of well-characterized childhood cancer survivors and sibling controls known to date. Previous work suggests that certain subsets of childhood cancer survivors are vulnerable to a variety of physical and

Studies

51

psychosocial problems, but the generalizability of these findings are limited by small sample sizes, data derived from single institutions, and lack of a control group. Furthermore, study in this field has yet to identify critical variables that influence (1) long-term survivors' psychosocial problems, but the generalizability of these findings are limited by small sample sizes, data derived from single institutions, and lack of a control group. Furthermore, study in this field has yet to identify critical variables that influence (1) long-term survivors' psychosocial status/quality of life, including their experiences with pain, and (2) behaviors that place them at risk for future health problems. The work to be conducted during the period of this functioning, and health behaviors. Physical, psychological, social and neurological factors that potentially influence these outcomes will be investigated. Specific hypotheses related to these outcomes are proposed and potentially moderating and mediating factors will be investigated. Psychosocial support interventions throughout a continuum of care- from diagnosis through treatment and into long-term survivorship-will be suggested. Plans for intervention research will be forthcoming. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: QUALITY OF LIFE IN ADULT CANCER SURVIVORS Principal Investigator & Institution: Carver, Charles S.; Professor; Psychology; University of Miami Coral Gables University Sta Coral Gables, Fl 33124 Timing: Fiscal Year 2001; Project Start 01-SEP-1998; Project End 31-AUG-2003 Summary: (Applicant's Description) This project will examine quality of life (QOL) in adult long-term survivors of cancer (five years or more cancer-free). Given what is seen as a lack of good measures, the project's first goal is to develop a measure of QOL for this group, based on extensive interviews of long-term cancer survivors and on sound principles of test construction. After development of this measure, the second goal will be to assess QOL in a tri-ethnic (Hispanic, non-Hispanic White, and African American) sample of survivors of breast, prostate, colorectal cancers, and Hodgkin's disease, yielding information on normative experiences of long-term survivors, on possible ethnic differences, and on long-term impact of adjuvant therapies. We will also examine this group prospectively, testing factors that may influence further change in their QOL over time. Indeed, studying how differences in personality, social context, coping patterns, etc. influence long-term QOL is the project's third goal, taking advantage of the fact that we have been studying psychosocial adaptation to breast cancer for many years. Women who participated in those earlier studies completed measures of several resilience and vulnerability factors at the time of their cancer diagnosis. Now, 5 to 13 years later, we will return to these women, assess QOL, and use the measures collected earlier to prospectively predict current QOL. We will be able to examine several personal and contextual variables as prospective predictors in this way. The fact that we have this information available on large numbers of women who were treated for breast cancer also permits us to conduct a very different kind of study of survivorship. In particular, we will be able to test these variables (collected early in the cancer experience) as predictors of who survives free from cancer at particular lengths of time after treatment. The idea that psychosocial variables play a role in recurrence (or its absence) is controversial. We will examine several psychosocial variables from our data sets that are relevant as predictors of recurrence. Conducting this research at this time will allow us to make use of - and further solidify - a resource that has been years in building. There is a large cadre of survivors of breast cancer about whom we know a good deal, thanks to their earlier research involvement. These people can continue

52

Hodgkin’s Disease

providing important information about the experience of cancer survivorship and what qualities make the process easier or harder. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: QUALITY OF LIFE OF AFRICAN AMERICAN CANCER SURVIVORS Principal Investigator & Institution: Ferrans, Carol E.; Medical-Surgical Nursing; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2001; Project Start 28-SEP-2001; Project End 31-AUG-2005 Summary: The purpose of this study is to determine the prevalence of long-term effects of cancer and describe their impact on the quality of life and cancer screening behaviors of African Americans. Issues specific to cancer survivorship for African Americans will be examined. Comparisons will be made with African Americans who have not had cancer to identify the differential impact of cancer on African Americans lives. The study will examine quality of life issues for survivors who have been treated for a variety of cancers: leukemia, Hodgkin's disease, colon, breast, and prostate cancer, which will make possible the identification of survivorship issues that are similar across groups, as well as those unique to each. In addition, this study will explore whether there are differences between African American cancer survivors who have participated in clinical trials and those who have not. Specific aims: the primary objective of this study is (1) To identify differences in quality of life between African American cancer survivors and African Americans who have not had cancer, who are similar in terms of age, gender, health insurance status, and education, to determine the prevalence of cancer-related problems and their effects on quality of life and cancer screening behaviors. The secondary objectives are (2) To examine differences in cancer- related problems and quality of life among survivors of different cancers; and to examine the effect of gender on these differences; and (3) To describe the physical, psychological, social, and economic differences between African American cancer survivors who participated in clinical trials and those who did not. This descriptive study has a casecontrol design. The cancer survivor sample (n = 500) will be drawn from completed CALGB clinical trials and cancer registries of selected CALGB institutions with large African American populations. Non-cancer controls (n = 500) will be African Americans who are selected via random digit dialing from the areas in which the cancer survivors reside. The controls as a group will be matched to the survivor group on age, gender, health insurance, status, and education level. Data will be collected by telephone interview and from medical records. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: RACE-SPECIFIC OCCUPATIONAL RISK FACTORS FOR CANCER Principal Investigator & Institution: Briggs, Nathaniel C.; Assistant Professor of Internal Medicine; Internal Medicine; Meharry Medical College 1005-D B Todd Blvd Nashville, Tn 37208 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Black men have overall age-adjusted rates of cancer incidence and mortality that are higher than any other U.S. population group. Findings from the 1996 Report on the National Occupational Research Agenda suggest that unidentified race-specific occupational risk factors for cancer may be important contributors to this disparity. An excess of occupational cancers among minorities is further underscored by a review revealing elevated non-white to white cancer mortality ratios in the majority of studies reporting any race-specific increases, with the greatest

Studies

53

racial disparity evident for hematolymphopoietic cancers. Data are sparse, however, on race-specific etiologic determinants. Moreover, published reports have generally been based on data from death certificates and other secondary sources that are of questionable validity because of racial disparities in accuracy. To address this information gap, the proposed project will use secondary data from the Selected Cancers Study (SCS) to investigate race-specific occupational risk factors for non-Hodgkin lymphoma (NHL), Hodgkin disease (HD), and soft tissue sarcoma (STS). The SCS was a large U.S. population-based case-control study conducted in the mid-1980s to examine associations between exposure of military troops to the defoliant herbicide Agent Orange during the Vietnam War and subsequent risk of these cancers. The study population comprised nearly 6,000 men aged 30 to 60 years, the majority of whom were directly interviewed. Study participants were asked about every full- and part-time job held for greater than or equal to 1 year since age 18. For each job, participants were queried about job title, main duties, type of business or industry, year job was started, and year job was ended; all responses were coded verbatim. In an analysis using dichotomous occupational exposure data from the SCS, we identified striking increases in risk of NHL, HD, and STS among Black men exposed to chromium or wood dust, whereas no risk factors were found for Whites. One aim of this project will be to extend the preliminary analysis to investigate dose-response relations. A second aim will be an extension of that analysis to investigate risk factors among Hispanic men. A third project aim will be to examine race-specific dose-response associations for cancer risks in relation to occupational chlorophenol exposures and agricultural vs. non-agricultural herbicide exposures. A fourth aim will be to explore race- and cancer-specific risk factors based on Standard Occupational Codes and Standard Industry Codes. Because the SCS database includes detailed occupational information for a study population large enough to provide substantial power to detect race-specific occupational cancer risk factors, it provides a unique and cost-effective opportunity to identify preventable risk factors that may be contributing to racial disparities in cancer incidence and mortality. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: RECONSTITUTION OF NK CELL REPERTOIRE Principal Investigator & Institution: Parham, Peter R.; Professor; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 11-JUL-2002; Project End 28-FEB-2007 Summary: Natural killer (NK) cells are lymphocytes that act early in the immune response. They can kill infected and allogeneic cells, secrete cytokines and contribute to inflammation. The actions of human NK cells are regulated by two families of cellsurface molecules, CD94:NKG2 and KIR, which include receptors that bind polymorphic determinants of HLA class I molecules. By differential expression of combinations of these genes, NK cells become highly diversified within each individual. Due to differences in gene number, gene content, and allelic polymorphism of KIR gene haplotypes NK cell receptor repertoires vary within the human population. In addition to possible contributions to alloreactions following transplantation, these properties provide new tools for assessing factors that influence NK cell receptor development. Under test is the hypothesis that NK cell receptor repertoires are genetically determined in patients receiving HLA-matched allogeneic bone marrow grafts. The NK cell repertoires of the donors and of the recipient, before and after transplant, will be characterized. The hypothesis genes encoding the HLA class I ligands play a lesser role. Similar study of autologous transplants will provide a control for effects due to disease

54

Hodgkin’s Disease

and therapy. Another control will come from assessment of NK-cell repertoire differences in healthy siblings having defined and variable degrees of HLA, KIR, and CD94:NKG2 identity. The results will provide valuable information on the nature, development, and reconstitution of the human NK-cell repertoire after bone marrow transplantation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: REGULATION OF EPSTEIN-BARR VIRUS LATENCY Principal Investigator & Institution: Lieberman, Paul M.; Associate Professor; Wistar Institute Philadelphia, Pa 191044268 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): Epstein-Barr virus (EBV) latent infection is associated with several human cancers, including Burkitt's lymphoma, Hodgkin's disease, and nasopharyngeal carcinoma. The latent viral genome exists as a multicopy episome that replicates in synchrony with the cellular chromosomal DNA. Latent cycle DNA replication initiates at OriP and EBNA1 is the only viral protein required for OriPdependent replication and plasmid maintenance. EBNA1 binds to multiple sites in OriP, but has no intrinsic helicase or other enzyme activity associated with DNA replication function. We have used DNA affinity chromatography to isolate and identify several cellular proteins that associate with OriP in an EBNA1-dependent manner. Our preliminary data indicates that these proteins contribute to plasmid maintenance and the regulation of DNA replication. Several of these proteins have known function at human telomeres, including Telomeric Repeat Binding Factor 2 (TRF2), hRap1, and Tankyrase. TRF2 and hRap1 bind telomeric repeats and regulate chromosome stability. We now show that EBNA1 stimulates TRF2 binding to the nonamer repeats (TTAGGG) in the Dyad symmetry region of OriP. Mutation of the nonamer repeats reduced plasmid maintenance function of OriP and sensitizes OriP to genotoxic stress. We propose that the nonamer-binding proteins function as a DNA damage checkpoint that regulates replication of OriP. Failure to regulate replication leads to a loss of stable plasmid maintenance. However, it is not clear how nonamer-binding proteins execute this function. In this application we propose to determine the structural organization of nonamer binding proteins at OriP. We will determine their protein interactions and their ability to effect single strand formation, subcellular localization, nuclear matrix attachment, and DNA looping between regions of OriP. We have also found that nonamer-binding proteins possess poly-ADP ribose activity, and we will determine how NAD levels and DNA damage may regulate the activity of PARP proteins associated with OriP. We will also determine if EBNA1 is a substrate of PARP in vivo, and if this modification regulates replication or plasmid maintenance function. We will investigate the role of nonamer-binding proteins in modifying OriP DNA and/or chromatin structure. Finally, we will determine if nonamers provide a DNA checkpoint function by arresting OriP replication in response to genotoxic stress. We hypothesize that the nonamer-binding proteins increase stability of the latent viral genome by protecting it from catastrophic recombination and degradation. The experiments proposed in this application will reveal important new insights into the mechanism of EBV latent cycle DNA replication and plasmid maintenance, and may have important implication for other latent herpesviruses, as well as the functions of cellular proteins involved in telomere maintenance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

Studies

•

55

Project Title: ROLE OF HERV-K18 SUPERANTIGEN IN EBV LYMPHOMAGENESIS Principal Investigator & Institution: Sutkowski, Natalie A.; Pathology; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): More than 90% of adults are latently infected throughout their lifetime with the ubiquitous herpesvirus Epstein-Barr virus (EBV). While EBV infection is usually asymptomatic during childhood, it is estimated that half of first-time infected adolescents or adults develop infectious mononucleosis, a disease characterized by polyclonal B cell activation and massive expansion of T cells. EBV is an oncogenic virus; it is associated with Burkitt's lymphoma, Hodgkin's disease and nasopharyngeal carcinoma. At least 1% of organ and bone marrow transplant recipients develop EBV+ lymphomas; and EBV lymphoproliferative disorders are common in AIDS patients. The tumors are often associated with vast T cell infiltrates. The SCID/hu mouse is well accepted as an animal model for EBV lymphomagenesis, because SCID mice adoptively transferred with EBV seropositive PBMC from healthy human donors develop EBV+ B cell lymphomas at a high rate. These tumors are strictly T cell dependent and can be prevented by blocking the B-T interaction. We have recently established that EBV transactivates a human endogenous retrovirus, HERV-K18, that encodes a superantigen, which strongly activates T cells. This is the first described report of a pathogen inducing a host cell superantigen. We propose that HERV-K18 Env superantigen activated T cells contribute to EBV lymphomagenesis. This proposal seeks to test whether blocking the superantigen driven T cell response prevents tumorigenesis in the SCID/hu lymphoma mouse model. We propose to block T cell activation by: I. developing monoclonal antibodies specific for the HERV-K18 superantigen; II. blocking CD28/ICOS costimulation; III. induction of T cell anergy; and IV. ligation of immunoinhibitory receptor PD-1. Since several other herpesviruses are associated with superantigen or superantigen-like activity, these experiments may have broad-reaching implications for herpesvirus biology. Overall, these studies represent a completely new approach towards understanding the potential role of T cells in herpesvirus oncogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: SPECIFIC ADOPTIVE IMMUNOTHERAPY OF VIRAL DISEASES Principal Investigator & Institution: Greenberg, Philip D.; Professor of Medicine; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2001 Summary: Studies performed since the last competitive renewal have demonstrated the feasibility of pursuing antigen-specific T cell therapy for treatment of human disease. Methods were developed for isolating and efficiently expanding in vitro CD4+ and CD8+ T cells clones with retention of normal function, and, in a Phase I trail; the adoptive transfer of large numbers of cloned CD8+ T cells specific for CMV was demonstrated to be non-toxic and to reconstitute deficient CD8+ T cell responses to CMV in immunodeficient bone marrow transplant (BMT) recipients. No patient with restored CD8+ T cell immunity developed CMV viremia or disease. In this project, we propose to use this T cell culture technology to determine if adoptive transfer of CMVspecific T cell clones can prevent early and late CMV infection in BMT recipients, and avoids toxicities associated with drug therapy. Several human tumors have been identified that express potentially immunogenic proteins. These include virusassociated malignancies, which provide attractive targets for immunologic therapies,

56

Hodgkin’s Disease

since the viral proteins represent tumor-specific antigens. A subset of patients with Hodgkin's disease express several EBV latent proteins in their tumor cells, and studies are proposed to treat this human malignancy with EBV-specific T cell clones. The specific aims are: 1) to perform a Phase II study of adoptive immunotherapy with CMVspecific T cell clones as prophylaxis for CMV disease in recipients of allogeneic BMT from HLA-matched family members -- the study will include transfer of both cytolytic CD8+ and helper CD4= T cell clones and will examine therapeutic efficacy, immunologic reconstitution, and reduction in the frequency of neutropenia, a toxicity associated with ganciclovir prophylaxis; 2) to perform a Phase II study of adoptive immunotherapy with CMV-specific T cell clones for prevention of late CMV disease (> day + 100 post- BMT) in recipients of allogeneic BMT from HLA-matched unrelated donors--the study will evaluate therapeutic efficacy, long-term immunologic reconstitution, and the feasibility of generating T cells for therapy from unrelated donors; and 3) to evaluate the feasibility safety, and potential efficacy of treating Hodgkin's disease patients with EBV+ tumors by adoptive transfer of CD8+ T cell clones reactive with the EBV-encoded LMP1 or LMP2 proteins expressed in ReedSternberg cells -- this pilot study will examine safety, persistence, localization of transferred CD8+ clones to sites of tumor, and potential antitumor activity in patients undergoing autologous or allogeneic BMT for relapsed/resistant Hodgkins' disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: STUDIES OF EPSTEIN-BARR VIRUS Principal Investigator & Institution: Miller, I George.; John F. Enders Professor; Pediatrics; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2001; Project Start 01-JAN-1979; Project End 31-DEC-2002 Summary: Epstein Barr virus (EBV) is associated with diverse cancers, including nasopharyngeal cancer, non-Hodgkin's lymphoma occurring in immunodeficient individuals, Hodgkin's disease and Burkitt's lymphoma. In all EBV-associated tumors the virus remains in a latent state of limited gene expression. Latency is maintained by regulation of the EBV BZLF1 gene, whose product ZEBRA, a b-ZIP transcriptional activator, obligates the virus to enter lytic replication. Our global objective is to understand the mechanism of this switch between latency and the lytic cycle. Studies of the functions of ZEBRA required for activation of lytic cycle gene expression focus on two groups of mutants that are discordant in their capacity to activate transcription and to disrupt latency. These mutants, containing alterations in the DNA recognition domain or in the accessory activation domain, should point to additional functions that are needed to activate the latent virus. Analysis of the downstream targets of ZEBRA include investigations of DNA context effects that permit a promoter to respond to ZEBRA, identification of cellular genes that are activated by ZEBRA, and identification of cellular and viral proteins that directly interact with the ZEBRA protein. Experiments that explore control of expression of the BZLF1 gene include determination whether Zp and Rp, the two promoters that control BZLF1 transcription, are coordinately or sequentially regulated. Clues to the relative importance of cellular or viral factors in BZLF1 regulation should come from study of well characterized EBV transformed cell lines that differ markedly in their responses to chemical inducing stimuli. The proposed experiments take a biologic perspective and utilize molecular genetic and biochemical techniques to explore a central unsolved question in the pathogenesis of this human tumor virus. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

Studies

•

57

Project Title: TCR TRANSDUCTION FOR EBV SPECIFIC IMMUNOTHERAPY Principal Investigator & Institution: Orentas, Rimas J.; Assistant Professor; Pediatrics; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532264801 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2005 Summary: (provided by applicant): TCR TRANSDUCTION FOR EBV-SPECIFIC IMMUNOTHERAPY. Adoptive immunotherapy with polyclonal cytotoxic T cell lines (CTL) has met with clinical success in the treatment of post-transplant lymphoma, an Epstein-Barr virus (EBV)-associated malignancy that expresses the most immunodominant EBV latency antigens. This strategy is not applicable to two other EBV-associated malignancies, Hodgkin's disease (appx. 50 percent of cases are EBVassociated) and nasopharyngeal carcinoma (100 percent EBV-associated). These malignancies only express the EBV latency antigens LMP-1, LMP-2, and EBNA-1; none of which induce a strong immune response. These represent sub-dominant tumorassociated antigens. The goal of this project is to provide an immunotherapeutic option to patients suffering from these diseases by cloning individual T cell receptor molecules (TCR) that recognize LMP-1 and LMP-2 in an HLA-restricted manner, and introducing these recombinant TCR into HLA-A2 lymphocytes. Toward that goal, CTL clones specific for LMP-2 will be generated, the TCR alpha and beta chains molecularly cloned, and then transferred to retroviral expression vectors. These vectors will then be used to transduce CTL clones of known specificity as well as activated primary lymphocytes in bulk culture. The specific aims of this project seek to determine which TCRs are the best candidates for genetic transduction by comparing the CTL activity of the original cell to the lytic activity newly conferred upon the transduced cell. It remains to be determined whether it is the primary sequence of the TCR or the physiology of the transduced cell that determines the cytolytic activity conferred by the new receptor. We will also determine the structure of the TCR-CD3 complex in transduced cells, and in examining the bulk transduced lymphocyte population determine which cells are capable of expressing the transduced receptor. Should the retroviral vector used in these studies not give long-term expression of the transduced TCR, we also propose a newer generation of retroviral vectors that would be used instead. Once transduced, the newly expressed TCR-alpha and beta chains will have to compete with the endogenous TCR elements for association with the CD3 receptor complex and subsequent transit to the cell surface. Data obtained from this project will allow correlation between levels of retroviral gene transduction, mRNA expression, intracellular protein expression (the assembly of ICR subunits in the endoplasmic reticulum), cell surface expression of transduced TCR, and lytic function to be made. With a better understanding of these first principles of functional ICR assembly in primary lymphocytes, other malignancies with known tumor-associated antigens could be targeted by this approach as well. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: THE EFFECTS OF HAART ON CANCER INCIDENCE IN AIDS CASES Principal Investigator & Institution: Scheer, Susan; San Francisco Dept of Public Health 101 Grove St, Room 308 San Francisco, Ca 94102 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 31-OCT-2004 Summary: (provided by applicant): AIDS-related morbidity and mortality has decreased greatly with the advent and use of highly active antiretroviral therapy (HAART). The incidence of some AIDS-defining cancers (Kaposi's sarcoma and non-Hodgkin's lymphoma) has declined significantly with the widespread use of HAART, while incidence rates of other cancers that are considered to be increased in HIV-infected

58

Hodgkin’s Disease

people (including Hodgkin's disease, cervical cancer and anal cancer) have shown no change in the post-HAART era. To further explore the effect of HAART on cancer incidence at the population level, we propose to match San Francisco AIDS cases diagnosed for the years 1990 through 2000 with California cancer cases diagnosed for the years 1988 through 2000. This match will allow us to examine the effect of HAART on temporal trends in both AIDS-defining cancers and non-AIDS-defining cancer incidence among AIDS patients in San Francisco. We will compare the time before HAART was introduced (1988-Nov 1995) to the years when HAART was widely available (Nov 1995- 2000). In addition, we will assess cancer survival time with immunologic status and clinical presentation of both AIDS-defining and non-AIDSdefining cancers among AIDS patients who use HAART and those who do not. Changes in morbidity and mortality among persons with AIDS are readily apparent in San Francisco, a national metropolitan area with the third most cumulative AIDS cases and a city in which over three-fourths of persons with AIDS have received HAART. The completeness of AIDS case reporting in San Francisco is 97% and follow-up chart review of AIDS cases is completed every 18 months providing up-to-date information regarding treatment use and diagnoses with subsequent AIDS diagnoses. The California Cancer Registry is one of the largest cancer registries in the world with approximately 120,000 new cases reported each year and is internationally recognized for its high quality cancer data. The San Francisco Department of Public Health AIDS registry provides a complete population-based dataset of AIDS cases in San Francisco allowing us to evaluate the impact that HAART use and improved survival with AIDS has on subsequent development of cancers. Given the respective strengths of the AIDS and cancer registries, we are uniquely situated to perform these investigations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: THE IMMUNE RESPONSE TO LATENT GAMMAHERPESVIRUS ANTIGENS Principal Investigator & Institution: Usherwood, Edward; Microbiology Immunology; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755

and

Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2004 Summary: (provided by applicant): This application focuses on the role of CD8+ T cells recognizing latent gammaherpesvirus proteins in the control of the latent infection. Latent infection with human gammaherpesviruses predisposes towards severe diseases such as Kaposi's sarcoma, Hodgkin's disease and lymphoproliferative disease. It is therefore crucial to understand the immunological mechanisms underlying the longterm control of gammaherpesviruses during latency. We propose to examine fundamental mechanisms behind the control of the latent infection in a mouse model, murine gammaherpesvirus. This model is highly tractable for immunological studies, and we have mapped an epitope recognized by CD8+ T cells within the latencyassociated M2 protein. We have also demonstrated that M2-specific T cells can reduce the number of latently infected cells during the establishment of latency. The studies proposed address the mechanism of CD8+ T cell control of latency. Aim 1: We will determine the role of the M2-specific CD8+ T cell response in the control of M2 expression in the latent infection. This aim builds on our preliminary data and seeks to gain a clearer understanding of the induction of the M2-specific CD8+ T cell response and it's role in both the early and long-term stages of the latent infection. Aim 2: We will test the hypothesis that vaccination with M2 can reduce the load of latently infected cells. We will vaccinate mice with M2 to determine if prior immunity to M2 interferes with either the establishment or maintenance of viral latency. We will also test whether

Studies

59

therapeutic vaccination with M2 is possible. Finally we will identify further epitopes in putative latency-associated proteins, with the aim of developing multivalent vaccines incorporating several viral antigens. Data obtained from these studies will contribute to the development of more effective vaccines for gammaherpesviruses. In addition they will increase our knowledge of the host-virus interaction during latent/chronic viral infections in general. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: TOWARDS A MOUSE MODEL OF CLASSICAL HODGKIN'S DISEASE Principal Investigator & Institution: Rajewsky, Klaus; Cbr Institute for Biomedical Research 800 Huntington Ave Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2008 Summary: (provided by applicant): Classical Hodgkin's disease (HD) is the most common lymphoma in the Western World. The malignant cells in HD are the so-called Hodgkin and Reed-Sternberg (HRS) cells, which comprise only a few percent or less of the lymphoma tissue. In roughly half of the patients, the HRS cells are infected with Epstein-Barr-Virus (EBV) and express the EBV-encoded membrane proteins LMP1 and LMP2A. These proteins are constitutively active and in B cells partially mimic signals of the CD40 co-receptor and the antigen receptor (BCR), respectively. Based on these circumstances and on our own molecular analysis of Ig gene rearrangements in micro manipulated HRS cells we have developed a scenario of HD pathogenesis. In this scenario, HRS cells derive in most instances from pre-apoptotic germinal center (GC) B cells rescued by some transforming event(s). In EBV+ HD, LMP1 and LMP2A may participate in this initial rescue. The aim of this proposal is to reconstruct this scenario in the mouse by conditional gene targeting techniques. We have developed a mouse mutant in which Cre recombinase is efficiently expressed in GC but not naive B cells. This will be used to target expression of LMP2A and/or LMP1 to GC B cells in vivo. The interference of the viral proteins with the GC reaction will be investigated. Rescue of pre-apoptotic GC B cells that have lost BCR expression because of somatic hypermutation might be observed, as well as lymphomagenesis, given the known oncogenic properties of LMP1. These experiments will be complemented by an attempt to target another potential tumor determinant of HRS cells into GC B cells, namely the activated form of Notch1. This molecule has recently been shown to be expressed in HRS cells at high levels and in an activated form. Notch1 is particularly attractive in this context, because it is involved in lineage decisions in lymphocyte progenitors, promoting T cell development. Curiously, HRS cells have down regulated many B cellspecific genes and express molecular markers of other hematopoietic lineages, including T cells. Notch1, which is also a potent oncogene if ectopically expressed, might thus contribute to this curious phenotype as well as to HRS cell transformation. Combining LMP2A, LMP1 and Notch1 expression in GC B cells by conditional gene targeting might lead to a mouse model of HD. Apart from lymphomagenesis, the proposed experiments should also lead to new insights into the biology of the GC reaction in the context of EBV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

60

Hodgkin’s Disease

•

Project Title: TRANS ONCOPROTEINS

ACTING

FUNCTION

OF

THE

V

AND

C

REL

Principal Investigator & Institution: Gelinas, Celine; Professor; Biochemistry; Univ of Med/Dent Nj-R W Johnson Med Sch Robert Wood Johnson Medical Sch Piscataway, Nj 08854 Timing: Fiscal Year 2001; Project Start 01-JUL-1991; Project End 30-JUN-2006 Summary: (Adapted from the investigator's abstract): The v-Rel oncoprotein of the highly oncogenic retrovirus reticuloendotheliosis virus strain T (Rev-T) induces aggressive and fatal leukemia/lymphoma in chickens and transgenic mice. Its cellular homolog c-Rel is essential for lymphoid cell survival and proliferation, and for immune and inflammatory responses. Both v-Rel and c-Rel belong to the Rel/NF-KB family of transcription factors. Members of this family share extensive sequence similarity in their N-terminal Rel-homology domain, activate the transcription of genes linked to kB DNA sites and exhibit related biological activities. Chromosomal amplification, rearrangement, overexpression and/or constitutive activation of rel/nf-kb genes are implicated in many human hematopoietic tumors such as lymphoma, leukemia, myeloma and Hodgkin's disease. Aberrant rel/nf-kb genes and activity are also observed in solid tumors such as lung, breast, colon, ovarian and prostate carcinomas. It is therefore important to elucidate how the ReI/NF-kB proteins function in oncogenesis and to understand their regulation. While most vertebrate cellular ReI/NF-kB factors have been implicated in human cancer, none of them is acutely oncogenic when expressed in primary cells or in transgenic mice. The retroviral oncoprotein v-Rel therefore provides an excellent and unique tool tO directly address the function and regulation of these factors in the physiologically relevant context of primary lymphoid cells. Our studies of the past few years support the notion that lymphoid cell transformation by v-Rel results from the activation of specific cellular genes, and point to its regulation by phosphorylation. Our analyses also demonstrated an absolute correlation between the anti-apoptotic and oncogenic activities of v-Rel transactivation mutants. This application for continuation of support will investigate how v-Relmediated transactivation effects cell survival, proliferation and oncogenesis (Aim. 1). Experiments are also proposed to further characterize the transactivation function of vRel and c-Rel and its mode of action (Aim. 2), and to explore the role of phosphorylation in its regulation (Aim. 3). Collectively, these studies will clarify the pathways through which the viral oncoprotein v-Rel functions in malignant lymphoid cell transformation. This work will also provide invaluable insights into the events necessary for the oncogenic conversion of cellular ReI/NF-KB factors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: TREATMENT OF CHILDHOOD CANCER Principal Investigator & Institution: Brecher, Martin L.; Roswell Park Cancer Institute Corp Buffalo, Ny 14263 Timing: Fiscal Year 2001; Project Start 01-JUL-1980; Project End 31-DEC-2002 Summary: Cooperative trials in pediatric cancer patients have played a major role in the remarkable improvement in cure of childhood cancers. Because most childhood cancers are rare, it is only through this mechanism that adequate numbers of patients can be accrued in reasonable lengths of time for randomized controlled studies. The Department of Pediatrics at Roswell Park Cancer Institute (RPCI) has actively participated in cooperative group trials via the Pediatric Oncology Group (POG) to answer treatment questions which would be impossible to answer were we to conduct

Studies

61

only single institution studies. Some pediatric solid tumors are so rare that national intergroup studies are required. We also participate in these intergroup studies. RPCI investigators are coordinators for a number of POG protocols including front-line studies for the treatment of advanced Hodgkin's disease, advanced small non- cleaved cell lymphoma, non-rhabdomyosarcoma soft tissue sarcomas, acute lymphoblastic leukemia in relapse, the National Wilms Tumor Study, brain tumors in infants, and the Intergroup Ewing's Sarcoma Study. Roswell Park investigators have also developed POG phase II studies of continuous infusion 5-fluouracil and the combination of cisplatin, ifosfamide and etoposide. Roswell Park investigators chair the Wilms Tumor Committee, the Neuroscience Subcommittee of the Brain Tumor Committee, and cochair the Pathology Discipline Core Committee, as well as being active on a number of other POG Core Committees. They have made major contributions over the last few years in the areas of solid tumor oncology, neuro- oncology and the treatment of lymphoid malignancies. We are strongly committed to the interdisciplinary approach to pediatric cancer and have established collaboration with the necessary clinical specialties including Radiation Medicine, Pediatric Surgery, Pediatric Neurology, Neurosurgery, and Orthopedic Surgery, as well as with researchers in immunology, pharmacology and molecular biology. As more children are cured of their cancers, the identification and prevention, when feasible, of complications of therapy have become imperative. We have been a major contributor to the identification and understanding of the long-term medical and psychosocial effects of the treatment of leukemia, Hodgkin's disease, and a number of solid tumors, both through the cooperative group mechanism and through institutional studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: TUMOR-ASSOCIATED HERPESVIRUSES CONFERENCE Principal Investigator & Institution: Raab-Traub, Nancy J.; Professor; Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): The Tenth International Meeting of the EBV Association will be held in Cairns, Australia on July 16th-21st, 2002. The theme of the meeting will be "Tumor Associated Herpesviruses" and will focus on EBV and Human Herpevirus 8 (HHV8), but also include gamma herpesvirus infection in animal model systems. Subsequent meetings will be held in Regensburg in 2004 and Boston in 2006. The biennial EBV symposium alternates between the Far East, America, and Europe and provides the only regular forum for EBV research. The meeting encompasses both clinical studies and basic research, providing a unique opportunity to expand our understanding of the molecular basis of EBV and cancer. Each of the sessions and workshops are configured to include molecular biology, immunology, pathology and epidemiology such that every session will have relevance to all attendees, which will promote communication and cross-fertilization of ideas. The proposed sessions will focus on: Primary EBV infections (including infectious mononucleosis, chronic fatigue and X-linked lymphoproliferative disease); Diagnosis and treatment of EBV diseases; Immunobiology and Pathology of EBV Infection; Lymphoid Tumors (including nonHodgkin's lymphoma, Hodgkin's disease and Burkitt's lymphoma); Epithelial tumors (including nasopharyngeal carcinoma gastric carcinomas and breast cancer); Recent advances in vaccine development and Transplantation. As well there will be workshops on "Herpesviruses and AIDS", "The diagnosis, epidemiology and treatment of nasopharyngeal carcinoma"; "Animal models of Disease" and "Oral Herpesvirus

62

Hodgkin’s Disease

Infections". The two sessions on the 21st July, Transplantation and Vaccine development, will be combined sessions with the International Herpesvirus workshop. The organization of the meeting has been arranged to 1. Stimulate communication and interactions internationally among clinical and basic scientists and students to facilitate exchange of materials and rapid movement of new basic information to clinical settings, 2. Recognize and encourage young investigators and 3. Highlight new developments in the field and identify areas for future investigation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: VALIDITY LYMPHOMAS

OF

SELF

REPORTED

FAMILY

HISTORY

OF

Principal Investigator & Institution: Glaser, Sally L.; Northern California Cancer Center 32960 Alvarado Niles Rd, Ste 600 Union City, Ca 94587 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2003 Summary: Hodgkin's disease (HD) risk is increased in family members of patients. If proband-reported family histories of HD were known to be accurate, efficient studies of HD family association, inheritance patterns and susceptibility genes could be conducted without additional patient contact, using new statistical methods and stored tumor tissues. However, no data exist on the validity of self-reported family history of HD or other lymphoma, with which HD is often confused. In a prior population-based, casecontrol study of HD for which we interviewed 645 women and enumerated their 1st-, 2nd-, and 3rd-degree blood relatives, we found a significant excess of familial HD, the first such population-based finding. The proposed R03 study will validate the positive family histories of HD and other lymphoma provided by 50 probands, against medical record and/or death certificate reports, to explore the utility of proband-reported family histories for future genetic studies of familial HD, and to provide the first populationbased description of validated familial HD and associated risk in women. The study will: 1) interview the 33 HD case and 17 population-control probands by phone for contact information on the 58 blood relatives they had reported as having HD or other lymphoma; 2) contact the 58 relatives or their next-of-kin by phone to obtain their cancer history and access to pathology reports and discharge summaries, or, as needed, death certificates, for diagnostic review; 3) obtain the diagnostic documents, and review and classify diagnoses per cancer-registry standards; 4) compare reported and documented diagnoses to calculate validity of proband-reported family history of HD and of other lymphoma, for 1st-, 2nd-, and selected 3rd-degree relatives; 5) describe validated familial HD and associated risk in the original population-based HD case series. Study strengths are: 1) inclusion of population-based, proband-derived histories for 1st-, 2nd-, and selected 3rd- relatives, so that findings are both generalizable and extend beyond 1st-degree relatives; 2) validation of HD and of other lymphomas, both reported in highrisk families but often hard to differentiate; 3) use of a documentation hierarchy: medical record, death certificate, and relative's self-report. Establishing validity of proband-reported lymphomas will help us determine the usefulness of high-risk pedigrees reported by HD probands, who could be identified for this purpose efficiently and in adequate numbers by cancer-registry screening, and will expand the literature on cancer-history validation to include HD. Study results also have implications to the utility of self- reported family history of lymphoma for counseling lymphoma family members about disease risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

Studies

•

63

Project Title: VIRAL ETIOLOGY OF HODGKINS DISEASE Principal Investigator & Institution: Mueller, Nancy E.; Professor; Epidemiology; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2001; Project Start 20-JUN-1997; Project End 31-MAY-2004 Summary: Recent findings on Hodgkin's disease (HD) present a number of important questions. The established risk factors point to age of infection as an important modifier of risk. Cases have altered antibody profiles to the Epstein-Barr virus (EBV) preceding and following diagnosis. The new finding is that 30-50% of HD cases' tumors contain monoclonal EBV genome, with a restricted latent protein expression. How these risk factor, serologic, and molecular data fit together and whether EBV-genome negative HD represents a separate etiology are unknown. This Program Project is designed to test three alternate models of the role of the EBV in the pathogenesis of HD: the EBV is solely related to EBV-genome positive HD with EBV-genome negative disease due to non-viral causes; HD is a virally induced malignancy with the EBV responsible for EBVgenome positive disease and another unidentified virus(es) linked to EBV- genome negative disease; or the EBV plays a crucial early role in the pathogenesis of essentially all HD cases but the genome is selectively lost in some patients. Three companion projects will address the following: the role of EBV in the epidemiology of HD (600 cases and 600 population controls); the association of pre- diagnosis EBV serology with EBV genome status of tumor biopsy in HD (200 cases and 200 matched controls); and characterization of the EBV infection and the cellular immune response in HD cases (160 cases and 160 bone marrow donor controls). The Projects are supported by a serology/pathology Core and an Administrative Core. The combined mutually standardized data from the population studies, plus extensive biomarkers including EBV serology and viral probes, and detailed immunologic markers will result in a substantial and rich database. The program brings together an experienced multidisciplinary group of investigators; by working together we should gain insight into the etiology of HD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: VIRAL TRANSCRIPTION IN EBV TRANSFORMED B CELLS Principal Investigator & Institution: Speck, Samuel H.; Professor; Microbiology and Immunology; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2002; Project Start 01-JUL-1986; Project End 31-MAR-2007 Summary: (provided by applicant): This is a competing renewal of an ROl grant with the long term goal of understanding how Epstein-Barr virus (EBV) gene expression is regulated during immortalizing latency. EBV establishes a life-long infection within the infected host, and is closely associated with the development of endemic Burkitt's lymphoma, nasopharyngeal carcinoma, 30-50 percent of Hodgkin's disease, and nearly half of the lymphomas that arise in immunosuppressed patients. Notably, EBV infection of peripheral resting B cells results in growth transformation resulting, ex vivo, in the generation of immortalized lymphoblastoid cell lines. Based on recent analyses of EBV infection in seropositive individuals, it seems likely that the ability of EBV to drive B cell proliferation, and subsequent differentiation, plays an important role in the dissemination of virus infected B cells and the establishment of a long-lived latency reservoir in memory B cells (in which there is very limited viral gene expression). Understanding how EBV regulates viral gene expression during immortalizing latency may ultimate provide strategies for interfering with this phase of the virus life cycle, which could interfere with the establishment of latency in the memory B cell

64

Hodgkin’s Disease

compartment. Within the scope of this proposal, we will continue to focus our analyses on identifying and characterizing cis-elements involved in regulated EBNA gene expression during the immortalizing latency program of EBV. Aim 1. Generation of a cottontop marmoset LCL immortalized with a packaging defective and replication null EBV to serve as an inducible reservoir for non-immortalizing EBV mutants. Aim 2. Generation and characterization of EBV harboring mutations in cis-elements thought to be involved in regulating EBNA gene transcription in EBV immortalized lymphoblastoid cell lines. Aim 3. Analysis of the requirements for Wp activity during initial stages of infection of primary B cells. Aim 4. Analysis of Wp methylation during the establishment and maintenance of immortalizing latency in B cells - role of methylation in regulating Wp activity in lymphoblastoid cell lines. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “Hodgkin’s disease” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for Hodgkin’s disease in the PubMed Central database: •

Reed-Sternberg cells and "bystander" lymphocytes in lymph nodes affected by Hodgkin's disease are infected with different strains of Epstein-Barr virus. by Meggetto F, Brousset P, Selves J, Delsol G, Mariame B.; 1997 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191371

The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. 3 4

Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.

With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print. 6 PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.

Studies

65

To generate your own bibliography of studies dealing with Hodgkin’s disease, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “Hodgkin’s disease” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for Hodgkin’s disease (hyperlinks lead to article summaries): •

A case of Hodgkin's disease presenting as lymphocytic interstitial pneumonitis. Author(s): Puri MM, Gupta K, Arora VK. Source: Indian J Chest Dis Allied Sci. 2003 April-June; 45(2): 139-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12715939&dopt=Abstract

•

A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBERpositive Hodgkin's disease. Author(s): Gan YJ, Razzouk BI, Su T, Sixbey JW. Source: American Journal of Pathology. 2002 March; 160(3): 781-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11891176&dopt=Abstract

•

A helping computer system prognosing the survival of patients with Hodgkin's disease. Author(s): Mateva NG, Nenova IS, Georgieva IG, Shtraklina NT, Doikova AD. Source: Folia Med (Plovdiv). 2003; 45(2): 30-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12943055&dopt=Abstract

•

A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Author(s): Proctor SJ, Mackie M, Dawson A, White J, Prescott RJ, Lucraft HL, Angus B, Jackson GH, Lennard AL, Hepplestone A, Taylor PR. Source: European Journal of Cancer (Oxford, England : 1990). 2002 April; 38(6): 795-806. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11937314&dopt=Abstract

•

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Author(s): Glossmann JP, Josting A, Pfistner B, Paulus U, Engert A; German Hodgkin's Lymphoma Study Group (GHSG). Source: Annals of Hematology. 2002 August; 81(8): 424-9. Epub 2002 August 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12223998&dopt=Abstract

•

A rare localization of Hodgkin's disease in the breast--a case report. Author(s): Wojtukiewicz MZ, Sawicki Z, Dzieciol J. Source: Rocz Akad Med Bialymst. 2001; 46: 87-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11780584&dopt=Abstract

66

Hodgkin’s Disease

•

A selective history of the therapy of Hodgkin's disease. Author(s): DeVita VT Jr. Source: British Journal of Haematology. 2003 September; 122(5): 718-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12930382&dopt=Abstract

•

Acquired icthyosis: a paraneoplastic skin manifestation of Hodgkin's disease. Author(s): Rizos E, Milionis HJ, Pavlidis N, Elisaf MS. Source: The Lancet Oncology. 2002 December; 3(12): 727. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12473513&dopt=Abstract

•

Advanced Hodgkin's disease: ABVD is better, yet is not good enough! Author(s): Diehl V. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 February 15; 21(4): 583-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12586791&dopt=Abstract

•

Age-specific survival after Hodgkin's disease in a population-based cohort (United States). Author(s): Clarke CA, Glaser SL, Prehn AW. Source: Cancer Causes & Control : Ccc. 2001 November; 12(9): 803-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11714108&dopt=Abstract

•

An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV+ve HD in young adults. Author(s): Alexander FE, Lawrence DJ, Freeland J, Krajewski AS, Angus B, Taylor GM, Jarrett RF. Source: International Journal of Cancer. Journal International Du Cancer. 2003 November 1; 107(2): 298-302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12949811&dopt=Abstract

•

Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Author(s): Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Source: International Journal of Radiation Oncology, Biology, Physics. 2003 January 1; 55(1): 36-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12504034&dopt=Abstract

Studies

67

•

Analysis of treatment results in advanced Hodgkin's disease: the case for adjuvant radiotherapy. Author(s): Dyduch M, Skolyszewski J, Korzeniowski S, Sokolowski A. Source: International Journal of Radiation Oncology, Biology, Physics. 2003 July 1; 56(3): 634-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12788168&dopt=Abstract

•

Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. Author(s): Meij P, Vervoort MB, Bloemena E, Schouten TE, Schwartz C, Grufferman S, Ambinder RF, Middeldorp JM. Source: Journal of Medical Virology. 2002 November; 68(3): 370-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12226824&dopt=Abstract

•

Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Author(s): Bernal F, Shams'ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Sillevis Smitt P, Graus F. Source: Neurology. 2003 January 28; 60(2): 230-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12552036&dopt=Abstract

•

Assessment of clonality of rosetting T lymphocytes in Hodgkin's disease by singlecell polymerase chain reaction: detection of clonality in a polyclonal background in a case of lymphocyte predominance Hodgkin's disease. Author(s): Trumper L, Jung W, Daus H, Mechtersheimer G, von Bonin F, Pfreundschuh M. Source: Annals of Hematology. 2001 November; 80(11): 653-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11757724&dopt=Abstract

•

Autologous hematopoietic stem cell transplantation for high-risk Hodgkin's disease: a single-center experience with the first 100 patients. Author(s): Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Stella-Holowiecka B, Kachel L, Wojciechowska M, Markiewicz M, Kata D. Source: Transplantation Proceedings. 2002 December; 34(8): 3378-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12493478&dopt=Abstract

68

Hodgkin’s Disease

•

Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Author(s): Constans M, Sureda A, Terol MJ, Arranz R, Caballero MD, Iriondo A, Jarque I, Carreras E, Moraleda JM, Carrera D, Leon A, Lopez A, Albo C, Diaz-Mediavilla J, Fernandez-Abellan P, Garcia-Ruiz JC, Hernandez-Navarro F, Mataix R, Petit J, Pascual MJ, Rifon J, Garcia-Conde J, Fernandez-Ranada JM, Mateos MV, Sierra J, Conde E; GEL/TAMO Cooperative Group. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 May; 14(5): 745-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12702529&dopt=Abstract

•

Autologous stem cell transplantation in Hodgkin's disease. Author(s): Avivi I, Goldstone AH. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 1: 122-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078893&dopt=Abstract

•

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Author(s): Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Heyman M, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L, Chambers S, MacFadden M, Cottler-Fox M, Chen T, Phillips G, Tricot G. Source: Bone Marrow Transplantation. 2002 February; 29(4): 303-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11896427&dopt=Abstract

•

Basic fibroblast growth factor and fibrosis in Hodgkin's disease. Author(s): Ohshima K, Sugihara M, Suzumiya J, Haraoka S, Kanda M, Shimazaki K, Katoh K, Kumagawa M, Kikuchi M. Source: Pathology, Research and Practice. 1999; 195(3): 149-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10220794&dopt=Abstract

•

BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Author(s): Rassidakis GZ, Medeiros LJ, McDonnell TJ, Viviani S, Bonfante V, Nadali G, Vassilakopoulos TP, Giardini R, Chilosi M, Kittas C, Gianni AM, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2002 February; 8(2): 488-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11839668&dopt=Abstract

Studies

69

•

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Author(s): Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Ruffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duhmke E, Georgii A, Loeffler M. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998; 9 Suppl 5: S67-71. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9926240&dopt=Abstract

•

Bilateral renal artery stenosis after abdominal radiotherapy for Hodgkin's disease. Author(s): Saka B, Bilge AK, Umman B, Yilmaz E, Nisanci Y, Erten N, Karan MA, Tascioglu C. Source: Int J Clin Pract. 2003 April; 57(3): 247-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12723735&dopt=Abstract

•

Biliary involvement in Hodgkin's disease. Author(s): Gupta A, Roebuck DJ, Michalski AJ. Source: Pediatric Radiology. 2002 March; 32(3): 202-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12164356&dopt=Abstract

•

Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Author(s): Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2000 November; 11(11): 1405-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11142480&dopt=Abstract

•

Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease. Author(s): Dolcetti R, Quaia M, Gloghini A, De Re V, Zancai P, Cariati R, Babuin L, Cilia AM, Rizzo S, Carbone A, Boiocchi M. Source: International Journal of Cancer. Journal International Du Cancer. 1999 January 18; 80(2): 240-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9935206&dopt=Abstract

70

Hodgkin’s Disease

•

Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481). Author(s): Wiernik PH, Leong T, Oken MM, Neiman RS, Habermann TM, Bennett JM, Schuster S, Glick JH. Source: Leukemia & Lymphoma. 2001 January; 40(3-4): 357-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426558&dopt=Abstract

•

Brain involvement in Hodgkin's disease: case reports and review of the literature. Author(s): Nakayama H, Tokuuye K, Kagami Y, Sumi M, Murayama S, Kawashima M, Imai A, Ikeda H, Tobinai K. Source: Radiat Med. 2000 May-June; 18(3): 205-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10972552&dopt=Abstract

•

Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2. Author(s): Gaffney DK, Hemmersmeier J, Holden J, Marshall J, Smith LM, Avizonis V, Tran T, Neuhausen SL. Source: International Journal of Radiation Oncology, Biology, Physics. 2001 February 1; 49(2): 539-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11173152&dopt=Abstract

•

Breast cancer following treatment of Hodgkin's disease--more reasons for less radiotherapy? Author(s): Wolf J, Schellong G, Diehl V. Source: European Journal of Cancer (Oxford, England : 1990). 1997 December; 33(14): 2293-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9616268&dopt=Abstract

•

Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients. Author(s): Cutuli B, Dhermain F, Borel C, de Larochefordiere A, Graic Y, de Lafontan B, Dilhyudy JM, Mignotte H, Tessier E, Tortochaux J, N'Guyen T, Bey P, Le Mevel-Le Pourhiet A, Velten M, Arriagada R. Source: European Journal of Cancer (Oxford, England : 1990). 1997 December; 33(14): 2315-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9616274&dopt=Abstract

•

Breast cancer in women after treatment for Hodgkin's disease. Author(s): Deniz K, O'Mahony S, Ross G, Purushotham A. Source: The Lancet Oncology. 2003 April; 4(4): 207-14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12681264&dopt=Abstract

Studies

71

•

Breast cancer in women following supradiaphragmatic irradiation for Hodgkin's disease. Author(s): Gervais-Fagnou DD, Girouard C, Laperriere N, Pintillie M, Goss PE. Source: Oncology. 1999 October; 57(3): 224-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10545791&dopt=Abstract

•

Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Author(s): Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA, Provencio M, de Lafontan B, de la Rochefordiere A, Cellai E, Graic Y, Kerbrat P, Alzieu C, Teissier E, Dilhuydy JM, Mignotte H, Velten M. Source: Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 2001 June; 59(3): 247-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11369065&dopt=Abstract

•

Breast cancer risk following irradiation for Hodgkin's disease. Author(s): Clemons M, Loijens L, Goss P. Source: Cancer Treatment Reviews. 2000 August; 26(4): 291-302. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10913384&dopt=Abstract

•

Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. Author(s): Diller L, Medeiros Nancarrow C, Shaffer K, Matulonis U, Mauch P, Neuberg D, Tarbell NJ, Litman H, Garber J. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 April 15; 20(8): 2085-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11956269&dopt=Abstract

•

Breast cancer, birth cohorts, and Epstein-Barr virus: methodological issues in exploring the “hygiene hypothesis” in relation to breast cancer, Hodgkin's disease, and stomach cancer. Author(s): Krieger N, Strong EF, Makosky C, Weuve J. Source: Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2003 May; 12(5): 405-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12750234&dopt=Abstract

•

Breast carcinoma in women previously treated for Hodgkin's disease: clinical and mammographic findings. Author(s): Tardivon AA, Garnier ML, Beaudre A, Girinsky T. Source: European Radiology. 1999; 9(8): 1666-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10525887&dopt=Abstract

72

Hodgkin’s Disease

•

British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease. Author(s): Moody AM, Pratt J, Hudson GV, Smith P, Lamont A, Williams MV. Source: Clin Oncol (R Coll Radiol). 2001; 13(4): 262-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11554622&dopt=Abstract

•

Can (18)F-FDG PET after first cycle chemotherapy predict the efficacy of therapy in Hodgkin's disease? Author(s): Rigacci L, Castagnoli A, Carpaneto A, Carrai V, Vaggelli L, Matteini M. Source: Haematologica. 2002 May; 87(5): Elt24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010684&dopt=Abstract

•

Cases from the Osler Medical Service at Johns Hopkins University. Hodgkin's disease with Pel-Ebstein fevers. Author(s): Talbot TR. Source: The American Journal of Medicine. 2002 March; 112(4): 312-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11893371&dopt=Abstract

•

CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. Author(s): Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, Mesina O, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McLaughlin P, Rodriguez MA, Romaguera J, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 March 1; 20(5): 1278-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11870170&dopt=Abstract

•

CD30 expression in L&H cells of Hodgkin's disease, nodular lymphocyte predominant type. Author(s): Ranjan P, Naresh KN. Source: Histopathology. 2003 April; 42(4): 406-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12653955&dopt=Abstract

•

cDNA arrays: gene expression profiles of Hodgkin's disease and anaplastic large cell lymphoma cell lines. Author(s): Thorns C, Gaiser T, Lange K, Merz H, Feller AC. Source: Pathology International. 2002 September; 52(9): 578-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12406187&dopt=Abstract

Studies

73

•

Central nervous system bleeding as a first manifestation of immunothrombocytopenic purpura in Hodgkin's disease. Author(s): Engin H, Abali H, Erman M, Karoglu A, Celik I, Guler N. Source: Haematologia. 2002; 31(4): 373-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12038523&dopt=Abstract

•

Challenging cases and diagnostic dilemmas: case 1. Tracheal compression in Hodgkin's disease. Author(s): Garrison MA, Glanton C, Rasnke M, Smith ME, Ornstein DL. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 August 1; 20(15): 3344-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149308&dopt=Abstract

•

Challenging cases and diagnostic dilemmas: case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease. Author(s): Bomanji JB, Syed R, Brock C, Jankowska P, Dogan A, Costa DC, Ell PJ, Lee SM. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 August 1; 20(15): 3347-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149309&dopt=Abstract

•

Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease. Author(s): Yahalom J. Source: Current Oncology Reports. 2002 September; 4(5): 415-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12162917&dopt=Abstract

•

Changing technology and Hodgkin's disease. Author(s): Lawrence G, Crawford J. Source: Oncology (Huntingt). 2002 September; 16(9): 1146. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12380943&dopt=Abstract

•

Chemotherapy for Hodgkin's disease. Author(s): Ekert H. Source: The New England Journal of Medicine. 2003 September 18; 349(12): 1186-7; Author Reply 1186-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13679536&dopt=Abstract

74

Hodgkin’s Disease

•

ChlVPP chemotherapy in children with stage IV Hodgkin's disease: results of the UKCCSG HD 8201 and HD 9201 studies. Author(s): Atra A, Higgs E, Capra M, Elsworth A, Imeson J, Radford M, Hewitt M; UKCCSG/Hodgkin's Disease Group. Source: British Journal of Haematology. 2002 December; 119(3): 647-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12437639&dopt=Abstract

•

Cigarette smoking and risk of Hodgkin's disease: a population-based case-control study. Author(s): Briggs NC, Hall HI, Brann EA, Moriarty CJ, Levine RS. Source: American Journal of Epidemiology. 2002 December 1; 156(11): 1011-20. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12446257&dopt=Abstract

•

Classification and prognostic value of serum copper/zinc ratio in Hodgkin's disease. Author(s): Cunzhi H, Jiexian J, Xianwen Z, Jingang G, Suling H. Source: Biological Trace Element Research. 2001 November; 83(2): 133-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11762530&dopt=Abstract

•

Clonally unrelated Hodgkin's disease following autologous stem cell transplant for B-cell lymphoma. Author(s): Fend F, Martinez A, Quintanilla-Martinez L, Sanz L, Combalia N, Raffeld M, Jaffe ES, Montserrat E, Campo E. Source: British Journal of Haematology. 2002 February; 116(2): 329-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11841433&dopt=Abstract

•

Coexistence of chronic lymphocytic leukemia and Hodgkin's disease. A case report. Author(s): Oberfield RA. Source: Jama : the Journal of the American Medical Association. 1966 March 7; 195(10): 865-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12608184&dopt=Abstract

•

Communication challenges in a young man with Hodgkin's disease. Author(s): Medoff E. Source: Cancer Practice. 2001 November-December; 9(6): 272-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11879328&dopt=Abstract

•

Consolidation radiotherapy in the treatment of advanced Hodgkin's disease: is it dead? Author(s): Prosnitz LR. Source: International Journal of Radiation Oncology, Biology, Physics. 2003 July 1; 56(3): 605-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12788163&dopt=Abstract

Studies

75

•

Controversies in early-stage Hodgkin's disease. Author(s): Ng AK, Mauch PM. Source: Oncology (Huntingt). 2002 May; 16(5): 588-95, 598; Discussion 600, 605, 609-18. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12108888&dopt=Abstract

•

Cutaneous granulomas as the first manifestation of Hodgkin's disease. Author(s): Macaya A, Servitje O, Moreno A, Peyri J. Source: Eur J Dermatol. 2003 May-June; 13(3): 299-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12804995&dopt=Abstract

•

Deciduoid mesothelioma of the pleura after radiation therapy for Hodgkin's disease presenting as a mediastinal mass. Author(s): Henley JD, Loehrer PJ Sr, Ulbright TM. Source: The American Journal of Surgical Pathology. 2001 April; 25(4): 547-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11257636&dopt=Abstract

•

Deletions within the epstein-barr virus latent membrane protein-1 oncogene in adult ordinary, HIV-associated and paediatric Hodgkin's disease. Author(s): Santon A, Bellas C. Source: Leukemia & Lymphoma. 2001 January; 40(3-4): 235-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426545&dopt=Abstract

•

Delirium resulting from paraneoplastic limbic encephalitis caused by Hodgkin's disease. Author(s): Kung S, Mueller PS, Geda YE, Krahn LE. Source: Psychosomatics. 2002 November-December; 43(6): 498-501. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12444235&dopt=Abstract

•

Demonstration by single-cell PCR that Reed--Sternberg cells and bystander B lymphocytes are infected by different Epstein--Barr virus strains in Hodgkin's disease. Author(s): Faumont N, Al Saati T, Brousset P, Offer C, Delsol G, Meggetto F. Source: The Journal of General Virology. 2001 May; 82(Pt 5): 1169-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11297691&dopt=Abstract

•

Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction. Author(s): Wagner HJ, Schlager F, Claviez A, Bucsky P. Source: European Journal of Cancer (Oxford, England : 1990). 2001 October; 37(15): 18537. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11576839&dopt=Abstract

76

Hodgkin’s Disease

•

Detection of Epstein-Barr virus in archival Hodgkin's disease specimens. Author(s): Flavell KJ, Linford JA, Flavell JR, Murray PG, Young LS, Scott K. Source: Molecular Pathology : Mp. 2000 June; 53(3): 162. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10897338&dopt=Abstract

•

Diagnostic and therapeutic quandaries in primary manifestation of Hodgkin's disease in the central nervous system. Author(s): Kalinka E, Robak T, Wrzesien-Kus A, Krykowski E, Warzocha K. Source: Annals of Hematology. 2002 May; 81(5): 289-91. Epub 2002 April 05. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12029540&dopt=Abstract

•

Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease. Author(s): Reiman T, Clarke ML, Dabbagh L, Vsianska M, Coupland RW, Belch AR, Baldwin SA, Young JD, Cass CE, Mackey JR. Source: Leukemia & Lymphoma. 2002 July; 43(7): 1435-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12389626&dopt=Abstract

•

Differential expression of sialyl and non-sialyl-CD15 antigens on Hodgkin-ReedSternberg cells: significance in Hodgkin's disease. Author(s): Benharroch D, Dima E, Levy A, Ohana-Malka O, Ariad S, Prinsloo I, Mejirovsky E, Sacks M, Gopas J. Source: Leukemia & Lymphoma. 2000 September; 39(1-2): 185-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10975398&dopt=Abstract

•

Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease. Author(s): Vermeer MH, Dukers DF, ten Berge RL, Bloemena E, Wu L, Vos W, de Vries E, Tensen CP, Meijer CJ, Willemze R. Source: Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 2002 August; 15(8): 838-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12181269&dopt=Abstract

•

Direct-antiglobulin-test-negative immune haemolytic anaemia and thrombocytopenia in a patient with Hodgkin's disease. Author(s): Kondo H, Oyamada T, Mori A, Sumi H, Kurosu K, Kajii E, Mikata A. Source: Acta Haematologica. 2001; 105(4): 233-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11528097&dopt=Abstract

Studies

77

•

Discrepancies in Epstein-Barr virus association at presentation and relapse of classical Hodgkin's disease: impact on pathogenesis. Author(s): Nerurkar AY, Vijayan P, Srinivas V, Soman CS, Dinshaw KA, Advani SH, Magrath I, Bhatia K, Naresh KN. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2000 April; 11(4): 475-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10847469&dopt=Abstract

•

Discrete epithelioid cells: useful clue to Hodgkin's disease cytodiagnosis. Author(s): Iyengar KR, Mutha S. Source: Diagnostic Cytopathology. 2002 March; 26(3): 142-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11892016&dopt=Abstract

•

Disseminated infection of the digestive tract caused by cytomegalic virus in a patient with Hodgkin's disease. Author(s): Becheanu G, Stoia R, Gheorghe C, Stamm B. Source: Journal of Cellular and Molecular Medicine. 2001 October-December; 5(4): 436-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12067479&dopt=Abstract

•

Do children with Hodgkin's disease have a better prognosis than adults? Application of a generalised linear model to a systematic review of published results. Author(s): Franklin J. Source: Studies in Health Technology and Informatics. 2000; 77: 18-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11187537&dopt=Abstract

•

Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Author(s): Dieckmann K, Potter R, Hofmann J, Heinzl H, Wagner W, Schellong G; Pediatric Cooperative Hodgkin Disease Study Group of the GPOH. Source: International Journal of Radiation Oncology, Biology, Physics. 2003 July 1; 56(3): 644-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12788169&dopt=Abstract

•

Does radiotherapy have to justify its use in Hodgkin's disease? Author(s): Gonzalez-San Segundo C, Santos-Miranda JA. Source: Acta Oncologica (Stockholm, Sweden). 2001; 40(1): 108-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11321653&dopt=Abstract

78

Hodgkin’s Disease

•

Dorothy Reed and Hodgkin's disease: a reflection after a century. Author(s): Zwitter M, Cohen JR, Barrett A, Robinton ED. Source: International Journal of Radiation Oncology, Biology, Physics. 2002 June 1; 53(2): 366-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12023141&dopt=Abstract

•

Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease. Author(s): Anselmo AP, Cavalieri E, Meloni G, Alimena G, Cantonetti M, Maurizi Enrici R, Tosti ME, Falchetto Osti M, Gianfelici V, Mandelli F. Source: Haematologica. 2002 May; 87(5): 507-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010664&dopt=Abstract

•

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Author(s): Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 January; 14(1): 123-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12488304&dopt=Abstract

•

Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Author(s): Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN. Source: British Journal of Haematology. 2002 June; 117(3): 629-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12028034&dopt=Abstract

•

Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Author(s): Carde P, Koscielny S, Franklin J, Axdorph U, Raemaekers J, Diehl V, Aleman B, Brosteanu O, Hasenclever D, Oberlin O, Bonvin N, Bjorkholm M. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 1: 86-91. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078910&dopt=Abstract

•

EBV-associated Hodgkin's disease in an HIV-infected child presenting with a hemophagocytic syndrome. Author(s): Preciado MV, De Matteo E, Fallo A, Chabay P, Drelichman G, Grinstein S. Source: Leukemia & Lymphoma. 2001 June; 42(1-2): 231-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11699213&dopt=Abstract

Studies

79

•

Editorial comment on detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction by Wagner and colleagues. Author(s): Magrath I. Source: European Journal of Cancer (Oxford, England : 1990). 2001 October; 37(15): 18125. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11576832&dopt=Abstract

•

Editorial comment: Hodgkin's disease in the setting of HIV. Author(s): Aboulafia DM. Source: Aids Read. 1999 March-April; 9(2): 132-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12728897&dopt=Abstract

•

Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease. Author(s): Villani F, Fede Catania A, Laffranchi A, Maffioli L, Viviani S, Bonfante V. Source: Cancer Investigation. 2003 April; 21(2): 185-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743983&dopt=Abstract

•

Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease. Author(s): Turturro F, Arnold MD, Frist AY, Seth P. Source: Leukemia & Lymphoma. 2002 June; 43(6): 1323-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12153002&dopt=Abstract

•

Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Author(s): Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE. Source: Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2001; 7(10): 552-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11760087&dopt=Abstract

•

Epidemiological surveillance of pediatric Hodgkin's disease in southern Iran. Author(s): Karimi M, Yarmohammadi H, Ghavanini AA, Kumar PV. Source: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2002 August; 8(8): Cr572-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12165744&dopt=Abstract

80

Hodgkin’s Disease

•

Epidural involvement in Hodgkin's disease. Author(s): Illes A, Miltenyi Z, Miltenyi L, Csecsei G, Szegedi G. Source: Haematologia. 2002; 32(2): 113-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12412730&dopt=Abstract

•

Epstein-Barr virus-associated hodgkin's disease in a patient with Wiskott-Aldrich syndrome. Author(s): Sasahara Y, Fujie H, Kumaki S, Ohashi Y, Minegishi M, Tsuchiya S. Source: Acta Paediatrica (Oslo, Norway : 1992). 2001 November; 90(11): 1348-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11808913&dopt=Abstract

•

Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis. Author(s): Mitarnun W, Pradutkanchana J, Takao S, Saechan V, Suwiwat S, Ishida T. Source: J Med Assoc Thai. 2002 May; 85(5): 552-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12188384&dopt=Abstract

•

Epstein-Barr virus-latent membrane protein 1 expression has a favorable influence in the outcome of patients with Hodgkin's Disease treated with chemotherapy. Author(s): Montalban C, Abraira V, Morente M, Acevedo A, Aguilera B, Bellas C, Fraga M, Del Moral RG, Menarguez J, Oliva H, Sanchez-Beato M, Piris MA. Source: Leukemia & Lymphoma. 2000 November; 39(5-6): 563-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11342339&dopt=Abstract

•

Erythropoietin (r-HuEPO) in the treatment of anemia of nodular sclerosis type Hodgkin's disease--a preliminary report. Author(s): Wojtukiewicz MZ, Sawicki Z, Radziwon P. Source: Rocz Akad Med Bialymst. 2000; 45: 145-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11712426&dopt=Abstract

•

Exposure to animals and selected risk factors among Canadian farm residents with Hodgkin's disease, multiple myeloma, or soft tissue sarcoma. Author(s): Pahwa P, McDuffie HH, Dosman JA, Robson D, McLaughlin JR, Spinelli JJ, Fincham S. Source: Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 2003 August; 45(8): 857-68. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12915787&dopt=Abstract

Studies

81

•

Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines. Author(s): Kis LL, Nagy N, Klein G, Klein E. Source: International Journal of Cancer. Journal International Du Cancer. 2003 May 1; 104(5): 658-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12594824&dopt=Abstract

•

Expression of the signal transduction molecule zeta in peripheral and tumourassociated lymphocytes in Hodgkin's disease in relation to the Epstein-Barr virus status of the tumour cells. Author(s): Sjoberg J, Andersson M, Garcia C, Palucka KA, Bjorkholm M, PorwitMacDonald A, Pisa P. Source: British Journal of Haematology. 2002 March; 116(4): 765-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11886379&dopt=Abstract

•

Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Author(s): Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Source: British Journal of Haematology. 2002 May; 117(2): 366-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11972519&dopt=Abstract

•

Extraintestinal Hodgkin's disease in a patient with Crohn's disease. Author(s): Calvo-Villas JM, Ramirez Sanchez MJ, Cuesta Tovar J, Garcia C. Source: Southern Medical Journal. 2003 June; 96(6): 632. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12938798&dopt=Abstract

•

F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Author(s): Rini JN, Manalili EY, Hoffman MA, Karayalcin G, Mehrotra B, Tomas MB, Palestro CJ. Source: Clinical Nuclear Medicine. 2002 August; 27(8): 572-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12170002&dopt=Abstract

•

Familial Hodgkin's disease in two siblings. Author(s): Thavaraj V, Kumar R, Arya LS. Source: Indian Pediatrics. 2002 January; 39(1): 79-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11805358&dopt=Abstract

•

Fatal septicemia and meningitis due to Morganella morganii in a patient with Hodgkin's disease. Author(s): Samonis G, Anatoliotaki M, Apostolakou H, Souglakos J, Georgoulias V. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(7): 553-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11515771&dopt=Abstract

82

Hodgkin’s Disease

•

Fatigue and psychiatric morbidity among Hodgkin's disease survivors. Author(s): Loge JH, Abrahamsen AF, Ekeberg, Kaasa S. Source: Journal of Pain and Symptom Management. 2000 February; 19(2): 91-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10699536&dopt=Abstract

•

Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Author(s): Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, Andre M, Lepage E, Ferme C. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1999 December; 10(12): 1485-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10643540&dopt=Abstract

•

Fertility after treatment for Hodgkin's disease. Author(s): Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 1: 138-47. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078896&dopt=Abstract

•

Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Author(s): Delwail V, Jais JP, Colonna P, Andrieu JM. Source: British Journal of Haematology. 2002 July; 118(1): 189-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100147&dopt=Abstract

•

Fine needle aspiration in Hodgkin's disease. Author(s): Oertel YC. Source: Acta Cytol. 2002 May-June; 46(3): 617. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12040667&dopt=Abstract

•

Fludarabine phosphate as an active and well tolerated salvage therapy in an elderly heavily pretreated Hodgkin's disease patient: a case report. Author(s): Bordonaro R, Ferrau F, Giuffrida D, Cali S, Priolo D, Colina P, Ursino M, Failla G. Source: Tumori. 1999 July-August; 85(4): 288-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10587034&dopt=Abstract

Studies

83

•

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Author(s): Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, MacManus MP, Ryan G, Januszewicz H, Wolf M. Source: The American Journal of Medicine. 2002 March; 112(4): 262-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11893364&dopt=Abstract

•

Focal pulmonary uptake of gallium-67 due to radiation pneumonitis: the case for a misdiagnosis of Hodgkin's disease progression. Author(s): Ruiz-Hernandez G, Gutierrez AM, Rodriguez J, Ferrer-Albiach E, MateoNavarro A, Garcia-Conde J. Source: Leukemia & Lymphoma. 2001 November-December; 42(6): 1429-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11911431&dopt=Abstract

•

Follow-up of Hodgkin's disease. American College of Radiology. ACR Appropriateness Criteria. Author(s): Deming RL, Constine LS, Elman AJ, Hoppe RT, Mauch PM, Dosoretz DE, Pistenmaa DA, Prosnitz LR, Wolkov HB, Yahalom J, Chauvenet A, Connors JM, Glick JH, Leibel S. Source: Radiology. 2000 June; 215 Suppl: 1269-79. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11037546&dopt=Abstract

•

Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Author(s): Dryver ET, Jernstrom H, Tompkins K, Buckstein R, Imrie KR. Source: British Journal of Cancer. 2003 August 4; 89(3): 482-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12888816&dopt=Abstract

•

Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Author(s): Vriesendorp HM, Quadri SM, Wyllie CT, Lai J, Borchardt PE, Harris L, Wucher R, Askew E, Schweichler L. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 1999 October; 5(10 Suppl): 3324S-3329S. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10541381&dopt=Abstract

•

Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Author(s): Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M, Stein H. Source: Blood. 1999 November 1; 94(9): 3108-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10556196&dopt=Abstract

84

Hodgkin’s Disease

•

From chronic lymphocytic leukemia to Hodgkin's disease: a case of prognostically favorable transformation. Author(s): Zinzani PL, Tani M, Stefoni V, Piccaluga PP, Baccarani M, Ascani S, Pileri S. Source: Leukemia Research. 2002 August; 26(8): 775-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12191574&dopt=Abstract

•

Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. Author(s): Vigouroux S, Milpied N, Andrieu JM, Colonna P, Ifrah N, Colombat P, Desablens B, Abgrall JF, Casassus P, Guilhot F, Briere J, Le Mevel A, Moreau P, Mechinaud F, Mahe B, Morineau N, Vigier M, Rapp MJ, Harousseau JL. Source: Bone Marrow Transplantation. 2002 May; 29(10): 833-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12058233&dopt=Abstract

•

Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Author(s): Dourakis SP, Tzemanakis E, Deutsch M, Kafiri G, Hadziyannis SJ. Source: European Journal of Gastroenterology & Hepatology. 1999 September; 11(9): 1055-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10503847&dopt=Abstract

•

Fulminant hepatic failure caused by adenovirus infection following bone marrow transplantation for Hodgkin's disease. Author(s): Somervaille TC, Kirk S, Dogan A, Landon GV, Mackinnon S. Source: Bone Marrow Transplantation. 1999 July; 24(1): 99-101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10435743&dopt=Abstract

•

Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. Author(s): Taylor GM, Gokhale DA, Crowther D, Woll PJ, Harris M, Ryder D, Ayres M, Radford JA. Source: British Journal of Cancer. 1999 July; 80(9): 1405-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10424743&dopt=Abstract

•

Ga-67-avid massive cellulitis within a chronic lymphedematous limb in a survivor of Hodgkin's disease. Author(s): Suga K, Ariga M, Motoyama K, Hara A, Kume N, Matsunaga N. Source: Clinical Nuclear Medicine. 2001 September; 26(9): 791-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11507304&dopt=Abstract

Studies

85

•

Gallium positivity in Hodgkin's disease. Author(s): Patterson K, Bomanji J. Source: British Journal of Haematology. 2000 May; 109(2): 257. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10848809&dopt=Abstract

•

Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value. Author(s): Castellani MR, Cefalo G, Terenziani M, Aliberti G, Maccauro M, Alessi A, Villano C, Bombardieri E. Source: Q J Nucl Med. 2003 March; 47(1): 22-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12714951&dopt=Abstract

•

Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. Author(s): Salloum E, Brandt DS, Caride VJ, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper DL. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 February; 15(2): 518-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9053473&dopt=Abstract

•

Gallium-67 scintigraphy in the management: Hodgkin's disease and non-Hodgkin's lymphoma. Author(s): Rehm PK. Source: Cancer Biotherapy & Radiopharmaceuticals. 1999 August; 14(4): 251-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10850311&dopt=Abstract

•

Gastric Hodgkin's disease presenting with radiological appearance of linitis plastica. Author(s): Ozyilkan O, Ozyilkan E. Source: The American Journal of Gastroenterology. 1999 December; 94(12): 3661-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10606350&dopt=Abstract

•

Gastrointestinal cancer after treatment of Hodgkin's disease. Author(s): Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT. Source: International Journal of Radiation Oncology, Biology, Physics. 1997 January 1; 37(1): 67-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9054878&dopt=Abstract

•

G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. Author(s): Gustavsson A. Source: Acta Oncologica (Stockholm, Sweden). 1997; 36(5): 483-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9292744&dopt=Abstract

86

Hodgkin’s Disease

•

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. Author(s): Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2000 July; 18(13): 2615-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10893294&dopt=Abstract

•

Gemcitabine is active in relapsed Hodgkin's disease. Author(s): Lucas JB, Horwitz SM, Horning SJ, Sayegh A. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1999 August; 17(8): 2627-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10561333&dopt=Abstract

•

Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Author(s): Devilard E, Bertucci F, Trempat P, Bouabdallah R, Loriod B, Giaconia A, Brousset P, Granjeaud S, Nguyen C, Birnbaum D, Birg F, Houlgatte R, Xerri L. Source: Oncogene. 2002 May 2; 21(19): 3095-102. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12082542&dopt=Abstract

•

Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia. Author(s): Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA, Matthews J, Foot NJ, Lister TA, Young BD, Rohatiner AZ. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 1: 40-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078901&dopt=Abstract

•

Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Author(s): Falzetti D, Crescenzi B, Matteuci C, Falini B, Martelli MF, Van Den Berghe H, Mecucci C. Source: Haematologica. 1999 April; 84(4): 298-305. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10190942&dopt=Abstract

•

Genotoxic effects of radiotherapy and chemotherapy on circulating lymphocytes in patients with Hodgkin's disease. Author(s): Bilban-Jakopin C, Bilban M. Source: Mutation Research. 2001 October 18; 497(1-2): 81-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11525910&dopt=Abstract

Studies

87

•

Geriatrics photo quiz. Hodgkin's disease. Author(s): Ross JS, Shua-Haim JR. Source: Geriatrics. 2000 April; 55(4): 22, 66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10771698&dopt=Abstract

•

Gluteal manifestation of advanced Hodgkin's disease. Author(s): Ariad S, Hatskelzon L, Benharroch D, Geffen DB. Source: Skeletal Radiology. 1997 October; 26(10): 622-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9361361&dopt=Abstract

•

Gonadal function following ABVD therapy for Hodgkin's disease. Author(s): Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 1997 August; 20(4): 354-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9256888&dopt=Abstract

•

Granuloma annulare associated with Hodgkin's disease. Author(s): Setoyama M, Kerdel FA, Byrnes JJ, Kanzaki T. Source: International Journal of Dermatology. 1997 June; 36(6): 445-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9248891&dopt=Abstract

•

Granulomatous reaction after chemotherapy for Hodgkin's disease. Author(s): Paydas S, Yavuz S, Disel U, Zeren H, Hasturk S, Hanta I, Ergin M, Sahin B. Source: Leukemia Research. 2002 October; 26(10): 967-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12163060&dopt=Abstract

•

Greater curability in advanced Hodgkin's disease? Author(s): Portlock CS. Source: Cancer J Sci Am. 1999 September-October; 5(5): 264-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10526665&dopt=Abstract

•

Haematoxylin and eosin staining in the diagnosis of Hodgkin's disease in Uganda. Author(s): Tumwine LK, Wabinga H, Odida M. Source: East Afr Med J. 2003 March; 80(3): 119-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12762425&dopt=Abstract

88

Hodgkin’s Disease

•

Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. Author(s): Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW, Fisher RI. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 September 15; 21(18): 3512-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12972528&dopt=Abstract

•

Hematologic malignancies with extramedullary spread of disease. Case 3. Extra-nodal Hodgkin's disease presenting as rapidly progressive liver failure. Author(s): Olnes M, Alli P, Freedman A, Auster M, Erlich R. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 May 1; 21(9): 1890-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12721270&dopt=Abstract

•

Hemophagocytic syndrome as the primary clinical symptom of Hodgkin's disease. Author(s): Kojima H, Takei N, Mukai Y, Hasegawa Y, Suzukawa K, Nagata M, Noguchi M, Mori N, Nagasawa T. Source: Annals of Hematology. 2003 January; 82(1): 53-6. Epub 2002 November 29. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12574967&dopt=Abstract

•

High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen. Author(s): Spina M, Re A, Vaccher E, Gabarre J, Tirelli U. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 April; 14(4): 655-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12649116&dopt=Abstract

•

High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Author(s): Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, de Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Giudice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. Source: Haematologica. 2003 May; 88(5): 522-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12745271&dopt=Abstract

•

HIV-associated Hodgkin's disease. Author(s): Cheung TW, Arai S. Source: Aids Read. 1999 March-April; 9(2): 131-7. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12728896&dopt=Abstract

Studies

89

•

HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus. Author(s): Massarweh S, Udden MM, Shahab I, Kroll M, Sears DA, Lynch GR, Teh BS, Lu HH. Source: American Journal of Hematology. 2003 March; 72(3): 216-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12605396&dopt=Abstract

•

Hodgkin's disease and scleroderma. Author(s): Duggal L, Gupta S, Aggarwal PK, Sachar VP, Bhalla S. Source: J Assoc Physicians India. 2002 September; 50: 1186-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12516708&dopt=Abstract

•

Hodgkin's disease etiology and novel viruses: clues from groups exposed to blood products. Author(s): Glaser SL, Clarke CA, Darrow LA. Source: International Journal of Cancer. Journal International Du Cancer. 2003 May 10; 104(6): 796-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12640690&dopt=Abstract

•

Hodgkin's disease in elderly patients (> or =60): clinical outcome and treatment strategies. Author(s): Kim HK, Silver B, Li S, Neuberg D, Mauch P. Source: International Journal of Radiation Oncology, Biology, Physics. 2003 June 1; 56(2): 556-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12738333&dopt=Abstract

•

Hodgkin's disease in the elderly: a population-based study. Author(s): Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR; Northern Region Lymphoma Group. Source: British Journal of Haematology. 2002 November; 119(2): 432-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12406082&dopt=Abstract

•

Hodgkin's disease in the setting of human immunodeficiency virus infection. Author(s): Calza L, Manfredi R, Colangeli V, Dentale N, Chiodo F. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(2): 136-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12693568&dopt=Abstract

•

Hodgkin's disease involving the large bowel. Author(s): Zemsky L, Katz H, Edelman M, Makower D. Source: Clinical Colorectal Cancer. 2001 November; 1(3): 185-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12450436&dopt=Abstract

90

Hodgkin’s Disease

•

Hodgkin's disease of bone marrow masquerading as a heavy plasma cell infiltration and fibrosis. Author(s): Joshi A, Aqel NM. Source: British Journal of Haematology. 2003 August; 122(3): 343. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12877660&dopt=Abstract

•

Hodgkin's disease: a model for interdisciplinary cancer management: 2002 Janeway lecture. Author(s): Hoppe RT. Source: Cancer Journal (Sudbury, Mass.). 2002 November-December; 8(6): 425-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12500848&dopt=Abstract

•

Hodgkin's disease: treatment of relapsed disease. Author(s): Cavalli FG. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 4: 159-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401683&dopt=Abstract

•

Hodgkin's disease--clinical trials and travails. Author(s): DeVita VT Jr. Source: The New England Journal of Medicine. 2003 June 12; 348(24): 2375-6. Erratum In: N Engl J Med. 2003 July 10; 349(2): 202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802021&dopt=Abstract

•

How do we define Hodgkin's disease? The authors' reply. Author(s): Pileri SA, Sabattini E, Ascani S, Zinzani PL, Falini B. Source: Journal of Clinical Pathology. 2003 February; 56(2): 159. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12560404&dopt=Abstract

•

Hypothyroidism and thyroiditis after therapy for Hodgkin's disease. Author(s): Illes A, Biro E, Miltenyi Z, Keresztes K, Varoczy L, Andras C, Sipka S, Bako G. Source: Acta Haematologica. 2003; 109(1): 11-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12486317&dopt=Abstract

•

Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Author(s): Canales MA, Fernandez-Jimenez MC, Martin A, Arrieta R, Caballero MD, Diez J, Quevedo E, Garcia-Bustos J, San Miguel JF, Hernandez-Navarro F. Source: Haematologica. 2001 May; 86(5): 494-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11410412&dopt=Abstract

Studies

91

•

Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience. Author(s): Zinzani PL. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003; 14 Suppl 1: I43-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736231&dopt=Abstract

•

Immunohistochemical detection of CD30 remains negative in nodular lymphocytepredominant Hodgkin's disease using enhanced antigen retrieval. Author(s): Roberts C, Jack F, Angus B, Reid A, Thompson WD. Source: Histopathology. 2002 February; 40(2): 166-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11952861&dopt=Abstract

•

Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease. Author(s): Carella AM, Beltrami G, Carella M Jr, Corsetti MT, Scalzulli RP, Greco M. Source: Haematologica. 2001 November; 86(11): 1121-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11694399&dopt=Abstract

•

Immunotherapy for Hodgkin's disease. Author(s): Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. Source: Annals of Hematology. 2002; 81 Suppl 2: S39-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12611071&dopt=Abstract

•

Immunotherapy shows promise in Hodgkin's disease. Author(s): Stephenson J. Source: The Lancet Oncology. 2001 June; 2(6): 329. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11905746&dopt=Abstract

•

Incidence of Hodgkin's disease in Nordic countries. Author(s): Hjalgrim H, Askling J, Pukkala E, Hansen S, Munksgaard L, Frisch M. Source: Lancet. 2001 July 28; 358(9278): 297-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11498219&dopt=Abstract

•

Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Author(s): Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J. Source: Leukemia & Lymphoma. 2001 February; 40(5-6): 499-509. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426523&dopt=Abstract

92

Hodgkin’s Disease

•

Intensified ABVP chemotherapy for the primary treatment of Hodgkin's disease. Author(s): Spector N, Costa MA, Morais JC, Biasoli I, Solza C, De Fatima Gaui M, Ferreira CG, Portugal RD, Loureiro M, Nucci M, Pulcheri W. Source: Oncol Rep. 2002 March-April; 9(2): 439-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11836623&dopt=Abstract

•

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Author(s): Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 January 15; 20(2): 467-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11786576&dopt=Abstract

•

Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Author(s): Reynolds GM, Billingham LJ, Gray LJ, Flavell JR, Najafipour S, Crocker J, Nelson P, Young LS, Murray PG. Source: British Journal of Haematology. 2002 July; 118(1): 195-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100148&dopt=Abstract

•

Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Author(s): Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Source: Histopathology. 2001 April; 38(4): 368-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11318902&dopt=Abstract

•

Interleukin-3 receptors in Hodgkin's disease. Author(s): Bosshart H. Source: American Journal of Pathology. 2003 January; 162(1): 355-6; Author Reply 356-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12507919&dopt=Abstract

•

Interventions for early stage Hodgkin's disease in children. Author(s): Louw G, Pinkerton CR. Source: Cochrane Database Syst Rev. 2002; (3): Cd002035. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12137640&dopt=Abstract

Studies

93

•

Intracellular bacteria in Hodgkin's disease and sclerosing mediastinal B-cell lymphoma: sign of a bacterial etiology? Author(s): Sauter C, Kurrer MO. Source: Swiss Medical Weekly : Official Journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology. 2002 June 15; 132(23-24): 312-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12362281&dopt=Abstract

•

Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease? Author(s): Carde P, Cavalli F, Diehl V, Franklin J. Source: The Hematology Journal : the Official Journal of the European Haematology Association / Eha. 2000; 1(4): 282-90. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11920203&dopt=Abstract

•

Is it wise to eliminate lymphography from the staging of Hodgkin's disease? Author(s): Guermazi A. Source: Leukemia & Lymphoma. 2001 August; 42(4): 655-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11697494&dopt=Abstract

•

Is there an association between total-body irradiation and secondary acute myelogenous leukemia/myelodysplastic syndrome in patients with relapsed/refractory Hodgkin's disease treated with autologous stem-cell transplantation? Author(s): Fung HC, Nademanee AP, Bhatia S, Forman SJ. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 August 1; 19(15): 3585-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11481369&dopt=Abstract

•

Isolated parenchymal lung involvement in children with stage IV Hodgkin's disease: results of the UKCCSG HD8201 and HD9201 studies. Author(s): Atra A, Higgs E, Capra M, Elsworth A, Imeson J, Radford M, Pinkerton R, Hewitt M; United Kingdom Children Cancer Study Group (UKCCSG)/Hodgkin's Disease Group. Source: British Journal of Haematology. 2002 November; 119(2): 441-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12406083&dopt=Abstract

•

Isolated, primary extranodal Hodgkin's disease of the spine: case report. Author(s): Citow JS, Rini B, Wollmann R, Macdonald RL. Source: Neurosurgery. 2001 August; 49(2): 453-6; Discussion 456-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11504124&dopt=Abstract

94

Hodgkin’s Disease

•

January 2001: A 37 year old man with a history of Hodgkin's disease. Author(s): Brown HG, Whiting DM, Prostko ER, Fox KR, Zhang J. Source: Brain Pathology (Zurich, Switzerland). 2001 July; 11(3): 387-8; 393. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11414479&dopt=Abstract

•

Kaposi sarcoma after treatment of Hodgkin's disease in a young adult non-AIDS patient: case report and review. Author(s): Deutsch M, Jacobs SA. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 2000 February; 23(1): 26-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10683069&dopt=Abstract

•

Karyotypic dissection of Hodgkin's disease cell lines reveals ectopic subtelomeres and ribosomal DNA at sites of multiple jumping translocations and genomic amplification. Author(s): MacLeod RA, Spitzer D, Bar-Am I, Sylvester JE, Kaufmann M, Wernich A, Drexler HG. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2000 October; 14(10): 1803-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11021756&dopt=Abstract

•

Laboratory diagnosis of Hodgkin's disease: what are the challenges? Author(s): Muchiri L. Source: East Afr Med J. 2003 March; 80(3): 117-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12762424&dopt=Abstract

•

Lack of platelet aggregation abnormality in Hodgkin's disease. Author(s): Kaptan K, Beyan C, Ozturk B, Cetin T, Ural AU, Avcu F, Ustun C, Yalcin A. Source: Haematologia. 2002; 31(4): 357-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12038520&dopt=Abstract

•

Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkin's disease. Author(s): Marafioti T, Jabri L, Pulford K, Brousset P, Mason DY, Delsol G. Source: British Journal of Haematology. 2003 February; 120(4): 671-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12588355&dopt=Abstract

•

Long-term cause-specific mortality of patients treated for Hodgkin's disease. Author(s): Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 September 15; 21(18): 3431-9. Epub 2003 July 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12885835&dopt=Abstract

Studies

95

•

Long-term follow-up of Hodgkin's disease trial. Author(s): Canellos GP, Niedzwiecki D. Source: The New England Journal of Medicine. 2002 May 2; 346(18): 1417-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11986425&dopt=Abstract

•

Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Author(s): Radman I, Basic N, Labar B, Kovacevic J, Aurer I, Bogdanic V, ZupancicSalek S, Nemet D, Jakic-Razumovic J, Mrsic M, Santek F, Grgic-Markulin L, Boban D. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 October; 13(10): 1650-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12377656&dopt=Abstract

•

Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Author(s): Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaloy S. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 November; 13(11): 1786-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12419752&dopt=Abstract

•

Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Author(s): Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, van't Veer MB, Fraumeni JF, Boice JD Jr, Clarke EA, Travis LB. Source: Radiation Research. 2003 February; 159(2): 161-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12537521&dopt=Abstract

•

Lung function and serum concentrations of different cytokines in patients submitted to radiotherapy and intermediate/high dose chemotherapy for Hodgkin's disease. Author(s): Villani F, Viola G, Vismara C, Laffranchi A, Di Russo A, Viviani S, Bonfante V. Source: Anticancer Res. 2002 July-August; 22(4): 2403-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174934&dopt=Abstract

•

Lymphocyte predominant Hodgkin's disease. Author(s): Ekstrand BC, Horning SJ. Source: Current Oncology Reports. 2002 September; 4(5): 424-33. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12162918&dopt=Abstract

96

Hodgkin’s Disease

•

Lymphocyte predominant Hodgkin's disease: more patience than patients. Author(s): Ekstrand BC, Horning SJ. Source: Cancer Journal (Sudbury, Mass.). 2002 September-October; 8(5): 367-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12416892&dopt=Abstract

•

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Author(s): Rueffer U, Breuer K, Josting A, Lathan B, Sieber M, Manzke O, Grotenhermen FJ, Tesch H, Bredenfeld H, Koch P, Nisters-Backes H, Wolf J, Engert A, Diehl V. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2001 September; 12(9): 1307-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11697845&dopt=Abstract

•

Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Author(s): Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD. Source: International Journal of Radiation Oncology, Biology, Physics. 2001 July 15; 50(4): 971-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11429225&dopt=Abstract

•

Marked decrease in the Epstein-Barr virus positivity rate in nodular sclerosis subtype Hodgkin's disease in Tokyo: trend between 1955 and 1999. Author(s): Takeuchi K, Morishita Y, Fukayama M, Mori S. Source: British Journal of Haematology. 2001 May; 113(2): 429-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11380410&dopt=Abstract

•

Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Author(s): Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundstrom C, Enblad G, Nilsson G. Source: British Journal of Haematology. 2001 September; 114(3): 616-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11552987&dopt=Abstract

•

Miller-Fisher syndrome and Hodgkin's disease. Author(s): Rubio-Nazabal E, Marey-Lopez J, Torres-Carrete JP, Alvarez-Perez P, Rey Del Corral P. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2002 September; 73(3): 344. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12185180&dopt=Abstract

Studies

97

•

Misleading Ga-67 uptake in a patient with Hodgkin's disease, mediastinal deviation, and pulmonary compression. Author(s): Stark P, Steinmetz A, Hefetz M, Hardoff R. Source: Clinical Nuclear Medicine. 2002 December; 27(12): 898-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12607876&dopt=Abstract

•

Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Author(s): McQuaker I, Haynes A, Stainer C, Byrne J, Russell N. Source: Bone Marrow Transplantation. 1999 October; 24(7): 715-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10516673&dopt=Abstract

•

Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Author(s): Behrens C, Travis LB, Wistuba II, Davis S, Maitra A, Clarke EA, Lynch CF, Glimelius B, Wiklund T, Tarone R, Gazdar AF. Source: Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2000 October; 9(10): 1027-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11045784&dopt=Abstract

•

Multiple cutaneous granular cell tumors in a child in remission for Hodgkin's disease. Author(s): De Raeve L, Roseeuw D, Otten J. Source: Journal of the American Academy of Dermatology. 2002 August; 47(2 Suppl): S180-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12140456&dopt=Abstract

•

Multiple synchronous pigmented basal cell carcinomas following radiotherapy for Hodgkin's disease. Author(s): Stante M, Salvini C, De Giorgi V, Carli P. Source: International Journal of Dermatology. 2002 April; 41(4): 208-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12031028&dopt=Abstract

•

Necrotizing glomerulonephritis associated with Hodgkin's disease. Author(s): Wolf G, Krenz I, Hegewisch-Becker S, Hossfeld DK, Helmchen U, Stahl RA. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2001 January; 16(1): 187-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11209025&dopt=Abstract

98

Hodgkin’s Disease

•

Nemaline myopathy: a possible late complication of Hodgkin's disease therapy. Author(s): Portlock CS, Boland P, Hays AP, Antonescu CR, Rosenblum MK. Source: Human Pathology. 2003 August; 34(8): 816-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14506646&dopt=Abstract

•

Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas. Author(s): Massarelli G, Onida GA, Piras MA, Marras V, Mura A, Tanda F. Source: Anticancer Res. 1999 September-October; 19(5B): 3933-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10628334&dopt=Abstract

•

New concepts for relapsed Hodgkin's disease. Author(s): Josting A, Raemakers JM, Diehl V, Engert A. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 1: 117-21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078892&dopt=Abstract

•

New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top. Author(s): Canellos GP. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 February 1; 20(3): 607-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11821436&dopt=Abstract

•

New treatments for Hodgkin's disease. Author(s): Glossmann JP, Josting A, Diehl V. Source: Curr Treat Options Oncol. 2002 August; 3(4): 283-90. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12074765&dopt=Abstract

•

Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. Author(s): Rueffer U, Josting A, Franklin J, May M, Sieber M, Breuer K, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 April 1; 19(7): 2026-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11310450&dopt=Abstract

Studies

99

•

NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. Author(s): Frias S, Van Hummelen P, Meistrich ML, Lowe XR, Hagemeister FB, Shelby MD, Bishop JB, Wyrobek AJ. Source: Cancer Research. 2003 January 1; 63(1): 44-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517776&dopt=Abstract

•

Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. Author(s): Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S, Dorken B, Zenke M, Stein H, Scheidereit C. Source: The Journal of Experimental Medicine. 2002 September 2; 196(5): 605-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12208876&dopt=Abstract

•

Nuclear transcription factor-kappaB in Hodgkin's disease. Author(s): Younes A, Garg A, Aggarwal BB. Source: Leukemia & Lymphoma. 2003 June; 44(6): 929-35. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12854890&dopt=Abstract

•

Occurrence of a myocardial infarction in a 31-year-old woman with severe hypercholesterolemia (type IIA hyperlipidemia) three years after mantle irradiation for stage IIA Hodgkin's disease. Author(s): Myers AM, Havranek E. Source: American Journal of Hematology. 1998 February; 57(2): 180-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9462555&dopt=Abstract

•

Occurrence of Hodgkin's disease and cutaneous B-cell lymphoma in the same patient: a report of two cases. Author(s): Servitje O, Marti RM, Estrach T, Palou J, Gallardo F, Limon A, Romagosa V. Source: Eur J Dermatol. 2000 January-February; 10(1): 43-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10694298&dopt=Abstract

•

Oncogene expression in tumour cells of pediatric Hodgkin's disease in Argentina-correlation with Epstein Barr virus presence. Author(s): Preciado MV, Cristobal E, Menarguez J, Martinez Montero JC, Diez B, De Matteo E, Grinstein S. Source: Pathology, Research and Practice. 1998; 194(1): 25-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9542744&dopt=Abstract

100 Hodgkin’s Disease

•

Optimizing combined modality therapy for Hodgkin's disease. Author(s): Prosnitz LR. Source: International Journal of Radiation Oncology, Biology, Physics. 2003 January 1; 55(1): 1-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12504028&dopt=Abstract

•

Outcome in Hodgkin's disease: a 20-year cohort of patients. Author(s): Ranaghan L, Markey GM, Morris TC. Source: Ulster Med J. 1998 November; 67(2): 91-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9885544&dopt=Abstract

•

Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience. Author(s): Harrison CN, Vaughan G, Devereux S, Linch DC. Source: European Journal of Haematology. 1998 August; 61(2): 109-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9714522&dopt=Abstract

•

Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. Author(s): Kobrinsky NL, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M, Warkentin P, Gilchrist GS, Cohen MD, Shina D, Meadows AT. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 May 1; 19(9): 2390-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11331317&dopt=Abstract

•

Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Author(s): Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003; 14 Suppl 1: I11-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736225&dopt=Abstract

•

Ovarian tissue banking in patients with Hodgkin's disease: is it safe? Author(s): Meirow D, Ben Yehuda D, Prus D, Poliack A, Schenker JG, Rachmilewitz EA, Lewin A. Source: Fertility and Sterility. 1998 June; 69(6): 996-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9627281&dopt=Abstract

Studies

101

•

Ovarian transposition by laparoscopy before radiotherapy in the treatment of Hodgkin's disease. Author(s): Classe JM, Mahe M, Moreau P, Rapp MJ, Maisonneuve H, Lemevel A, Bourdin S, Harousseau JL, Cuilliere JC. Source: Cancer. 1998 October 1; 83(7): 1420-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9762944&dopt=Abstract

•

Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review. Author(s): Adiga GU, Abebe L, Wiernik PH. Source: American Journal of Hematology. 2003 April; 72(4): 267-73. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12666139&dopt=Abstract

•

Pediatric Hodgkin's disease--up, up, and beyond. Author(s): Donaldson SS. Source: International Journal of Radiation Oncology, Biology, Physics. 2002 September 1; 54(1): 1-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12182968&dopt=Abstract

•

Primary Hodgkin's disease of the nasopharynx: a rare but bona fide disease. Author(s): Abbes I, Mrad K, Sassi S, Jellouli M, Kochbati L, Maalej M, Ben Romdhane K. Source: Pathologica. 2002 December; 94(6): 314-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540996&dopt=Abstract

•

Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Author(s): Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 February; 14(2): 268-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12562654&dopt=Abstract

•

Primary treatment of Hodgkin's disease. Author(s): Canellos GP. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 4: 153-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401682&dopt=Abstract

102 Hodgkin’s Disease

•

Prognostic factors for children with Hodgkin's disease treated with combinedmodality therapy. Author(s): Smith RS, Chen Q, Hudson MM, Link MP, Kun L, Weinstein H, Billett A, Marcus KJ, Tarbell NJ, Donaldson SS. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 May 15; 21(10): 2026-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743158&dopt=Abstract

•

Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. Author(s): Ribera JM, Navarro JT, Oriol A, Lopez-Guillermo A, Sureda A, Abella E, Hernandez-Rivas JA, Xicoy B, Grau J, Batlle M, Feliu E. Source: Aids (London, England). 2002 September 27; 16(14): 1973-6. Erratum In: Aids. 2003 January 3; 17(1): 145. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12351963&dopt=Abstract

•

Prognostic role of natural killer cells in pediatric mixed cellularity and nodular sclerosing Hodgkin's disease. Author(s): Ortac R, Aktas S, Diniz G, Erbay A, Vergin C. Source: Anal Quant Cytol Histol. 2002 October; 24(5): 249-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12408556&dopt=Abstract

•

Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. Author(s): Guay C, Lepine M, Verreault J, Benard F. Source: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 2003 August; 44(8): 1225-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12902411&dopt=Abstract

•

Pseudomembranous tracheobronchial aspergillosis: a rare manifestation of invasive aspergillosis in a non-neutropenic patient with Hodgkin's disease. Author(s): Buchheidt D, Weiss A, Reiter S, Hartung G, Hehlmann R. Source: Mycoses. 2003 February; 46(1-2): 51-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12588484&dopt=Abstract

•

Quality assurance: Hodgkin's disease and beyond. Author(s): Gogna K. Source: Australasian Radiology. 2000 November; 44(4): 367-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11103532&dopt=Abstract

Studies

103

•

Quality of life and psychological well-being in Spanish long-term survivors of Hodgkin's disease: results of a controlled pilot study. Author(s): Gil-Fernandez J, Ramos C, Tamayo T, Tomas F, Figuera A, Arranz R, Martinez-Chamorro C, Fernandez-Ranada M. Source: Annals of Hematology. 2003 January; 82(1): 14-8. Epub 2002 December 19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12574958&dopt=Abstract

•

Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group. Author(s): Flechtner H, Ruffer JU, Henry-Amar M, Mellink WA, Sieber M, Ferme C, Eghbali H, Josting A, Diehl V. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998; 9 Suppl 5: S147-54. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9926255&dopt=Abstract

•

Quality of life in survivors of Hodgkin's disease. Author(s): Norum J, Wist EA. Source: Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 1996 June; 5(3): 367-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8763805&dopt=Abstract

•

Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. Author(s): Dukers DF, Jaspars LH, Vos W, Oudejans JJ, Hayes D, Cillessen S, Middeldorp JM, Meijer CJ. Source: The Journal of Pathology. 2000 February; 190(2): 143-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10657011&dopt=Abstract

•

Radiation therapy in the treatment of Hodgkin's disease--do you see what I see? Author(s): Longo DL. Source: Journal of the National Cancer Institute. 2003 July 2; 95(13): 928-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12837820&dopt=Abstract

•

Radiotherapy for advanced Hodgkin's disease. Author(s): Gupta T, Sanghavi V, Laskar S. Source: The New England Journal of Medicine. 2003 September 18; 349(12): 1187-8; Author Reply 1187-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13679537&dopt=Abstract

104 Hodgkin’s Disease

•

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. Author(s): Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 February 15; 21(4): 607-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12586796&dopt=Abstract

•

Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy, by Nachman et al. Author(s): Ekert H, Ashley D. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 March 15; 21(6): 1192; Author Reply 1192. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12637492&dopt=Abstract

•

Rare, late complications in a patient with Hodgkin's disease. Author(s): Illes A, Gergely L, Miltenyi Z, Keresztes K, Olvaszto S, Redl P, Danko K. Source: Haematologia. 2002; 32(4): 509-18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12803127&dopt=Abstract

•

Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677-683. Author(s): Agarwal B, Naresh KN. Source: The Journal of Pathology. 2003 October; 201(2): 334-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14517852&dopt=Abstract

•

Re: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. Author(s): Narod S, Lubinski J. Source: Journal of the National Cancer Institute. 2003 October 15; 95(20): 1552. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14559880&dopt=Abstract

•

Rearranged Epstein-Barr virus genome in Hodgkin's disease and angioimmunoblastic lymphadenopathy: Swiss results. Author(s): Knecht H, Odermatt BF. Source: American Journal of Pathology. 2003 July; 163(1): 369-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12819043&dopt=Abstract

Studies

105

•

Reproductive factors in Hodgkin's disease in women. Author(s): Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF. Source: American Journal of Epidemiology. 2003 September 15; 158(6): 553-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12965881&dopt=Abstract

•

Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. Author(s): van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS. Source: Journal of the National Cancer Institute. 2003 July 2; 95(13): 971-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12837833&dopt=Abstract

•

Sacroiliitis as a manifestation of Hodgkin's disease in young females. Author(s): Saviola G, Abdi Ali L, Trentanni C, Notarangelo LD, Desiati F, Lupi E, Pontikaki I, Gerloni V. Source: Clin Exp Rheumatol. 2003 March-April; 21(2): 270. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12747293&dopt=Abstract

•

Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases. Author(s): de Hemricourt E, De Boeck K, Hilte F, Abib A, Kockx M, Vandevivere J, De Bock R. Source: Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 2003 January-February; 5(1): 15-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14499156&dopt=Abstract

•

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Author(s): Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V; The German Hodgkin's Lymphoma Study Group. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 September 15; 21(18): 3440-6. Epub 2003 March 07. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668650&dopt=Abstract

•

Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. Author(s): Blackhall FH, Atkinson AD, Maaya MB, Ryder WD, Horne G, Brison DR, Lieberman BA, Radford JA. Source: British Journal of Cancer. 2002 August 12; 87(4): 381-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12177773&dopt=Abstract

106 Hodgkin’s Disease

•

Sequential development of Hodgkin's disease and CD30+ diffuse large B-cell lymphoma in a patient with MALT-type lymphoma: evidence of different clonal origin of single microdissected Reed-Sternberg cells. Author(s): Parrens M, Vergier B, Fitoussi O, Lahet C, Belleannee G, Marit G, Dubus P, de Mascarel A, Delfau-Larue MH, Merlio JP. Source: The American Journal of Surgical Pathology. 2002 December; 26(12): 1634-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12459631&dopt=Abstract

•

Severely hyperkeratotic erythroderma associated with Hodgkin's disease: does a high serum level of granulocyte-colony stimulating factor contribute to formation of skin lesions? Author(s): Arita K, Akiyama M, Sakai T, Shimizu H. Source: Journal of the American Academy of Dermatology. 2003 October; 49(4): 772-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14512943&dopt=Abstract

•

Spontaneous regression of HIV-associated Hodgkin's disease. Author(s): Parekh S, Koduri PR. Source: American Journal of Hematology. 2003 February; 72(2): 153-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12555225&dopt=Abstract

•

Spontaneous regression of Hodgkin's disease: two case reports and a review of the literature. Author(s): Mangel J, Barth D, Berinstein NL, Imrie KR. Source: Hematology (Amsterdam, Netherlands). 2003 June; 8(3): 191-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12745644&dopt=Abstract

•

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. Author(s): Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dorken B, Muller-Hermelink HK, Duhmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Source: The New England Journal of Medicine. 2003 June 12; 348(24): 2386-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802024&dopt=Abstract

•

Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Author(s): Proctor SJ, Jackson GH, Lennard A, Angus B, Wood K, Lucraft HL, White J, Windebank K, Taylor PR; Northern Region Lymphoma Group. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003; 14 Suppl 1: I47-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736232&dopt=Abstract

Studies

107

•

Thallium-201 imaging in evaluation of Hodgkin's disease. Author(s): Dadparvar S, Hussain R, Esteves F, Yu JQ, Grewal RK, Arif S, Cruz R, Barbaria CJ, Woods K, Styler MJ. Source: Cancer Journal (Sudbury, Mass.). 2002 November-December; 8(6): 469-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12500856&dopt=Abstract

•

The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. Author(s): Flavell KJ, Billingham LJ, Biddulph JP, Gray L, Flavell JR, Constandinou CM, Young LS, Murray PG. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 February; 14(2): 282-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12562657&dopt=Abstract

•

The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Author(s): Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM, Armitage JO. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 September; 13(9): 1370-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196362&dopt=Abstract

•

The management of stage I-II supradiaphragmatic Hodgkin's disease with chemotherapy alone. Author(s): Provencio M, Espana P, Millan I, Sanchez A, Cantos B, Bonilla F. Source: Leukemia & Lymphoma. 2003 February; 44(2): 263-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12688343&dopt=Abstract

•

The strong correlation between serum copper level and the copper/zinc ratio to histopathological changes, clinical stage, and prognosis of Hodgkin's disease. Author(s): Gozdasoglu S, Akar N. Source: Biological Trace Element Research. 2003 February; 91(2): 191-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12719614&dopt=Abstract

•

Thymic epithelial hyperplasia with nodular sclerosis Hodgkin's disease. Author(s): Ito W, Kojima K, Fujiwara K, Nanba Y, Yoshino T, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Tanimoto M. Source: Leukemia & Lymphoma. 2002 November; 43(11): 2229-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12533053&dopt=Abstract

108 Hodgkin’s Disease

•

Thyroid nodules and survivors of Hodgkin's disease. Author(s): Oeffinger KC, Sklar CA, Hudson MM. Source: American Family Physician. 2003 September 15; 68(6): 1016, 1018-9; Discussion 1019. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14524392&dopt=Abstract

•

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Author(s): Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK, Diehl V, Engert A; Participating Centers. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 October; 13(10): 1628-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12377653&dopt=Abstract

•

Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study. Author(s): Economopoulos T, Fountzilas G, Dimopoulos MA, Papageorgiou S, Xiros N, Kalantzis D, Dervenoulas J, Raptis S. Source: European Journal of Haematology. 2003 October; 71(4): 257-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12950234&dopt=Abstract

•

Trends in mortality from Hodgkin's disease in western and eastern Europe. Author(s): Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Source: British Journal of Cancer. 2002 July 29; 87(3): 291-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12177797&dopt=Abstract

•

Unusual association of Hodgkin's disease and sarcoidosis. Author(s): Simsek S, van Leuven F, Bronsveld W, Ooms GH, Groeneveld AB, de Graaff CS. Source: The Netherlands Journal of Medicine. 2002 December; 60(11): 438-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12685492&dopt=Abstract

•

Unusual manifestations of Hodgkin's disease. Author(s): Lowenthal MN. Source: Isr Med Assoc J. 2003 March; 5(3): 230; Author Reply 230. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12725154&dopt=Abstract

•

Unusual manifestations of Hodgkin's disease. Author(s): Roif M, Miller EB, Kneller A, Landau Z. Source: Isr Med Assoc J. 2003 January; 5(1): 62-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12592964&dopt=Abstract

Studies

109

•

Unusual presentation of Hodgkin's disease mimicking inflammatory bowel disease. Author(s): Vincenzi B, Finolezzi E, Fossati C, Verzi A, Santini D, Tonini G, Arullani A, Avvisati G. Source: Leukemia & Lymphoma. 2001 July; 42(3): 521-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11699419&dopt=Abstract

•

Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90. Author(s): Dieckmann K, Potter R, Wagner W, Prott FJ, Hornig-Franz I, Rath B, Schellong G. Source: Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 2002 February; 62(2): 191-200. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11937246&dopt=Abstract

•

Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits? Author(s): Kewalramani T, Moskowitz CH. Source: Current Oncology Reports. 2001 May; 3(3): 271-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11296139&dopt=Abstract

•

Usefulness of K-1 (CD-30) marker in Hodgkin's disease. Author(s): Shakoor KA, Saleh A, Khanzada MS. Source: J Pak Med Assoc. 2002 October; 52(10): 442-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12553671&dopt=Abstract

•

Usefulness of the prognostic score for advanced Hodgkin's disease in patients with human immunodeficiency virus-associated Hodgkin's lymphoma. Author(s): Ribera JM, Navarro JT, Oriol A, Vaquero M, Grau J, Feliu E. Source: Haematologica. 2000 March; 85(3): 325-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10702829&dopt=Abstract

•

Utility and outcomes of fine-needle aspiration biopsy in Hodgkin's disease. Author(s): Moreland WS, Geisinger KR. Source: Diagnostic Cytopathology. 2002 May; 26(5): 278-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11992367&dopt=Abstract

•

Utility of CD15, CD30 & CD45 in the immunohistochemical diagnosis of Hodgkin's disease by antigen retrieval method. Author(s): Arici DS, Aker H, Gungor M. Source: The Indian Journal of Medical Research. 1999 January; 109: 33-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10489740&dopt=Abstract

110 Hodgkin’s Disease

•

Value of fine needle aspiration cytology in the initial diagnosis of Hodgkin's disease. Analysis of 188 cases with an emphasis on diagnostic pitfalls. Author(s): Jimenez-Heffernan JA, Vicandi B, Lopez-Ferrer P, Hardisson D, Viguer JM. Source: Acta Cytol. 2001 May-June; 45(3): 300-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11393058&dopt=Abstract

•

Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Author(s): Zinzani PL, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M, Piccaluga PP, Tura S. Source: Haematologica. 2000 September; 85(9): 926-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10980630&dopt=Abstract

•

VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. Author(s): Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 July 15; 20(14): 3081-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12118021&dopt=Abstract

•

Vanishing bile duct syndrome in Hodgkin's disease: case report. Author(s): Rossini MS, Lorand-Metze I, Oliveira GB, Souza CA. Source: Sao Paulo Medical Journal = Revista Paulista De Medicina. 2000 September 7; 118(5): 154-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11018850&dopt=Abstract

•

Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin's disease. Author(s): Komurcu S, Ozet A, Altundag MK, Arpaci F, Ozturk B, Celasun B, Tezcan Y. Source: Annals of Hematology. 2002 January; 81(1): 57-8. Epub 2001 December 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11807639&dopt=Abstract

•

Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease. Author(s): Saif MW, Hamilton JM, Allegra CJ. Source: Leukemia & Lymphoma. 2000 October; 39(3-4): 421-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11342324&dopt=Abstract

Studies

111

•

Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-ReedSternberg cells in Hodgkin's disease. Author(s): Doussis-Anagnostopoulou IA, Talks KL, Turley H, Debnam P, Tan DC, Mariatos G, Gorgoulis V, Kittas C, Gatter KC. Source: The Journal of Pathology. 2002 August; 197(5): 677-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12210089&dopt=Abstract

•

Very late relapse of Hodgkin's disease: a report of five patients. Author(s): Shihabi S, Deutsch M, Jacobs SA. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 2001 December; 24(6): 576-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11801757&dopt=Abstract

•

Virus-like agents from patients with Hodgkin's disease. Author(s): Eisinger M, Fox SM, De Harven E, Biedler JL, Sanders FK. Source: Nature. 1971 September 10; 233(5315): 104-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12058748&dopt=Abstract

•

Vitiligo at the sites of irradiation in a patient with Hodgkin's disease. Author(s): Pajonk F, Weissenberger C, Witucki G, Henke M. Source: Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft. [et Al]. 2002 March; 178(3): 159-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11962193&dopt=Abstract

•

What causes Hodgkin's disease in children? Author(s): Stiller CA. Source: European Journal of Cancer (Oxford, England : 1990). 1998 March; 34(4): 523-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9713303&dopt=Abstract

•

What is the best position of the arms in mantle field for Hodgkin's disease? Author(s): Pergolizzi S, Settineri N, Gaeta M, Scribano E, Santacaterina A, Ascenti G, Frosina P, de Renzis C. Source: International Journal of Radiation Oncology, Biology, Physics. 2000 January 1; 46(1): 119-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10656382&dopt=Abstract

•

What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy? Author(s): Mundt AJ, Connell PP, Mansur DB. Source: Radiation Oncology Investigations. 1999; 7(6): 353-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10644058&dopt=Abstract

112 Hodgkin’s Disease

•

What is the role for adjuvant radiation therapy in advanced Hodgkin's disease? Author(s): Mauch P. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 March; 16(3): 815-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9508161&dopt=Abstract

•

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Author(s): Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, Rigo P. Source: Nuclear Medicine Communications. 1999 January; 20(1): 13-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9949408&dopt=Abstract

•

Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. Author(s): Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, Hawkin RA, Maddahi J, Phelps ME. Source: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 1997 March; 38(3): 343-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9074514&dopt=Abstract

•

Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Author(s): Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Source: Haematologica. 2001 March; 86(3): 266-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11255273&dopt=Abstract

•

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Author(s): Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, Textoris F, Ansen S, Franklin J, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H. Source: Annals of Hematology. 2002 January; 81(1): 20-5. Epub 2001 December 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11807631&dopt=Abstract

•

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Author(s): Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Source: Blood. 1999 July 15; 94(2): 429-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10397709&dopt=Abstract

Studies

113

•

Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Author(s): Rudiger T, Jaffe ES, Delsol G, deWolf-Peeters C, Gascoyne RD, Georgii A, Harris NL, Kadin ME, MacLennan KA, Poppema S, Stein H, Weiss LE, MullerHermelink HK. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998; 9 Suppl 5: S31-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9926235&dopt=Abstract

•

X-chromosome inactivation analysis of isolated Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. Author(s): Chang HW, Chong SM, Peh SC, Lee SH. Source: British Journal of Haematology. 1999 December; 107(3): 641-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10583270&dopt=Abstract

•

XRT for stage IV Hodgkin's disease? Less chaff please. Author(s): Beitler JJ. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 August; 16(8): 2893. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9704746&dopt=Abstract

115

CHAPTER 2. NUTRITION AND HODGKIN’S DISEASE Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and Hodgkin’s disease.

Finding Nutrition Studies on Hodgkin’s Disease The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail: [email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “Hodgkin’s disease” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.

7 Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.

116 Hodgkin’s Disease

The following information is typical of that found when using the “Full IBIDS Database” to search for “Hodgkin’s disease” (or a synonym): •

A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Author(s): Department of Internal Medicine I, University of Koeln, Joseph-StelzmannStrasse 9, D-50924 Koeln, Germany. Source: Schnell, R Staak, O Borchmann, P Schwartz, C Matthey, B Hansen, H Schindler, J Ghetie, V Vitetta, E S Diehl, V Engert, A Clin-Cancer-Res. 2002 June; 8(6): 1779-86 10780432

•

A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. Author(s): Department of Haematology, Oncology Hospital, National Medical Centre, Mexico, D.F., Mexico. Source: Aviles, A Delgado, S Clin-Lab-Haematol. 1998 April; 20(2): 95-9 0141-9854

•

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Author(s): First Department of Internal Medicine, University Hospital Cologne, JosephStelzmann-Str. 9, 50931 Cologne, Germany. Source: Glossmann, J P Josting, A Pfistner, B Paulus, U Engert, A Ann-Hematol. 2002 August; 81(8): 424-9 0939-5555

•

ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease. Author(s): Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy. Source: Zinzani, P L Magagnoli, M Frezza, G Barbieri, E Gherlinzoni, F Galuppi, A Bendandi, M Merla, E Albertini, P Babini, L Tura, S Leuk-Lymphoma. 1999 February; 32(5-6): 553-9 1042-8194

•

Advanced Hodgkin's disease: ABVD is better, yet is not good enough! Source: Diehl, V J-Clin-Oncol. 2003 February 15; 21(4): 583-5 0732-183X

•

Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Author(s): Hematology Division, National Cancer Center Hospital, Tokyo, Japan. Source: Takenaka, T Mikuni, C Miura, A Sasaki, T Suzuki, H Hotta, T Hirano, M Fukuhara, S Sugiyama, H Nasu, K Dohi, H Kozuru, M Tomonaga, M Tajima, K Niimi, M Fukuda, H Mukai, K Shimoyama, M Jpn-J-Clin-Oncol. 2000 March; 30(3): 146-52 03682811

•

An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU. Author(s): Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK. Source: Lennard, A L Carey, P J Jackson, G H Proctor, S J Cancer-Chemother-Pharmacol. 1990; 26(4): 301-5 0344-5704

•

Approach to Hodgkin's lymphoma in the new millennium. Author(s): Division of Hematology/Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA. [email protected]

Nutrition

117

Source: Fung, Henry C Nademanee, Auayporn P Hematol-Oncol. 2002 March; 20(1): 115 0278-0232 •

Association between alopecia and response to aggressive chemotherapy in patients with Hodgkin's disease. Author(s): Department of Medicine, Meir Hospital Kfar Saba and Sackler Faculty of Medicine, Tel Aviv University, Israel. Source: Lishner, M Manor, Y Kitay Cohen, Y Avishay, A E Med-Hypotheses. 1999 November; 53(5): 447-9 0306-9877

•

Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Author(s): Autologous Bone Marrow Transplantation Unit, Ospedale S. Martino, Genoa, Italy. Source: Carella, A M Carlier, P Congiu, A Occhini, D Nati, S Santini, G Pierluigi, D Giordano, D Bacigalupo, A Damasio, E Bone-Marrow-Transplant. 1991 August; 8(2): 99103 0268-3369

•

Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. Author(s): Department of Hematology, Hospital Universitario de la Princesa, Madrid, Spain. Source: Arranz, R Tomas, J F Gil Fernandez, J J Martinez Chamorro, C Granados, E Alegre, A Figuera, A Vazquez, L Camara, R Fernandez Ranada, J M Bone-MarrowTransplant. 1998 April; 21(8): 779-86 0268-3369

•

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term followup and analysis of prognostic factors. Author(s): Department of Medicine, University of Rochester School of Medicine and Dentistry, NY, USA. Source: Lancet, J E Rapoport, A P Brasacchio, R Eberly, S Raubertas, R F Linder, T Muhs, A Duerst, R E Abboud, C N Packman, C H DiPersio, J F Constine, L S Rowe, J M Liesveld, J L Bone-Marrow-Transplant. 1998 August; 22(3): 265-71 0268-3369

•

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Author(s): Department of Internal Medicine, University of Cologne, Germany. [email protected] Source: Diehl, V Franklin, J Hasenclever, D Tesch, H Pfreundschuh, M Lathan, B Paulus, U Sieber, M Rueffer, J U Sextro, M Engert, A Wolf, J Hermann, R Holmer, L Stappert Jahn, U Winnerlein Trump, E Wulf, G Krause, S Glunz, A von Kalle, K Bischoff, H Haedicke, C Duehmke, E Georgii, A Loeffler, M J-Clin-Oncol. 1998 December; 16(12): 3810-21 0732-183X

•

Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481). Author(s): OLM Comprehensive Cancer Center, New York Medical College, Bronx 10466, USA. [email protected] Source: Wiernik, P H Leong, T Oken, M M Neiman, R S Habermann, T M Bennett, J M Schuster, S Glick, J H Leuk-Lymphoma. 2001 January; 40(3-4): 357-63 1042-8194

118 Hodgkin’s Disease

•

British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. Author(s): YCRC Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK. Source: Hancock, B W Vaughan Hudson, G Vaughan Hudson, B Haybittle, J L Bennett, M H MacLennan, K A Jelliffe, A M Br-J-Cancer. 1991 April; 63(4): 579-82 0007-0920

•

CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. Author(s): Department of Lymphoma-Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Source: Rassidakis, George Z Medeiros, L Jeffrey Viviani, Simonetta Bonfante, Valeria Nadali, Gian Paolo Vassilakopoulos, Theodoros P Mesina, Ofelia Herling, Marco Angelopoulou, Maria K Giardini, Roberto Chilosi, Marco Kittas, Christos McLaughlin, Peter Rodriguez, M Alma Romaguera, Jorge Bonadonna, Gianni Gianni, Alessandro M Pizzolo, Giovanni Pangalis, Gerassimos A Cabanillas, Fernando Sarris, Andreas H JClin-Oncol. 2002 Mar 1; 20(5): 1278-87 0732-183X

•

Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease. Author(s): Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA. [email protected] Source: Yahalom, J Curr-Oncol-Repage 2002 September; 4(5): 415-23 1523-3790

•

Chemotherapy of Hodgkin's disease. Author(s): Institut Gustave-Roussy, Villejuif, France. Source: Carde, P Nouv-Rev-Fr-Hematol. 1990; 32(2): 169-73

•

CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity. Author(s): Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330. Source: Vose, J M Bierman, P J Anderson, J R Weisenburger, D Moravec, D F Sorensen, S Hutchins, M Dowling, M D Howe, D Okerbloom, J et al. J-Clin-Oncol. 1991 August; 9(8): 1421-5 0732-183X

•

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Author(s): Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. Source: Selby, P Patel, P Milan, S Meldrum, M Mansi, J Mbidde, E Brada, M Perren, T Forgeson, G Gore, M et al. Br-J-Cancer. 1990 August; 62(2): 279-85 0007-0920

•

ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients. Author(s): Servizio Oncologico Cantonale, Ospedale San Giovanni, Bellinzona, Switzerland. Source: Saletti, P Zucca, E Gueneau, M Peccatori, F Cavalli, F Martinelli, G LeukLymphoma. 1999 April; 33(3-4): 313-9 1042-8194

•

ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. Author(s): Department of Medical Oncology, Christie Hospital, Manchester, UK. [email protected]

Nutrition

119

Source: Radford, J A Rohatiner, A Z S Ryder, W D J Deakin, D P Barbui, T Lucie, N P Rossi, A Dunlop, D J Cowan, R A Wilkinson, P M Gupta, R K James, R D Shamash, J Chang, J Crowther, D Lister, T A J-Clin-Oncol. 2002 July 1; 20(13): 2988-94 0732-183X •

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5SMPT-dgA) in Hodgkin's lymphoma. Author(s): Klinik I fuer Innere Medizin, Universitaet zu Koeln, Germany. Source: Schnell, R Vitetta, E Schindler, J Barth, S Winkler, U Borchmann, P Hansmann, M L Diehl, V Ghetie, V Engert, A Leuk-Lymphoma. 1998 August; 30(5-6): 525-37 10428194

•

Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and nonHodgkin's lymphoma. Author(s): University Hospital, The Norwegian Radium Hospital, Montebello, Oslo. Source: Aurlien, E Holte, H Pharo, A Kvaloy, S Jakobsen, E Smeland, E B Kvalheim, G Bone-Marrow-Transplant. 1998 May; 21(9): 873-8 0268-3369

•

Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial. Author(s): National Cancer Institute of Canada Clinical Trials Group, Kingston. Source: Yelle, L Bergsagel, D Basco, V Brown, T Bush, R Gillies, J Israels, L Miller, A Rideout, D Whitelaw, D et al. J-Clin-Oncol. 1991 November; 9(11): 1983-93 0732-183X

•

Communication challenges in a young man with Hodgkin's disease. Author(s): Yale New Haven Hospital, New Haven, Connecticut, USA. Source: Medoff, E Cancer-Pract. 2001 Nov-December; 9(6): 272-6 1065-4704

•

Comparison of high-dose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease: an analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania. Author(s): Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia 19104. Source: Maity, A Goldwein, J W Lange, B D'Angio, G J J-Clin-Oncol. 1992 June; 10(6): 929-35 0732-183X

•

Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease. Author(s): National Cancer Institute, Bratislava, Czechoslovakia. Source: Koza, I Bohunicky, L Mocikova, K Gyarfas, J Svancarova, L Mardiak, J Spanik, S Fuchsberger, P Thalmeinerova, Z Sufliarsky, J et al. Neoplasma. 1991; 38(6): 583-93 00282685

•

Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Author(s): Dipartimento Biotecnologie Celluari ed Ematologia, Universita La Sapienza, Rome, Italy. Source: Anselmo, A P Meloni, G Cavalieri, E Proia, A Enrici, R M Funaro, D Pescarmona, E Mandelli, F Ann-Hematol. 2000 February; 79(2): 79-82 0939-5555

•

EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Author(s): National and Kapodistrian University of Athens, First Department of Internal Medicine, Laikon General Hospital, Greece. Source: Angelopoulou, M K Vassilakopoulos, T P Siakantaris, M P Kontopidou, F N Boussiotis, V A Papavassiliou, C Kittas, C Pangalis, G A Leuk-Lymphoma. 2000 March; 37(1-2): 131-43 1042-8194

120 Hodgkin’s Disease

•

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease. Author(s): Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. Source: Perren, T J Selby, P J Milan, S Meldrum, M McElwain, T J Br-J-Cancer. 1990 June; 61(6): 919-23 0007-0920

•

Functional imaging of Hodgkin's disease with FDG-PET and gallium-67. Author(s): Department of Nuclear Medicine, University of Bonn, Germany. [email protected] Source: Willkomm, P Palmedo, H Grunwald, F Ruhlmann, J Biersack, H J Nuklearmedizin. 1998; 37(7): 251-3 0029-5566

•

Greater curability in advanced Hodgkin's disease? Author(s): Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6007, USA. Source: Portlock, C S Cancer-J-Sci-Am. 1999 Sep-October; 5(5): 264-5 1081-4442

•

Haematological toxicity compromises MOPP/ABVD chemotherapy in Hodgkin's disease. Author(s): Departments of Haematology, Plymouth Hospitals, Devon, UK. Source: Goodrick, M J Daniel, F Prentice, A G Copplestone, J A Tyrrell, C J Clin-Oncol(R-Coll-Radiol). 1991 May; 3(3): 151-4 0936-6555

•

High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. Author(s): Department of Pediatric Hematology and Oncology, University Children's Hospital, Germany. [email protected] Source: Schellong, G Potter, R Bramswig, J Wagner, W Prott, F J Dorffel, W Korholz, D Mann, G Rath, B Reiter, A Weissbach, G Riepenhausen, M Thiemann, M Schwarze, E W J-Clin-Oncol. 1999 December; 17(12): 3736-44 0732-183X

•

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Author(s): University College Medical School, London, UK. Source: Harrison, C N Gregory, W Hudson, G V Devereux, S Goldstone, A H Hancock, B Winfield, D MacMillan, A K Hoskin, P Newland, A C Milligan, D Linch, D C Br-JCancer. 1999 October; 81(3): 476-83 0007-0920

•

High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Author(s): Division of Medical Oncology C, Istituto Nazionale Tumori, Milan, Italy. [email protected] Source: Bonfante, V Viviani, S Devizzi, L Di Russo, A Di Nicola, M Magni, M Matteucci, P Grisanti, S Valagussa, P Bonadonna, G Gianni, A M Eur-J-Haematol-Suppl. 2001 July; (64): 51-5 0902-4506

•

High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Author(s): Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway. Source: Blystad, A K Holte, H Kvaloy, S Smeland, E Delabie, J Kvalheim, G BoneMarrow-Transplant. 2001 November; 28(9): 849-57 0268-3369

Nutrition

121

•

Hodgkin's disease complicated by the nephrotic syndrome in a man with KugelbergWelander disease. Author(s): Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia. Source: Thomson, J A Seymour, J F Wolf, M Leuk-Lymphoma. 2001 July; 42(3): 561-6 1042-8194

•

Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicincontaining regimen. Author(s): University of Nebraska Medical Center, Omaha, NE 68198-7680, USA. [email protected] Source: Weekes, Colin D Vose, Julie M Lynch, Jim C Weisenburger, Dennis D Bierman, Philip J Greiner, Timothy Bociek, Gregory Enke, Charles Bast, Martin Chan, Wing C Armitage, James O J-Clin-Oncol. 2002 February 15; 20(4): 1087-93 0732-183X

•

Hodgkin's disease of the liver; prognosis and possible indications for radiotherapy. Author(s): Department of Radiotherapy and Oncology, Royal Marsden Hospital, Sutton, Surrey, UK. Source: O'Brien, P Crow, J Brada, M Ashley, S Horwich, A Clin-Oncol-(R-Coll-Radiol). 1991 July; 3(4): 189-92 0936-6555

•

Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Author(s): Beth Israel Deaconess Medical Center, Division of Hematology/Oncology, Farber Cancer Institute, MA, USA. Source: Wheeler, C Khurshid, A Ibrahim, J Elias, A Mauch, P Ault, K Antin, J LeukLymphoma. 2001 February; 40(5-6): 499-509 1042-8194

•

Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. Author(s): Department d'Oncologie/Hematologie, Hopital Laennec, Paris, France. Source: Andrieu, J M Ifrah, N Payen, C Fermanian, J Coscas, Y Flandrin, G J-Clin-Oncol. 1990 July; 8(7): 1148-54 0732-183X

•

Intensive chemotherapy and low-dose radiotherapy for the treatment of advancedstage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. Author(s): Hackensack Medical Center, NJ. Source: Weiner, M A Leventhal, B G Marcus, R Brecher, M Ternberg, J Behm, F G Cantor, A Wharam, M Chauvenet, A J-Clin-Oncol. 1991 September; 9(9): 1591-8 0732183X

•

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Author(s): Groupe d'Etudes des Lymphomes de l'Adulte, Hopital Saint-Louis, Paris, France. [email protected] Source: Ferme, Christophe Mounier, Nicolas Divine, Marine Brice, Pauline Stamatoullas, Aspasia Reman, Oumedaly Voillat, Laurent Jaubert, Jerome Lederlin, Pierre Colin, Philippe Berger, Francoise Salles, Gilles J-Clin-Oncol. 2002 January 15; 20(2): 467-75 0732-183X

•

Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome. Author(s): Department of Hematology/Oncology, Bretonneau Hospital, Tours, France.

122 Hodgkin’s Disease

Source: Delain, M Cartron, G Bout, M Benboubker, L Linassier, C Lamagnere, J P Colombat, P Leuk-Lymphoma. 1999 July; 34(3-4): 305-13 1042-8194 •

Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease? Author(s): Institute Gustav-Roussy, Villejuif, France. [email protected] Source: Carde, P Cavalli, F Diehl, V Franklin, J Hematol-J. 2000; 1(4): 282-90 1466-4860

•

Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapyresults of the French Society of Pediatric Oncology Study MDH90. Author(s): Departments of Pediatric Hematology and Oncology, Hopital d'Enfants Armand Trousseau, Institut Curie, Hopital Saint Louis, Paris, France. [email protected] Source: Landman Parker, J Pacquement, H Leblanc, T Habrand, J L Terrier Lacombe, M J Bertrand, Y Perel, Y Robert, A Coze, C Thuret, I Donadieu, J Schaison, G Leverger, G Lemerle, J Oberlin, O J-Clin-Oncol. 2000 April; 18(7): 1500-7 0732-183X

•

Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Author(s): Division of Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy. Source: Viviani, S Bonfante, V Santoro, A Zanini, M Devizzi, L Di Russo, A D Soncini, F Villani, F Ragni, G Valagussa, P Bonadonna, G Cancer-J-Sci-Am. 1999 Sep-October; 5(5): 275-82 1081-4442

•

Lung cancer after treatment of Hodgkin's disease--a case report. Author(s): Istituto di Anatomia e Istologia Patologica, Universita degli Studi, Perugia Ospedale Civile S. Maria, Terni, Italy. Source: Cristallini, E G Buzzi, F Santoro, S Bolis, G B Acta-Oncol. 1991; 30(5): 651-2 0284186X

•

Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group. Author(s): Departments of Oncology, University of Uppsala, Akademiska Hospital, Sweden. Source: Enblad, G Glimelius, B Hagberg, H Lindemalm, C Acta-Oncol. 1990; 29(3): 297301 0284-186X

•

Midkine expression in Reed-Sternberg cells of Hodgkin's disease. Author(s): First Department of Internal Medicine, Nagoya University School of Medicine, Japan. Source: Kato, H Watanabe, K Murari, M Isogai, C Kinoshita, T Nagai, H Ohashi, H Nagasaka, T Kadomatsu, K Muramatsu, H Muramatsu, T Saito, H Mori, N Murate, T Leuk-Lymphoma. 2000 April; 37(3-4): 415-24 1042-8194

•

Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease. Author(s): Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10467, USA. Source: Wiernik, P H Dutcher, J P Einzig, A I Sparano, J Frank, M Friedenberg, W Cancer-J-Sci-Am. 1998 Jul-August; 4(4): 254-60 1081-4442

•

Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Author(s): Department of Haematology, Nottingham City Hospital, Nottingham, UK.

Nutrition

123

Source: McQuaker, I Haynes, A Stainer, C Byrne, J Russell, N Bone-Marrow-Transplant. 1999 October; 24(7): 715-22 0268-3369 •

MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. Author(s): C.S. Mott Children's Hospital, Ann Arbor, MI, USA. [email protected] Source: Hutchinson, R J Fryer, C J Davis, P C Nachman, J Krailo, M D O'Brien, R T Collins, R D Whalen, T Reardon, D Trigg, M E Gilchrist, G S J-Clin-Oncol. 1998 March; 16(3): 897-906 0732-183X

•

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. Author(s): University of Pennsylvania Cancer Center, Philadelphia 19104-4283, USA. [email protected] Source: Glick, J H Young, M L Harrington, D Schilsky, R L Beck, T Neiman, R Fisher, R I Peterson, B A Oken, M M J-Clin-Oncol. 1998 January; 16(1): 19-26 0732-183X

•

Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Author(s): Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA. Source: Seropian, S Nadkarni, R Jillella, A P Salloum, E Burtness, B Hu, G L Zelterman, D Cooper, D L Bone-Marrow-Transplant. 1999 Mar; 23(6): 599-605 0268-3369

•

Nitrosourea derivatives for the treatment of Hodgkin's disease involving the central nervous system: a study of 23 cases. Author(s): Department of Clinical Chemotherapy, NN Petrov Research Institute of Oncology, USSR Ministry of Health, Leningrad. Source: Gershanovich, M L Arkhipov, A I Vilensky, B S Bull-Cancer. 1990; 77(8): 821-8 0007-4551

•

Peroneal mononeuropathy in pediatric Hodgkin's disease. Author(s): Department of Pediatrics, Nishi-Kobe Medical Center, Kobe, Japan. [email protected] Source: Matsubara, K Nigami, H Harigaya, H Osaki, M Baba, K Leuk-Lymphoma. 2000 December; 40(1-2): 205-7 1042-8194

•

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. Author(s): Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Source: Press, O W LeBlanc, M Lichter, A S Grogan, T M Unger, J M Wasserman, T H Gaynor, E R Peterson, B A Miller, T P Fisher, R I J-Clin-Oncol. 2001 November 15; 19(22): 4238-44 0732-183X

•

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Author(s): Service d'Hematologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and UPRES-JE 1879 Hemopathies, Lymphoides malignes, Universite Claude Bernard, Pierre-Benite, France. Source: Warzocha, K Bienvenu, J Ribeiro, P Moullet, I Dumontet, C Neidhardt Berard, E M Coiffier, B Salles, G Br-J-Cancer. 1998 June; 77(12): 2357-62 0007-0920

124 Hodgkin’s Disease

•

Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. Author(s): Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021. Source: Straus, D J Gaynor, J J Myers, J Merke, D P Caravelli, J Chapman, D Yahalom, J Clarkson, B D J-Clin-Oncol. 1990 July; 8(7): 1173-86 0732-183X

•

Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. Author(s): University of Louisville, School of Medicine, James Graham Brown Cancer Center, Division of Hematology/Oncology, KY 40202, USA. Source: Fleming, D R Wolff, S N Fay, J W Brown, R A Lynch, J P Bolwell, B J Stevens, D A Goodman, S A Greer, J P Stein, R S Pineiro, L A Collins, R H Goldsmith, L J Herzig, G P Herzig, R H Leuk-Lymphoma. 1999 September; 35(1-2): 91-8 1042-8194

•

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. Author(s): Division of Cancer Treatment, National Cancer Institute, Bethesda, MD. Source: Longo, D L Glatstein, E Duffey, P L Young, R C Hubbard, S M Urba, W J Wesley, M N Raubitschek, A Jaffe, E S Wiernik, P H et al. J-Clin-Oncol. 1991 June; 9(6): 906-17 0732-183X

•

Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute. Author(s): Masaryk Memorial Cancer Institute, Brno, Czech Republic. [email protected] Source: Petera, J Macharova, H Pohankova, R Malir, A Coupek, P Konecny, M Patera, J Pecina, J Drbal, J Koukalova, H Vasova, I Neoplasma. 2000; 47(2): 129-32 0028-2685

•

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. Author(s): Department of Medicine, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA. [email protected] Source: Duggan, D B Petroni, G R Johnson, J L Glick, J H Fisher, R I Connors, J M Canellos, G P Peterson, B A J-Clin-Oncol. 2003 February 15; 21(4): 607-14 0732-183X

•

Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Author(s): Glasgow Royal Infirmary University NHS Trust, UK. Source: Dunlop, D J Eatock, M M Paul, J Anderson, S Reed, N S Soukop, M Lucie, N Fitzsimmons, E J Tansey, P Steward, W P Clin-Oncol-(R-Coll-Radiol). 1998; 10(2): 107-14 0936-6555

•

Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Author(s): Division of Hematology Oncology, Lymphoma Unit, Tupper Research Institute, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA. Source: Kanteti, R Miller, K McCann, J Roitman, D Morelli, J Hurley, C Berkman, E Schenkein, D Bone-Marrow-Transplant. 1999 September; 24(5): 473-81 0268-3369

•

Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage

Nutrition

125

Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Author(s): German Hodgkin's Lymphoma Study Group, Cologne, Germany. [email protected] Source: Sieber, Markus Tesch, Hans Pfistner, Beate Rueffer, Ulrich Lathan, Bernd Brosteanu, Oana Paulus, Ursula Koch, Tina Pfreundschuh, Michael Loeffler, Markus Engert, Andreas Josting, Andreas Wolf, Jurgen Hasenclever, Dirk Franklin, Jeremy Duehmke, Eckhart Georgii, Axel Schalk, Klaus Peter Kirchner, Hartmut Doelken, Gottfried Munker, Reinhold Koch, Peter Herrmann, Richard Greil, Richard Anselmo, Anna Paola Diehl, Volker J-Clin-Oncol. 2002 January 15; 20(2): 476-84 0732-183X •

Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Author(s): Institute of Oncology, Ljubljana, Slovenia. [email protected] Source: Markovic, S Drozina, G Vovk, M Fidler Jenko, M Hepatogastroenterology. 1999 Sep-October; 46(29): 2925-30 0172-6390

•

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Author(s): Leukemia/Bone Marrow Transplantation Program of British Columbia: Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Canada. Source: Reece, D E Nevill, T J Sayegh, A Spinelli, J J Brockington, D A Barnett, M J Klingemann, H G Connors, J M Nantel, S H Shepherd, J D Sutherland, H J Voss, N J Fairey, R N O'Reilly, S E Phillips, G L Bone-Marrow-Transplant. 1999 June; 23(11): 11318 0268-3369

•

Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study. Author(s): Department of Pediatrics, Medical College of Virginia, P.O. Box 980646, Richmond, VA 23298-0646, USA. [email protected] Source: Laver, J H Mahmoud, H Pick, T E Hutchinson, R E Weinstein, H J Schwenn, M Weitzman, S Murphy, S B Ochoa, S Shuster, J J Leuk-Lymphoma. 2001 July; 42(3): 399405 1042-8194

•

Secondary uncommon solid neoplasms in cured Hodgkin's disease and follow-up of the original B-DOPA chemotherapy patient group. Author(s): Cancer Center, Medical Center of Boston, Massachusetts 02120. Source: Lokich, J J Am-J-Clin-Oncol. 1990 June; 13(3): 247-50 0277-3732

•

Serum antithrombin III and alpha-2-antiplasmin concentrations in patients with Hodgkin's disease in the course of chemotherapy. Author(s): Department of Laboratory Clinical Diagnostics, Bialystok, Poland. Source: Dabrowska, M Kemona, H Prokopowicz, J Kretowska, J Kiluk, S Neoplasma. 1991; 38(3): 249-52 0028-2685

•

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. Author(s): Division of Medical Oncology A, Istituto Nazionale Tumori, Milano, Italy. Source: Viviani, S Camerini, E Bonfante, V Santoro, A Balzarotti, M Fornier, M Devizzi, L Verderio, P Valagussa, P Bonadonna, G Br-J-Cancer. 1998 March; 77(6): 992-7 00070920

126 Hodgkin’s Disease

•

Stanford V and radiotherapy for Hodgkin's disease. Author(s): Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Source: Portlock, C S Curr-Oncol-Repage 2002 September; 4(5): 413 1523-3790

•

T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease. Author(s): Institute of Medical Oncology, Inselspital, University of Berne, Switzerland. Source: Battig, B Mueller Garamvoelgyi, E Cogliatti, S B Schmid, U Kappeler, A Cerny, T Laissue, J A Fey, M F Leuk-Lymphoma. 1999 April; 33(3-4): 393-8 1042-8194

•

The clonal relationship between nodular sclerosis Hodgkin's disease with a clonal Reed-Sternberg cell population and a subsequent B-cell small noncleaved cell lymphoma. Author(s): Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198-3135, USA. Source: Ohno, T Trenn, G Wu, G Abou Elella, A Reis, H E Chan, W C Mod-Pathol. 1998 May; 11(5): 485-90 0893-3952

•

The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function. Author(s): CRC Department of Medical Oncology, Christie Hospital, Manchester, UK. Source: Radford, J A Testa, N G Crowther, D Br-J-Cancer. 1990 July; 62(1): 127-32 00070920

•

The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease. Author(s): Departments of Oncology, Radiology, and Clinical Immunology, Genetics and Pathology, University of Uppsala, University Hospital, Uppsala, Sweden. [email protected] Source: Molin, D Glimelius, B Sundstrom, C Venge, P Enblad, G Leuk-Lymphoma. 2001 July; 42(3): 457-65 1042-8194

•

Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin's disease. Author(s): Department of Paediatric Oncology, St Bartholomew's Hospital, London, UK. Source: Shafford, E A Kingston, J E Healy, J C Webb, J A Plowman, P N Reznek, R H BrJ-Cancer. 1999 May; 80(5-6): 808-14 0007-0920

•

Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Author(s): Division of Cancer Treatment, National Cancer Institute, Bethesda, MD. Source: Longo, D L Duffey, P L DeVita, V T Wiernik, P H Hubbard, S M Phares, J C Bastian, A W Jaffe, E S Young, R C J-Clin-Oncol. 1991 August; 9(8): 1409-20 0732-183X

•

Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy. Author(s): Department of Pediatrics, American University of Beirut Medical Center, Lebanon. Source: Muwakkit, S Geara, F Nabbout, B Farah, R A Shabb, N S Hajjar, T Khogali, M Radiat-Oncol-Investig. 1999; 7(6): 365-73 1065-7541

•

Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation. Author(s): Institut d'Hematologie, Hopital Saint-Louis, Paris, France. Source: Brice, P Gisselbrecht, C Ferme, C Lepage, E Baruchel, A Marolleau, J P Gerota, O Boiron, M Nouv-Rev-Fr-Hematol. 1991; 33(3): 267-72

Nutrition

127

•

Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy. Author(s): Hematology and Medical Oncology Service, Clinic and University Hospital of Valencia, Spain. [email protected] Source: Tormo, M Terol, M J Marugan, I Solano, C Benet, I Garcia Conde, J LeukLymphoma. 1999 June; 34(1-2): 137-42 1042-8194

•

Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy. Author(s): Hopital du St-Sacrement, Quebec City, Canada. Source: Cantin, G L'Esperance, B Yelle, L Desjardins, L Couture, F Bergeron, M Lacroix, L Dufresne, J Belanger, D Ouellet, P A Hewitt, L A Pirc, L Gyger, M Cancer-ChemotherPharmacol. 1999; 43(6): 503-6 0344-5704

•

VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. Author(s): Stanford University Medical Center, Stanford, CA, USA. [email protected] Source: Donaldson, Sarah S Hudson, Melissa M Lamborn, Kathleen R Link, Michael P Kun, Larry Billett, Amy Louise Marcus, Karen C Hurwitz, Craig A Young, Jeffrey A Tarbell, Nancy J Weinstein, Howard J J-Clin-Oncol. 2002 July 15; 20(14): 3081-7 0732183X

•

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. Author(s): Medicine Branch, National Cancer Institute, Bethesda, MD 20892, USA. Source: Little, R Wittes, R E Longo, D L Wilson, W H J-Clin-Oncol. 1998 February; 16(2): 584-8 0732-183X

•

VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Author(s): Service de Medecine C, Institut Gustave-Roussy, Villejuif, France. Source: Ribrag, V Nasr, F Bouhris, J H Bosq, J Brault, P Girinsky, T Cosset, J M Munck, J N Corti, C Decaudin, D Pico, J L Hayat, M Carde, P Bone-Marrow-Transplant. 1998 May; 21(10): 969-74 0268-3369

•

What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease? Author(s): Department of Haematology, University College Hospital, School of Medicine, London, U.K. Source: McMillan, A Goldstone, A Leuk-Res. 1991; 15(4): 237-43 0145-2126

Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •

healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0

•

The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov

128 Hodgkin’s Disease

•

The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov

•

The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/

•

The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/

•

Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/

•

Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/

•

Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/

Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •

AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats

•

Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html

•

Google: http://directory.google.com/Top/Health/Nutrition/

•

Healthnotes: http://www.healthnotes.com/

•

Open Directory Project: http://dmoz.org/Health/Nutrition/

•

Yahoo.com: http://dir.yahoo.com/Health/Nutrition/

•

WebMD®Health: http://my.webmd.com/nutrition

•

WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html

129

CHAPTER 3. ALTERNATIVE MEDICINE AND HODGKIN’S DISEASE Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to Hodgkin’s disease. At the conclusion of this chapter, we will provide additional sources.

National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to Hodgkin’s disease and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “Hodgkin’s disease” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to Hodgkin’s disease: •

2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Author(s): Delbeke D, Martin WH, Morgan DS, Kinney MC, Feurer I, Kovalsky E, Arrowsmith T, Greer JP. Source: Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 2002 January; 4(1): 105-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14538054&dopt=Abstract

•

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Author(s): Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G.

130 Hodgkin’s Disease

Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2000 October; 11(10): 1273-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11106116&dopt=Abstract •

99Tcm-tetrofosmin scintigraphy in Hodgkin's disease. Author(s): Aigner RM, Fueger GF, Zinke W, Sill H. Source: Nuclear Medicine Communications. 1997 March; 18(3): 252-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9106779&dopt=Abstract

•

A case of primary refractory Hodgkin's disease treated successfully with paclitaxel. Author(s): Kallab AM, Dainer P. Source: American Journal of Hematology. 1999 March; 60(3): 248. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10072122&dopt=Abstract

•

A cure model with time-changing risk factor: an application to the analysis of secondary leukaemia. A report from the International Database on Hodgkin's Disease. Author(s): Tsodikov A, Loeffler M, Yakovlev A. Source: Statistics in Medicine. 1998 January 15; 17(1): 27-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9463847&dopt=Abstract

•

A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's disease. Author(s): Shankar AG, Ashley S, Atra A, Kingston JE, Mott M, Pinkerton CR. Source: European Journal of Cancer (Oxford, England : 1990). 1998 December; 34(13): 2058-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10070311&dopt=Abstract

•

A phase I study of interleukin-6 after autologous bone marrow transplantation for patients with poor prognosis Hodgkin's disease. Author(s): Imrie KR, Sheridan B, Colwill R, Crump M, Stewart AK, McCrae J, Danish R, Sutton D, Romeyer F, Keating A. Source: Leukemia & Lymphoma. 1997 May; 25(5-6): 555-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9250827&dopt=Abstract

•

A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. Author(s): Aviles A, Delgado S. Source: Clinical and Laboratory Haematology. 1998 April; 20(2): 95-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9681219&dopt=Abstract

•

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent

Alternative Medicine 131

high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Author(s): Glossmann JP, Josting A, Pfistner B, Paulus U, Engert A; German Hodgkin's Lymphoma Study Group (GHSG). Source: Annals of Hematology. 2002 August; 81(8): 424-9. Epub 2002 August 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12223998&dopt=Abstract •

ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease. Author(s): Zinzani PL, Magagnoli M, Frezza G, Barbieri E, Gherlinzoni F, Galuppi A, Bendandi M, Merla E, Albertini P, Babini L, Tura S. Source: Leukemia & Lymphoma. 1999 February; 32(5-6): 553-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10048428&dopt=Abstract

•

ABVD chemotherapy of Hodgkin's disease. Author(s): Molnar Z, Schneider T, Varady E, Fleischmann T. Source: Neoplasma. 1997; 44(4): 263-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9473781&dopt=Abstract

•

Activity of infusional etoposide, vincristine, and doxorubicin with bolus cyclophosphamide (EPOCH) in relapsed Hodgkin's disease. Author(s): Stokoe CT, Ogden J, Jain VK. Source: The Oncologist. 2001; 6(5): 428-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11675520&dopt=Abstract

•

Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Author(s): Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2000 September; 11(9): 1105-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11061603&dopt=Abstract

•

Advanced Hodgkin's disease: ABVD is better, yet is not good enough! Author(s): Diehl V. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 February 15; 21(4): 583-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12586791&dopt=Abstract

•

Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience. Author(s): Chim CS, Kwong YL, Lie AK, Lee CK, Ho FC, Liang R.

132 Hodgkin’s Disease

Source: American Journal of Hematology. 1999 July; 61(3): 159-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10398307&dopt=Abstract •

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Author(s): Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Source: Lancet. 2002 June 15; 359(9323): 2065-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12086759&dopt=Abstract

•

Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Author(s): Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M. Source: Japanese Journal of Clinical Oncology. 2000 March; 30(3): 146-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10798542&dopt=Abstract

•

Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Author(s): Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW, Wilson WH, Wittes RE, Jaffe ES, Hubbard SM, DeVita VT Jr. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 November; 15(11): 3338-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9363863&dopt=Abstract

•

Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Author(s): Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Source: International Journal of Radiation Oncology, Biology, Physics. 2003 January 1; 55(1): 36-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12504034&dopt=Abstract

•

Analysis of treatment results in advanced Hodgkin's disease: the case for adjuvant radiotherapy. Author(s): Dyduch M, Skolyszewski J, Korzeniowski S, Sokolowski A.

Alternative Medicine 133

Source: International Journal of Radiation Oncology, Biology, Physics. 2003 July 1; 56(3): 634-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12788168&dopt=Abstract •

Aortic dissection in a patient receiving chemotherapy for Hodgkin's disease--a case report. Author(s): Golden MA, Vaughn DJ, Crooks GW, Holland GA, Bavaria JE. Source: Angiology. 1997 December; 48(12): 1063-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9404833&dopt=Abstract

•

Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages? Author(s): Andrieu JM, Colonna P. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 June; 16(6): 2283. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9626234&dopt=Abstract

•

Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. Author(s): Salloum E, Tanoue LT, Wackers FJ, Zelterman D, Hu GL, Cooper DL. Source: Cancer Investigation. 1999; 17(3): 171-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10099655&dopt=Abstract

•

Association between alopecia and response to aggressive chemotherapy in patients with Hodgkin's disease. Author(s): Lishner M, Manor Y, Kitay-Cohen Y, Avishay AE. Source: Medical Hypotheses. 1999 November; 53(5): 447-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10616048&dopt=Abstract

•

Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival--results of a Cancer and Leukemia Group B study. Author(s): Coleman M, Rafla S, Propert KJ, Glicksman A, Peterson B, Nissen N, Brunner K, Holland JF, Anderson JR, Gottlieb A, Kaufman T. Source: International Journal of Radiation Oncology, Biology, Physics. 1998 June 1; 41(3): 639-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9635714&dopt=Abstract

•

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. Author(s): Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT.

134 Hodgkin’s Disease

Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2000 December 1; 18(23): 3918-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11099321&dopt=Abstract •

Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. Author(s): Arranz R, Tomas JF, Gil-Fernandez JJ, Martinez-Chamorro C, Granados E, Alegre A, Figuera A, Vazquez L, Camara R, Fernandez-Ranada JM. Source: Bone Marrow Transplantation. 1998 April; 21(8): 779-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9603401&dopt=Abstract

•

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term followup and analysis of prognostic factors. Author(s): Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, Muhs A, Duerst RE, Abboud CN, Packman CH, DiPersio JF, Constine LS, Rowe JM, Liesveld JL. Source: Bone Marrow Transplantation. 1998 August; 22(3): 265-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9720740&dopt=Abstract

•

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Author(s): Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Ruffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duhmke E, Georgii A, Loeffler M. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998; 9 Suppl 5: S67-71. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9926240&dopt=Abstract

•

BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Author(s): Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1997 February; 8(2): 143-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9093722&dopt=Abstract

•

Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481). Author(s): Wiernik PH, Leong T, Oken MM, Neiman RS, Habermann TM, Bennett JM, Schuster S, Glick JH.

Alternative Medicine 135

Source: Leukemia & Lymphoma. 2001 January; 40(3-4): 357-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426558&dopt=Abstract •

British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease. Author(s): Moody AM, Pratt J, Hudson GV, Smith P, Lamont A, Williams MV. Source: Clin Oncol (R Coll Radiol). 2001; 13(4): 262-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11554622&dopt=Abstract

•

Can (18)F-FDG PET after first cycle chemotherapy predict the efficacy of therapy in Hodgkin's disease? Author(s): Rigacci L, Castagnoli A, Carpaneto A, Carrai V, Vaggelli L, Matteini M. Source: Haematologica. 2002 May; 87(5): Elt24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010684&dopt=Abstract

•

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Author(s): Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Source: British Journal of Haematology. 2001 November; 115(2): 272-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11703321&dopt=Abstract

•

CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. Author(s): Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, Mesina O, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McLaughlin P, Rodriguez MA, Romaguera J, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 March 1; 20(5): 1278-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11870170&dopt=Abstract

•

Challenging cases and diagnostic dilemmas: case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease. Author(s): Bomanji JB, Syed R, Brock C, Jankowska P, Dogan A, Costa DC, Ell PJ, Lee SM. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 August 1; 20(15): 3347-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149309&dopt=Abstract

136 Hodgkin’s Disease

•

Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease. Author(s): Yahalom J. Source: Current Oncology Reports. 2002 September; 4(5): 415-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12162917&dopt=Abstract

•

Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). Author(s): Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L. Source: Journal of Acquired Immune Deficiency Syndromes (1999). 2000 August 15; 24(5): 444-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11035615&dopt=Abstract

•

Chemotherapy for Hodgkin's disease. Author(s): Ekert H. Source: The New England Journal of Medicine. 2003 September 18; 349(12): 1186-7; Author Reply 1186-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13679536&dopt=Abstract

•

ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Author(s): Hancock BW, Gregory WM, Cullen MH, Hudson GV, Burton A, Selby P, Maclennan KA, Jack A, Bessell EM, Smith P, Linch DC; British National Lymphoma Investigation; Central Lymphoma Group. Source: British Journal of Cancer. 2001 May 18; 84(10): 1293-300. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11355937&dopt=Abstract

•

ChlVPP chemotherapy in children with stage IV Hodgkin's disease: results of the UKCCSG HD 8201 and HD 9201 studies. Author(s): Atra A, Higgs E, Capra M, Elsworth A, Imeson J, Radford M, Hewitt M; UKCCSG/Hodgkin's Disease Group. Source: British Journal of Haematology. 2002 December; 119(3): 647-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12437639&dopt=Abstract

•

ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients. Author(s): Saletti P, Zucca E, Gueneau M, Peccatori F, Cavalli F, Martinelli G. Source: Leukemia & Lymphoma. 1999 April; 33(3-4): 313-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10221511&dopt=Abstract

Alternative Medicine 137

•

ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. Author(s): Radford JA, Rohatiner AZ, Ryder WD, Deakin DP, Barbui T, Lucie NP, Rossi A, Dunlop DJ, Cowan RA, Wilkinson PM, Gupta RK, James RD, Shamash J, Chang J, Crowther D, Lister TA. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 July 1; 20(13): 2988-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12089229&dopt=Abstract

•

Circulating immune complexes in advanced Hodgkin's disease: qualitative analysis and prognostic significance. Author(s): Tomasevic Z, Jelic S. Source: Arch Immunol Ther Exp (Warsz). 2000; 48(3): 195-200. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10912625&dopt=Abstract

•

Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Author(s): Lang O, Bihl H, Hultenschmidt B, Sautter-Bihl ML. Source: Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft. [et Al]. 2001 March; 177(3): 138-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11285771&dopt=Abstract

•

Communication challenges in a young man with Hodgkin's disease. Author(s): Medoff E. Source: Cancer Practice. 2001 November-December; 9(6): 272-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11879328&dopt=Abstract

•

Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Author(s): Ferme C, Sebban C, Hennequin C, Divine M, Lederlin P, Gabarre J, Ferrant A, Caillot D, Bordessoule D, Brice P, Moullet I, Berger F, Lepage E. Source: Blood. 2000 April 1; 95(7): 2246-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10733492&dopt=Abstract

•

Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Author(s): Anselmo AP, Meloni G, Cavalieri E, Proia A, Enrici RM, Funaro D, Pescarmona E, Mandelli F. Source: Annals of Hematology. 2000 February; 79(2): 79-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10741919&dopt=Abstract

138 Hodgkin’s Disease

•

Coxalgia as the initial symptom in Hodgkin's disease: a case report. Author(s): Sekine I, Sasaki Y, Hasebe T, Umeda T, Mukai K. Source: Japanese Journal of Clinical Oncology. 1997 October; 27(5): 353-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9390217&dopt=Abstract

•

Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Author(s): Franklin J, Diehl V. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 1: 98-101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078913&dopt=Abstract

•

Cutaneous granulomas as the first manifestation of Hodgkin's disease. Author(s): Macaya A, Servitje O, Moreno A, Peyri J. Source: Eur J Dermatol. 2003 May-June; 13(3): 299-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12804995&dopt=Abstract

•

Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856. Author(s): Lester EP, Petroni GR, Barcos M, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E 3rd, Peterson BA. Source: Cancer Investigation. 2001; 19(5): 447-58. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11458812&dopt=Abstract

•

Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Author(s): Dieckmann K, Potter R, Hofmann J, Heinzl H, Wagner W, Schellong G; Pediatric Cooperative Hodgkin Disease Study Group of the GPOH. Source: International Journal of Radiation Oncology, Biology, Physics. 2003 July 1; 56(3): 644-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12788169&dopt=Abstract

•

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. Author(s): Loeffler M, Diehl V, Pfreundschuh M, Ruhl U, Hasenclever D, Nisters-Backes H, Sieber M, Tesch H, Franklin J, Geilen W, Bartels H, Cartoni C, Dolken G, Enzian J, Fuchs R, Gassmann W, Gerhartz H, Hagen-Aukamp U, Hiller E, Hinkelbein H, Hinterberger W, Kirchner H, Koch P, Kruger B, Schwarze EW, et al. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 June; 15(6): 2275-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9196141&dopt=Abstract

Alternative Medicine 139

•

Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Author(s): Stewart DA, Guo D, Gluck S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA. Source: Bone Marrow Transplantation. 2000 August; 26(4): 383-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10982284&dopt=Abstract

•

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Author(s): Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 January; 14(1): 123-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12488304&dopt=Abstract

•

Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Author(s): Carde P, Koscielny S, Franklin J, Axdorph U, Raemaekers J, Diehl V, Aleman B, Brosteanu O, Hasenclever D, Oberlin O, Bonvin N, Bjorkholm M. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 1: 86-91. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078910&dopt=Abstract

•

EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Author(s): Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kontopidou FN, Boussiotis VA, Papavassiliou C, Kittas C, Pangalis GA. Source: Leukemia & Lymphoma. 2000 March; 37(1-2): 131-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10721777&dopt=Abstract

•

Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease. Author(s): Villani F, Fede Catania A, Laffranchi A, Maffioli L, Viviani S, Bonfante V. Source: Cancer Investigation. 2003 April; 21(2): 185-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743983&dopt=Abstract

•

Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Author(s): Murray PG, Billingham LJ, Hassan HT, Flavell JR, Nelson PN, Scott K, Reynolds G, Constandinou CM, Kerr DJ, Devey EC, Crocker J, Young LS. Source: Blood. 1999 July 15; 94(2): 442-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10397711&dopt=Abstract

140 Hodgkin’s Disease

•

Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Author(s): Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE. Source: Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2001; 7(10): 552-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11760087&dopt=Abstract

•

Efficacy of standard treatment in patients with Hodgkin's disease--a single center experience. Author(s): Geissler K, Gisslinger H, Knobl P, Sperr W, Valent P, Dieckmann K, Chott A, Potter R, Lechner K, Jager U. Source: Wiener Klinische Wochenschrift. 2000 July 28; 112(14): 624-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11008324&dopt=Abstract

•

Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease. Author(s): Zinzani PL, Magagnoli M, Bendandi M, Barbieri E, Galuppi A, Gherlinzoni F, Tani M, Albertini P, Stefoni V, Babini L, Tura S. Source: Haematologica. 2000 July; 85(7): 729-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10897125&dopt=Abstract

•

ESHAP is an active regimen for relapsing Hodgkin's disease. Author(s): Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A, Pastor M. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1999 May; 10(5): 593-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10416011&dopt=Abstract

•

Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Author(s): Spaepen K, Mortelmans L. Source: Q J Nucl Med. 2001 September; 45(3): 269-73. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11788819&dopt=Abstract

•

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Author(s): Josting A, Katay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998 March; 9(3): 289-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9602263&dopt=Abstract

Alternative Medicine 141

•

Fertility after treatment for Hodgkin's disease. Author(s): Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 1: 138-47. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078896&dopt=Abstract

•

Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Author(s): Delwail V, Jais JP, Colonna P, Andrieu JM. Source: British Journal of Haematology. 2002 July; 118(1): 189-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100147&dopt=Abstract

•

Functional imaging of Hodgkin's disease with FDG-PET and gallium-67. Author(s): Willkomm P, Palmedo H, Grunwald F, Ruhlmann J, Biersack HJ. Source: Nuklearmedizin. 1998; 37(7): 251-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9830616&dopt=Abstract

•

Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. Author(s): Salloum E, Brandt DS, Caride VJ, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper DL. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 February; 15(2): 518-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9053473&dopt=Abstract

•

G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. Author(s): Gustavsson A. Source: Acta Oncologica (Stockholm, Sweden). 1997; 36(5): 483-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9292744&dopt=Abstract

•

Gemcitabine is active in relapsed Hodgkin's disease. Author(s): Lucas JB, Horwitz SM, Horning SJ, Sayegh A. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1999 August; 17(8): 2627-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10561333&dopt=Abstract

•

Gluteal manifestation of advanced Hodgkin's disease. Author(s): Ariad S, Hatskelzon L, Benharroch D, Geffen DB. Source: Skeletal Radiology. 1997 October; 26(10): 622-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9361361&dopt=Abstract

142 Hodgkin’s Disease

•

Gonadal function following ABVD therapy for Hodgkin's disease. Author(s): Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 1997 August; 20(4): 354-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9256888&dopt=Abstract

•

Granuloma annulare associated with Hodgkin's disease. Author(s): Setoyama M, Kerdel FA, Byrnes JJ, Kanzaki T. Source: International Journal of Dermatology. 1997 June; 36(6): 445-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9248891&dopt=Abstract

•

Greater curability in advanced Hodgkin's disease? Author(s): Portlock CS. Source: Cancer J Sci Am. 1999 September-October; 5(5): 264-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10526665&dopt=Abstract

•

Henoch-Schonlein purpura associated with segmental and focal proliferative glomerulonephritis in a patient with Hodgkin's disease. Author(s): Blanco P, Denisi R, Rispal P, Deminiere C, Pellegrin JL, Leng B, Aparicio M. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 1999 January; 14(1): 179-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10052501&dopt=Abstract

•

High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. Author(s): Schellong G, Potter R, Bramswig J, Wagner W, Prott FJ, Dorffel W, Korholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Thiemann M, Schwarze EW. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1999 December; 17(12): 3736-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10577845&dopt=Abstract

•

High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. Author(s): Jackson GH, Angus B, Carey PJ, Finney RD, Galloway MJ, Goff DK, Haynes A, Lennard AL, Leonard RC, McQuaker IG, Proctor SJ, Russell N, Windebank K, Taylor PR; Scotland and Newcastle Lymphoma Group. Source: Leukemia & Lymphoma. 2000 May; 37(5-6): 561-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11042516&dopt=Abstract

•

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major

Alternative Medicine 143

increased risk of secondary MDS/AML. Author(s): Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC. Source: British Journal of Cancer. 1999 October; 81(3): 476-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10507773&dopt=Abstract •

High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Author(s): Argiris A, Seropian S, Cooper DL. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2000 June; 11(6): 665-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10942053&dopt=Abstract

•

High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Author(s): Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E 3rd, Kadin M, Antin J. Source: Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 1997 June; 3(2): 98-106. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9267670&dopt=Abstract

•

High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Author(s): Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, Matteucci P, Grisanti S, Valagussa P, Bonadonna G, Gianni AM. Source: European Journal of Haematology. Supplementum. 2001 July; (64): 51-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11486403&dopt=Abstract

•

High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Author(s): Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH. Source: European Journal of Haematology. Supplementum. 2001 July; (64): 28-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11486397&dopt=Abstract

•

High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Author(s): Blystad AK, Holte H, Kvaloy S, Smeland E, Delabie J, Kvalheim G. Source: Bone Marrow Transplantation. 2001 November; 28(9): 849-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11781645&dopt=Abstract

144 Hodgkin’s Disease

•

HIV-associated Hodgkin's disease. Author(s): Powles T, Bower M. Source: International Journal of Std & Aids. 2000 August; 11(8): 492-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10990330&dopt=Abstract

•

HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus. Author(s): Massarweh S, Udden MM, Shahab I, Kroll M, Sears DA, Lynch GR, Teh BS, Lu HH. Source: American Journal of Hematology. 2003 March; 72(3): 216-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12605396&dopt=Abstract

•

Hodgkin's disease and the risk of acute leukemia in successfully treated patients. Author(s): Valagussa P, Bonadonna G. Source: Haematologica. 1998 September; 83(9): 769-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9825571&dopt=Abstract

•

Hodgkin's disease as a second malignant neoplasm in childhood: report of a case and review of the literature. Author(s): Ragusa R, Russo S, Villari L, Schiliro G. Source: Pediatric Hematology and Oncology. 2001 September; 18(6): 407-14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11554236&dopt=Abstract

•

Hodgkin's disease complicated by the nephrotic syndrome in a man with KugelbergWelander disease. Author(s): Thomson JA, Seymour JF, Wolf M. Source: Leukemia & Lymphoma. 2001 July; 42(3): 561-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11699426&dopt=Abstract

•

Hodgkin's disease following extranodal marginal zone B-cell lymphoma in remission. Author(s): Shimizu K, Hara K, Yatabe Y. Source: International Journal of Hematology. 1999 February; 69(2): 96-100. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10071458&dopt=Abstract

•

Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Author(s): Errante D, Gabarre J, Ridolfo AL, Rossi G, Nosari AM, Gisselbrecht C, Kerneis Y, Mazzetti F, Vaccher E, Talamini R, Carbone A, Tirelli U.

Alternative Medicine 145

Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1999 February; 10(2): 189-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10093688&dopt=Abstract •

Hodgkin's disease in 82 Turkish children diagnosed over a 10-year period: epidemiological, clinical, and histopathologic features and prognosis with prolonged chemotherapy. Author(s): Ertem U, Duru F, Dagdemir A, Tacyildiz N, Pamir A, Akcayoz A, Uluoglu O, Tezic T. Source: Pediatric Hematology and Oncology. 1997 July-August; 14(4): 359-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9211540&dopt=Abstract

•

Hodgkin's disease in children in southern Africa: epidemiological characteristics, morbidity and long-term outcome. Author(s): Hesseling PB, Wessels G, Van Jaarsveld D, Van Riet FA. Source: Annals of Tropical Paediatrics. 1997 December; 17(4): 367-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9578798&dopt=Abstract

•

Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor. Author(s): Gastaldi R, Martino P, Gentile G, Picardi V, De Propris MS, Pirillo MF, De Vellis A, Mandelli F. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 July; 13(7): 1158-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12176798&dopt=Abstract

•

Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicincontaining regimen. Author(s): Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bierman PJ, Greiner T, Bociek G, Enke C, Bast M, Chan WC, Armitage JO; Nebraska Lymphoma Study Group. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 February 15; 20(4): 1087-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844834&dopt=Abstract

•

Hodgkin's disease with primary manifestation in the liver. Author(s): Chim CS, Choy C, Ooi CG, Liang R. Source: Leukemia & Lymphoma. 2000 May; 37(5-6): 629-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11042525&dopt=Abstract

•

Hodgkin's disease, work, and the environment. A review. Author(s): McCunney RJ.

146 Hodgkin’s Disease

Source: Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 1999 January; 41(1): 36-46. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9924719&dopt=Abstract •

Hodgkin's disease: clinical presentation and treatment. Author(s): Tirelli U, Vaccher E, Spina M, Carbone A. Source: Cancer Treat Res. 2001; 104: 247-65. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11191130&dopt=Abstract

•

Hodgkin's disease--clinical trials and travails. Author(s): DeVita VT Jr. Source: The New England Journal of Medicine. 2003 June 12; 348(24): 2375-6. Erratum In: N Engl J Med. 2003 July 10; 349(2): 202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802021&dopt=Abstract

•

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Author(s): Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P, Bonadonna G. Source: British Journal of Haematology. 1998 November; 103(2): 533-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9827930&dopt=Abstract

•

Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience. Author(s): Zinzani PL. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003; 14 Suppl 1: I43-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736231&dopt=Abstract

•

Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Author(s): Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J. Source: Leukemia & Lymphoma. 2001 February; 40(5-6): 499-509. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426523&dopt=Abstract

•

Intensified ABVP chemotherapy for the primary treatment of Hodgkin's disease. Author(s): Spector N, Costa MA, Morais JC, Biasoli I, Solza C, De Fatima Gaui M, Ferreira CG, Portugal RD, Loureiro M, Nucci M, Pulcheri W. Source: Oncol Rep. 2002 March-April; 9(2): 439-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11836623&dopt=Abstract

Alternative Medicine 147

•

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Author(s): Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 January 15; 20(2): 467-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11786576&dopt=Abstract

•

Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome. Author(s): Delain M, Cartron G, Bout M, Benboubker L, Linassier C, Lamagnere JP, Colombat P. Source: Leukemia & Lymphoma. 1999 July; 34(3-4): 305-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10439367&dopt=Abstract

•

Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease. Author(s): Ashigbi MY, Venkatraj U, Agarwal V, Bello J, Wiernik PH. Source: Medical and Pediatric Oncology. 1997 April; 28(4): 255-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9078321&dopt=Abstract

•

Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease? Author(s): Carde P, Cavalli F, Diehl V, Franklin J. Source: The Hematology Journal : the Official Journal of the European Haematology Association / Eha. 2000; 1(4): 282-90. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11920203&dopt=Abstract

•

Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: importance of immunocytochemistry. Author(s): Gopal AK, Schuetze SM, Maloney DG, Weiden PL. Source: Blood. 1999 October 1; 94(7): 2537. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10576806&dopt=Abstract

•

Late pulmonary toxicity after treatment for Hodgkin's disease. Author(s): Villani F, De Maria P, Bonfante V, Viviani S, Laffranchi A, Dell'oca I, Dirusso A, Zanini M. Source: Anticancer Res. 1997 November-December; 17(6D): 4739-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9494599&dopt=Abstract

•

Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapyresults of the French Society of Pediatric Oncology Study MDH90. Author(s): Landman-Parker J, Pacquement H, Leblanc T, Habrand JL, Terrier-Lacombe

148 Hodgkin’s Disease

MJ, Bertrand Y, Perel Y, Robert A, Coze C, Thuret I, Donadieu J, Schaison G, Leverger G, Lemerle J, Oberlin O. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2000 April; 18(7): 1500-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10735898&dopt=Abstract •

Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease. Author(s): Gobbi PG, Broglia C, Berte R, Petrilli MP, Molica S, Angrilli F, Iannitto E, Ghirardelli ML, Di Renzo N, Cavanna L, Ascari E. Source: Haematologica. 2000 July; 85(7): 722-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10897124&dopt=Abstract

•

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Author(s): Martin A, Fernandez-Jimenez MC, Caballero MD, Canales MA, Perez-Simon JA, Garcia de Bustos J, Vazquez L, Hernandez-Navarro F, San Miguel JF. Source: British Journal of Haematology. 2001 April; 113(1): 161-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11328296&dopt=Abstract

•

Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Author(s): Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G. Source: Cancer J Sci Am. 1999 September-October; 5(5): 275-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10526668&dopt=Abstract

•

Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Author(s): Radman I, Basic N, Labar B, Kovacevic J, Aurer I, Bogdanic V, ZupancicSalek S, Nemet D, Jakic-Razumovic J, Mrsic M, Santek F, Grgic-Markulin L, Boban D. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 October; 13(10): 1650-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12377656&dopt=Abstract

•

Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. Author(s): Schellong G, Riepenhausen M, Creutzig U, Ritter J, Harbott J, Mann G, Gadner H. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 June; 15(6): 2247-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9196137&dopt=Abstract

Alternative Medicine 149

•

Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. Author(s): Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, Lister TA, Rohatiner AZ, Vaughan Hudson G, Williams MV, Linch DC. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 March 15; 19(6): 1610-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11250989&dopt=Abstract

•

Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease. Author(s): Villani F, Dell'Oca I, De Maria P, Viola G, Di Russo A, Viviani S, Bonfante V. Source: Anticancer Res. 1999 September-October; 19(5C): 4475-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10650795&dopt=Abstract

•

Lymphomatoid papulosis followed by Hodgkin's disease. Author(s): Silva MM, Morais JC, Spector N, Maceira J, Sousa MA, Filgueira AL. Source: International Journal of Dermatology. 1998 July; 37(7): 541-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9679697&dopt=Abstract

•

Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study. Author(s): Enblad G, Hagberg H, Gustavsson A, Glimelius B. Source: European Journal of Haematology. 1998 March; 60(3): 166-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9548415&dopt=Abstract

•

Misleading Ga-67 uptake in a patient with Hodgkin's disease, mediastinal deviation, and pulmonary compression. Author(s): Stark P, Steinmetz A, Hefetz M, Hardoff R. Source: Clinical Nuclear Medicine. 2002 December; 27(12): 898-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12607876&dopt=Abstract

•

Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease. Author(s): Wiernik PH, Dutcher JP, Einzig AI, Sparano J, Frank M, Friedenberg W. Source: Cancer J Sci Am. 1998 July-August; 4(4): 254-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9689984&dopt=Abstract

•

Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Author(s): McQuaker I, Haynes A, Stainer C, Byrne J, Russell N.

150 Hodgkin’s Disease

Source: Bone Marrow Transplantation. 1999 October; 24(7): 715-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10516673&dopt=Abstract •

Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. Author(s): Copelan EA, Ceselski SK, Ezzone SA, Lasky LC, Penza SL, Bechtel TP, Klein JL, Hehmeyer DM, Scholl MD, Marshall DD, Elder PJ, Risley GL, Avalos BR. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 February; 15(2): 759-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9053502&dopt=Abstract

•

Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Author(s): Loeffler M, Hasenclever D, Diehl V. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998; 9 Suppl 5: S73-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9926241&dopt=Abstract

•

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Author(s): Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Ruffer U, Engert A, Franklin J, Pfreundschuh M, Schalk KP, Schwieder G, Wulf G, Dolken G, Worst P, Koch P, Schmitz N, Bruntsch U, Tirier C, Muller U, Loeffler M. Source: Blood. 1998 December 15; 92(12): 4560-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9845521&dopt=Abstract

•

MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. Author(s): Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT, Collins RD, Whalen T, Reardon D, Trigg ME, Gilchrist GS. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 March; 16(3): 897-906. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9508171&dopt=Abstract

•

MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians. Author(s): Andrieu JM, Yilmaz U, Colonna P. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1999 February; 17(2): 730-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10080622&dopt=Abstract

Alternative Medicine 151

•

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. Author(s): Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 January; 16(1): 19-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9440718&dopt=Abstract

•

Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Author(s): Seropian S, Nadkarni R, Jillella AP, Salloum E, Burtness B, Hu GL, Zelterman D, Cooper DL. Source: Bone Marrow Transplantation. 1999 March; 23(6): 599-605. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10217191&dopt=Abstract

•

New drugs in the treatment of Hodgkin's disease. Author(s): Borchmann P, Schnell R, Diehl V, Engert A. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998; 9 Suppl 5: S103-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9926247&dopt=Abstract

•

New treatments for Hodgkin's disease. Author(s): Glossmann JP, Josting A, Diehl V. Source: Curr Treat Options Oncol. 2002 August; 3(4): 283-90. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12074765&dopt=Abstract

•

NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. Author(s): Frias S, Van Hummelen P, Meistrich ML, Lowe XR, Hagemeister FB, Shelby MD, Bishop JB, Wyrobek AJ. Source: Cancer Research. 2003 January 1; 63(1): 44-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517776&dopt=Abstract

•

Occurrence of Hodgkin's disease and cutaneous B-cell lymphoma in the same patient: a report of two cases. Author(s): Servitje O, Marti RM, Estrach T, Palou J, Gallardo F, Limon A, Romagosa V. Source: Eur J Dermatol. 2000 January-February; 10(1): 43-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10694298&dopt=Abstract

•

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. Author(s): Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G.

152 Hodgkin’s Disease

Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 February; 15(2): 528-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9053474&dopt=Abstract •

Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. Author(s): Kobrinsky NL, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M, Warkentin P, Gilchrist GS, Cohen MD, Shina D, Meadows AT. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 May 1; 19(9): 2390-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11331317&dopt=Abstract

•

Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Author(s): Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003; 14 Suppl 1: I11-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736225&dopt=Abstract

•

PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease. Author(s): Simmonds PD, Mead GM, Sweetenham JW, O'Callaghan A, Smartt P, Kerr J, Hamilton CR, Golding PF, Milne AE, Whitehouse JM. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1997 March; 8(3): 259-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9137795&dopt=Abstract

•

Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review. Author(s): Adiga GU, Abebe L, Wiernik PH. Source: American Journal of Hematology. 2003 April; 72(4): 267-73. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12666139&dopt=Abstract

•

Pediatric Hodgkin's disease: treatment in the late 1990s. Author(s): Schellong G. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998; 9 Suppl 5: S115-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9926249&dopt=Abstract

•

Peroneal mononeuropathy in pediatric Hodgkin's disease. Author(s): Matsubara K, Nigami H, Harigaya H, Osaki M, Baba K.

Alternative Medicine 153

Source: Leukemia & Lymphoma. 2000 December; 40(1-2): 205-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426622&dopt=Abstract •

Persistent paraneoplastic neurologic syndrome after successful therapy of Hodgkin's disease. Author(s): Maslovsky I, Volchek L, Blumental R, Ducach A, Lugassy G. Source: European Journal of Haematology. 2001 January; 66(1): 63-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11168510&dopt=Abstract

•

PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Author(s): Schiepers C, Filmont JE, Czernin J. Source: European Journal of Nuclear Medicine and Molecular Imaging. 2003 June; 30 Suppl 1: S82-8. Epub 2003 April 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12719922&dopt=Abstract

•

PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Author(s): Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. Source: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 2002 August; 43(8): 1018-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12163626&dopt=Abstract

•

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. Author(s): Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 November 15; 19(22): 4238-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11709567&dopt=Abstract

•

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Author(s): Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, Coiffier B, Salles G. Source: British Journal of Cancer. 1998 June; 77(12): 2357-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9649158&dopt=Abstract

•

Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Author(s): Wiedmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, Adams S, Hor G, Hoelzer D, Mitrou PS.

154 Hodgkin’s Disease

Source: Leukemia & Lymphoma. 1999 August; 34(5-6): 545-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10492078&dopt=Abstract •

Pregnancy after treatment of secondary acute promyelocytic leukemia following Hodgkin's disease: a case report. Author(s): Elezovic I, Colovic M, Tomin D, Boskovic D. Source: Medical Oncology (Northwood, London, England). 2000 August; 17(3): 222-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10962534&dopt=Abstract

•

Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr virus association and review of the literature. Author(s): Klein R, Mullges W, Bendszus M, Woydt M, Kreipe H, Roggendorf W. Source: The American Journal of Surgical Pathology. 1999 April; 23(4): 477-81. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10199479&dopt=Abstract

•

Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Author(s): Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 February; 14(2): 268-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12562654&dopt=Abstract

•

Problems in Hodgkin's disease management. Author(s): Aisenberg AC. Source: Blood. 1999 February 1; 93(3): 761-79. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9920825&dopt=Abstract

•

Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. Author(s): Guay C, Lepine M, Verreault J, Benard F. Source: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 2003 August; 44(8): 1225-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12902411&dopt=Abstract

•

Progressive disease after ABMT for Hodgkin's disease. Author(s): Bolwell BJ, Kalaycio M, Goormastic M, Dannley R, Andresen SW, Lichtin A, Overmoyer B, Pohlman B. Source: Bone Marrow Transplantation. 1997 November; 20(9): 761-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9384478&dopt=Abstract

•

Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American

Alternative Medicine 155

Marrow Transplant Group. Author(s): Fleming DR, Wolff SN, Fay JW, Brown RA, Lynch JP, Bolwell BJ, Stevens DA, Goodman SA, Greer JP, Stein RS, Pineiro LA, Collins RH, Goldsmith LJ, Herzig GP, Herzig RH. Source: Leukemia & Lymphoma. 1999 September; 35(1-2): 91-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10512166&dopt=Abstract •

Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. Author(s): Elconin JH, Roberts KB, Rizzieri DA, Vermont C, Clough RW, Kim C, Dodge RK, Prosnitz LR. Source: International Journal of Radiation Oncology, Biology, Physics. 2000 November 1; 48(4): 1097-105. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11072168&dopt=Abstract

•

Radiation techniques for the treatment of Hodgkin's disease with combined modality therapy or radiation alone. Author(s): Prosnitz LR, Brizel DM, Light KL. Source: International Journal of Radiation Oncology, Biology, Physics. 1997 November 1; 39(4): 885-95. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9369138&dopt=Abstract

•

Radiation therapy in the treatment of Hodgkin's disease--do you see what I see? Author(s): Longo DL. Source: Journal of the National Cancer Institute. 2003 July 2; 95(13): 928-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12837820&dopt=Abstract

•

Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Author(s): Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, Hagemeister F, Hess M, Cabanillas F, Cox JD. Source: Cancer Journal (Sudbury, Mass.). 2002 September-October; 8(5): 377-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12416895&dopt=Abstract

•

Radiotherapy for advanced Hodgkin's disease. Author(s): Gupta T, Sanghavi V, Laskar S. Source: The New England Journal of Medicine. 2003 September 18; 349(12): 1187-8; Author Reply 1187-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13679537&dopt=Abstract

•

Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute. Author(s): Petera J, Macharova H, Pohankova R, Malir A, Coupek P, Konecny M, Patera J, Pecina J, Drbal J, Koukalova H, Vasova I.

156 Hodgkin’s Disease

Source: Neoplasma. 2000; 47(2): 129-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10985481&dopt=Abstract •

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. Author(s): Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 February 15; 21(4): 607-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12586796&dopt=Abstract

•

Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. Author(s): Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K; Children's Cancer Group. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 September 15; 20(18): 3765-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12228196&dopt=Abstract

•

Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Author(s): Dunlop DJ, Eatock MM, Paul J, Anderson S, Reed NS, Soukop M, Lucie N, Fitzsimmons EJ, Tansey P, Steward WP. Source: Clin Oncol (R Coll Radiol). 1998; 10(2): 107-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9610900&dopt=Abstract

•

Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. Author(s): Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, Ternberg JL, Behm FG, Wharam MD Jr, Chauvenet AR. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 August; 15(8): 2769-79. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9256118&dopt=Abstract

•

Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. Author(s): Pavlovsky S, Schvartzman E, Lastiri F, Magnasco H, Corrado C, Raslawski E, Cancela ME, Ardaiz MC, Cerutti I, Rosso A, Bruno S, Aranguren PN, Salvarezza A, Donato H, Dibar E, Zirone S.

Alternative Medicine 157

Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 July; 15(7): 2652-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9215837&dopt=Abstract •

Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Author(s): Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D. Source: Bone Marrow Transplantation. 1999 September; 24(5): 473-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10482930&dopt=Abstract

•

Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. Author(s): Meistrich ML, Wilson G, Mathur K, Fuller LM, Rodriguez MA, McLaughlin P, Romaguera JE, Cabanillas FF, Ha CS, Lipshultz LI, Hagemeister FB. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 December; 15(12): 3488-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9396402&dopt=Abstract

•

Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. Author(s): Keilholz U, Szelenyi H, Siehl J, Foss HD, Knauf W, Thiel E. Source: Leukemia & Lymphoma. 1999 November; 35(5-6): 641-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10609806&dopt=Abstract

•

Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP). Author(s): Dubey P, Wilson G, Mathur KK, Hagemeister FB, Fuller LM, Ha CS, Cox JD, Meistrich ML. Source: International Journal of Radiation Oncology, Biology, Physics. 2000 February 1; 46(3): 609-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10701740&dopt=Abstract

•

Recurrent mediastinal mass in a child with Hodgkin's disease following successful therapy: a diagnostic challenge. Author(s): Feldges A, Wagner HP, Bubeck B, Kehrer B, Ries G, Schmid U, Waibel P. Source: Pediatric Surgery International. 1997; 12(8): 613-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9354739&dopt=Abstract

•

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV

158 Hodgkin’s Disease

plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Author(s): Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, Klingemann HG, Connors JM, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Fairey RN, O'Reilly SE, Phillips GL. Source: Bone Marrow Transplantation. 1999 June; 23(11): 1131-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10382952&dopt=Abstract •

Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD. Author(s): Enrici RM, Anselmo AP, Donato V, Falchetto Osti M, Santoro M, Tombolini V, Mandelli F. Source: Haematologica. 1999 October; 84(10): 917-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10509040&dopt=Abstract

•

Relapse of Hodgkin's disease after 10 years of complete remission: case report. Author(s): Mwanda OW, Othieno-Abinya N. Source: East Afr Med J. 1998 March; 75(3): 192-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9640822&dopt=Abstract

•

Renal Hodgkin's disease. Author(s): Pilatrino C, Cataldi A, Guerrasio A, Saglio G. Source: British Journal of Haematology. 2002 March; 116(4): 732. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11886375&dopt=Abstract

•

Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease. Author(s): Crosbie OM, Crown JP, Nolan NP, Murray R, Hegarty JE. Source: Hepatology (Baltimore, Md.). 1997 July; 26(1): 5-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9214445&dopt=Abstract

•

Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II and IIIA). Author(s): Andre M, Brice P, Cazals D, Hennequin C, Ferme C, Kerneis Y, Rousselot P, Zini JM, Lepage E, Gisselbrecht C. Source: Hematology and Cell Therapy. 1997 April; 39(2): 59-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9168301&dopt=Abstract

•

Risk-adapted therapy for clinical stage I-II Hodgkin's disease: 7-years results of radiotherapy alone for low-risk disease, and ABVD and radiotherapy for high-risk disease. Author(s): MacKenzie RG, Franssen E, Wong R, Sawka C, Berinstein N, Cowan DH, Senn J, Poldre P.

Alternative Medicine 159

Source: Clin Oncol (R Coll Radiol). 2000; 12(5): 278-88. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11315710&dopt=Abstract •

Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Author(s): Fernandez-Jimenez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernandez-Navarro F. Source: Haematologica. 1999 November; 84(11): 1007-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10553161&dopt=Abstract

•

Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Author(s): Wirth A, Corry J, Laidlaw C, Matthews J, Liew KH. Source: International Journal of Radiation Oncology, Biology, Physics. 1997 October 1; 39(3): 599-607. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9336139&dopt=Abstract

•

Second cancer among long-term survivors from Hodgkin's disease. Author(s): Nyandoto P, Muhonen T, Joensuu H. Source: International Journal of Radiation Oncology, Biology, Physics. 1998 September 1; 42(2): 373-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9788418&dopt=Abstract

•

Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Author(s): Ahmed T, Lake DE, Beer M, Feldman EJ, Preti RA, Seiter K, Helson L, Mittelman A, Kancherla R, Ascensao J, Akhtar T, Cook P, Goldberg R, Coleman M. Source: Bone Marrow Transplantation. 1997 March; 19(5): 449-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9052910&dopt=Abstract

•

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. Author(s): Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, Fornier M, Devizzi L, Verderio P, Valagussa P, Bonadonna G. Source: British Journal of Cancer. 1998 March; 77(6): 992-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9528846&dopt=Abstract

•

Spontaneous regression of Hodgkin's disease: two case reports and a review of the literature. Author(s): Mangel J, Barth D, Berinstein NL, Imrie KR. Source: Hematology (Amsterdam, Netherlands). 2003 June; 8(3): 191-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12745644&dopt=Abstract

160 Hodgkin’s Disease

•

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. Author(s): Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dorken B, Muller-Hermelink HK, Duhmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Source: The New England Journal of Medicine. 2003 June 12; 348(24): 2386-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802024&dopt=Abstract

•

Stanford V and radiotherapy for Hodgkin's disease. Author(s): Portlock CS. Source: Current Oncology Reports. 2002 September; 4(5): 413. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12162915&dopt=Abstract

•

Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection. Author(s): Spina M, Gabarre J, Fasan M, Vaccher E, Tirelli U. Source: Aids (London, England). 2000 July 7; 14(10): 1457-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10930165&dopt=Abstract

•

Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. Author(s): Horning SJ, Hoppe RT, Mason J, Brown BW, Hancock SL, Baer D, Rosenberg SA. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 May; 15(5): 1736-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9164180&dopt=Abstract

•

Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Author(s): Proctor SJ, Jackson GH, Lennard A, Angus B, Wood K, Lucraft HL, White J, Windebank K, Taylor PR; Northern Region Lymphoma Group. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003; 14 Suppl 1: I47-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736232&dopt=Abstract

•

Subdiaphragmatic Hodgkin's disease: the University of Florida experience. Author(s): Hull MC, Mendenhall NP, Colgan ME. Source: International Journal of Radiation Oncology, Biology, Physics. 2002 January 1; 52(1): 161-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11777634&dopt=Abstract

Alternative Medicine 161

•

Systemic fusariosis after a preparative regimen including thiotepa, VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's disease. Author(s): Miyazaki M, Miyakoshi S, Kami M, Mori M, Kishi Y, Inagawa H, Machida U, Matsumura T, Kawagoe S, Ueyama J, Morinaga S, Matsushita H, Muto Y. Source: Leukemia & Lymphoma. 2001 January; 40(3-4): 441-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426570&dopt=Abstract

•

T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease. Author(s): Battig B, Mueller-Garamvoelgyi E, Cogliatti SB, Schmid U, Kappeler A, Cerny T, Laissue JA, Fey MF. Source: Leukemia & Lymphoma. 1999 April; 33(3-4): 393-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10221522&dopt=Abstract

•

Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages. Author(s): Andrieu JM, Jais JP, Colonna P, Desablens B, Briere J, Francois S, Harousseau JL, Casassus P, Lemevel A, Le Prise PY, Ghandour C, Guilhot F, Lejeune F. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998 February; 9(2): 195-203. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9553666&dopt=Abstract

•

Thallium-201 scintigraphy is not predictive of late cardiac complications in patients with Hodgkin's disease treated with mediastinal radiation. Author(s): Girinsky T, Cordova A, Rey A, Cosset JM, Tertian G, Pierga JY. Source: International Journal of Radiation Oncology, Biology, Physics. 2000 December 1; 48(5): 1503-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11121655&dopt=Abstract

•

The clonal relationship between nodular sclerosis Hodgkin's disease with a clonal Reed-Sternberg cell population and a subsequent B-cell small noncleaved cell lymphoma. Author(s): Ohno T, Trenn G, Wu G, Abou-Elella A, Reis HE, Chan WC. Source: Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 1998 May; 11(5): 485-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9619603&dopt=Abstract

•

The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Author(s): Gerres L, Bramswig JH, Schlegel W, Jurgens H, Schellong G. Source: Cancer. 1998 November 15; 83(10): 2217-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9827728&dopt=Abstract

•

The emergence of Hodgkin's disease in a patient with long-standing chronic lymphocytic leukemia--case report and review of the literature. Author(s): Samuelsson J, Lundberg LG.

162 Hodgkin’s Disease

Source: Acta Oncologica (Stockholm, Sweden). 1997; 36(3): 351-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9208913&dopt=Abstract •

The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Author(s): Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C. Source: Haematologica. 1998 September; 83(9): 812-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9825578&dopt=Abstract

•

The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Author(s): Cellai E, Magrini SM, Masala G, Alterini R, Costantini AS, Rigacci L, Olmastroni L, Papi MG, Spediacci MA, Innocenti F, Bellesi G, Ferrini PR, Biti G. Source: International Journal of Radiation Oncology, Biology, Physics. 2001 April 1; 49(5): 1327-37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11286841&dopt=Abstract

•

The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease. Author(s): Molin D, Glimelius B, Sundstrom C, Venge P, Enblad G. Source: Leukemia & Lymphoma. 2001 July; 42(3): 457-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11699410&dopt=Abstract

•

Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group. Author(s): Tsang RW, Gospodarowicz MK, Sutcliffe SB, Crump M, Keating A. Source: European Journal of Cancer (Oxford, England : 1990). 1999 January; 35(1): 73-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10211091&dopt=Abstract

•

Transfection of caspase-3 in the caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis. Author(s): Wrone-Smith T, Izban KF, Ergin M, Cosar EF, Hsi ED, Alkan S. Source: Experimental Hematology. 2001 May; 29(5): 572-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11376869&dopt=Abstract

Alternative Medicine 163

•

Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy. Author(s): Kirchner EM, Ebsen M, Kirchner J, Theegarten D, Voigtmann R. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2001 August; 12(8): 1169-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11583202&dopt=Abstract

•

Transverse leukonychia following chemotherapy in a patient with Hodgkin's disease. Author(s): Naumann R, Wozel G. Source: Eur J Dermatol. 2000 July-August; 10(5): 392-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10882950&dopt=Abstract

•

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. Author(s): Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1997 April; 15(4): 1638-45. Erratum In: J Clin Oncol 1997 July; 15(7): 2762. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9193364&dopt=Abstract

•

Treatment of advanced stage Hodgkin's disease. Author(s): Tesch H, Sieber M, Diehl V; German Hodgkin Study Group. Source: Oncology. 2001; 60(2): 101-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11244323&dopt=Abstract

•

Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Author(s): Baez F, Ocampo E, Conter V, Flores A, Gutierrez T, Malta A, Pacheco C, Palacios R, Biondi A, Riva L, Sala A, Silvestri D, Cavalli F, Sessa C, Casanova M, Masera G. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1997 March; 8(3): 247-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9137793&dopt=Abstract

•

Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Author(s): Brusamolino E, Lunghi F, Orlandi E, Astori C, Passamonti F, Barate C, Pagnucco G, Baio A, Franchini P, Lazzarino M, Bernasconi C. Source: Haematologica. 2000 October; 85(10): 1032-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025593&dopt=Abstract

•

Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin,

164 Hodgkin’s Disease

vinblastine, and dacarbazine (ABVD) courses without radiotherapy. Author(s): van den Berg H, Stuve W, Behrendt H. Source: Medical and Pediatric Oncology. 1997 July; 29(1): 23-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9142201&dopt=Abstract •

Treatment of Hodgkin's disease in children with VAMP (vinblastine, adriamycin, methotrexate, prednisone) and VEPA (vinblastine, etoposide, prednisone, adriamycin). Author(s): Kavan P, Kabickova E, Koutecky J, McClain K, Gajdos P, Kodet R, Slavik Z, Tousovska K. Source: Pediatric Hematology and Oncology. 1999 March-April; 16(2): 141-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10100274&dopt=Abstract

•

Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study. Author(s): Economopoulos T, Fountzilas G, Dimopoulos MA, Papageorgiou S, Xiros N, Kalantzis D, Dervenoulas J, Raptis S. Source: European Journal of Haematology. 2003 October; 71(4): 257-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12950234&dopt=Abstract

•

Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy. Author(s): Muwakkit S, Geara F, Nabbout B, Farah RA, Shabb NS, Hajjar T, Khogali M. Source: Radiation Oncology Investigations. 1999; 7(6): 365-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10644060&dopt=Abstract

•

Treatment of refractory Hodgkin's disease with modified Stanford V program. Author(s): Aviles A, Neri N, Garcia EL, Talavera A, Diaz-Maqueo JC. Source: Medical Oncology (Northwood, London, England). 2001; 18(4): 261-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11918452&dopt=Abstract

•

Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy. Author(s): Tormo M, Terol MJ, Marugan I, Solano C, Benet I, Garcia-Conde J. Source: Leukemia & Lymphoma. 1999 June; 34(1-2): 137-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10350341&dopt=Abstract

•

Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects. Author(s): Cutuli B, Petit T, Hoffstetter S, Velten M, Dufour P, Giron C, Lederlin P, Jung GM, Bergerat JP, Maloisel F, Bey P, Oberling F. Source: Oncol Rep. 1998 November-December; 5(6): 1513-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9769397&dopt=Abstract

Alternative Medicine 165

•

Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Author(s): Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, Cahn JY, Pico JL, Bastion Y, Kuentz M, Nedellec G, Attal M, Ferme C, Gisselbrecht C. Source: Blood. 1998 September 15; 92(6): 1933-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9731050&dopt=Abstract

•

VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. Author(s): Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 July 15; 20(14): 3081-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12118021&dopt=Abstract

•

Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin's disease. Author(s): Komurcu S, Ozet A, Altundag MK, Arpaci F, Ozturk B, Celasun B, Tezcan Y. Source: Annals of Hematology. 2002 January; 81(1): 57-8. Epub 2001 December 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11807639&dopt=Abstract

•

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. Author(s): Little R, Wittes RE, Longo DL, Wilson WH. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 February; 16(2): 584-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9469345&dopt=Abstract

•

VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Author(s): Ribrag V, Nasr F, Bouhris JH, Bosq J, Brault P, Girinsky T, Cosset JM, Munck JN, Corti C, Decaudin D, Pico JL, Hayat M, Carde P. Source: Bone Marrow Transplantation. 1998 May; 21(10): 969-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9632268&dopt=Abstract

•

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Author(s): Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Source: Blood. 1999 July 15; 94(2): 429-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10397709&dopt=Abstract

166 Hodgkin’s Disease

Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •

Alternative Medicine Foundation, Inc.: http://www.herbmed.org/

•

AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats

•

Chinese Medicine: http://www.newcenturynutrition.com/

•

drkoop.com®: http://www.drkoop.com/InteractiveMedicine/IndexC.html

•

Family Village: http://www.familyvillage.wisc.edu/med_altn.htm

•

Google: http://directory.google.com/Top/Health/Alternative/

•

Healthnotes: http://www.healthnotes.com/

•

MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine

•

Open Directory Project: http://dmoz.org/Health/Alternative/

•

HealthGate: http://www.tnp.com/

•

WebMD®Health: http://my.webmd.com/drugs_and_herbs

•

WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html

•

Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/

The following is a specific Web list relating to Hodgkin’s disease; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •

General Overview Amyloidosis Source: Integrative Medicine Communications; www.drkoop.com Angioedema Source: Integrative Medicine Communications; www.drkoop.com Leukemia Source: Integrative Medicine Communications; www.drkoop.com Lymphoma Source: Integrative Medicine Communications; www.drkoop.com

•

Herbs and Supplements Aristolochia Alternative names: Snakeroot, Guaco; Aristolochia sp Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org

Alternative Medicine 167

Momordica Alternative names: Bitter Gourd, Karela; Momordica charantia Linn. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Thuja Occid Alternative names: Arbor Vitae; Thuja occidentalis Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Thuja Plicata Alternative names: Western Red Cedar Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org

General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.

169

CHAPTER 4. DISSERTATIONS ON HODGKIN’S DISEASE Overview In this chapter, we will give you a bibliography on recent dissertations relating to Hodgkin’s disease. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “Hodgkin’s disease” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on Hodgkin’s disease, we have not necessarily excluded non-medical dissertations in this bibliography.

Dissertations on Hodgkin’s Disease ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to Hodgkin’s disease. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •

Hodgkin's Disease and the Issue of Cure: Myth or Reality? (Cancer) by Glajchen, Myra, DSW from Columbia University, 1989, 198 pages http://wwwlib.umi.com/dissertations/fullcit/9005874

•

Sexual Adjustment among Survivors of Hodgkin's Disease by Parsonnet, Lissa; PhD from New York University, 1999, 120 pages http://wwwlib.umi.com/dissertations/fullcit/9946365

•

The Epidemiology of Hodgkin's Disease in Newfoundland by Buehler, Sharon Lyn Kelly; PhD from Memorial University of Newfoundland (Canada), 1983 http://wwwlib.umi.com/dissertations/fullcit/NK63582

170 Hodgkin’s Disease

Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.

171

CHAPTER 5. CLINICAL TRIALS AND HODGKIN’S DISEASE Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning Hodgkin’s disease.

Recent Trials on Hodgkin’s Disease The following is a list of recent trials dedicated to Hodgkin’s disease.8 Further information on a trial is available at the Web site indicated. •

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Condition(s): adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00052442

•

A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma Condition(s): Lymphoma, Non-Hodgkin; Hodgkin's Lymphoma Study Status: This study is currently recruiting patients.

8

These are listed at www.ClinicalTrials.gov.

172 Hodgkin’s Disease

Sponsor(s): Abbott Laboratories Purpose - Excerpt: The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00061672 •

Autologous Cytotoxic T-Lymphocytes in Treating Patients With Relapsed EpsteinBarr Virus-Associated Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Condition(s): Hodgkin's lymphoma; childhood small noncleaved cell lymphoma; NonHodgkin's Lymphoma; post-transplant lymphoproliferative disorder; recurrent and refractory childhood Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Baylor College of Medicine; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's cytotoxic T lymphocytes in the laboratory and reinfusing them may cause a stronger immune response to kill Epstein-Barr virus-associated cancer cells. PURPOSE: Phase I trial to study the effectiveness of autologous cytotoxic T-lymphocytes in treating patients who have relapsed Epstein-Barr virus-associated Hodgkin's lymphoma or non-Hodgkin's lymphoma. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00070226

•

Biological Therapy in Treating Patients With Lymphoma or Lymphoproliferative Disease Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Memorial Sloan-Kettering Cancer Center Purpose - Excerpt: RATIONALE: Some types of lymphoma or lymphoproliferative disease are associated with Epstein-Barr virus. White blood cells from donors who are immune to Epstein-Barr virus may be an effective treatment for those cancers. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy in treating patients with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease. Phase(s): Phase I; Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002663

Clinical Trials 173

•

Biological Therapy in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma Condition(s): recurrent adult Hodgkin's lymphoma; recurrent/refractory childhood Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): UAB Comprehensive Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Donor white blood cells that are treated in the laboratory with Epstein-Barr virus and donor peripheral stem cell transplantation may be effective treatments for Hodgkin's lymphoma. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have progressive, relapsed, or refractory Hodgkin's lymphoma. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00006100

•

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma Condition(s): adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma; Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndroMen Study Status: This study is currently recruiting patients. Sponsor(s): Robert H. Lurie Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and radiation therapy and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy and radiation therapy plus bone marrow or peripheral stem cell transplantation in treating patients who have refractory or relapsed T-cell lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma. Phase(s): Phase I; Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00004907

•

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Condition(s): recurrent adult Hodgkin's lymphoma; recurrent/refractory childhood Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)

174 Hodgkin’s Disease

Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients with refractory or relapsed Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00003631 •

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children with Newly Diagnosed Hodgkin's Disease Condition(s): childhood Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Children's Oncology Group; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy xrays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with or without additional chemotherapy and/or radiation therapy in treating children who have newly diagnosed Hodgkin's disease. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00025259

•

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Hodgkin's Lymphoma Condition(s): recurrent adult Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): German Hodgkin's Lymphoma Study Group; EORTC Lymphoma Cooperative Group; EBMT Solid Tumors Working Party Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctors to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which combination chemotherapy regimen given before peripheral stem cell transplantation is more effective in treating relapsed Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens followed by peripheral stem cell transplantation in treating patients who have relapsed Hodgkin's lymphoma.

Clinical Trials 175

Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00025636 •

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Condition(s): stage I adult Hodgkin's lymphoma; stage II adult Hodgkin's lymphoma; stage III adult Hodgkin's lymphoma; stage IV adult Hodgkin's lymphoma; recurrent adult Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Fox Chase Cancer Center Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with relapsed or refractory Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002522

•

Combination Chemotherapy Followed by Donor Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Genetic Disorders Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; plasma cell neoplasm Study Status: This study is currently recruiting patients. Sponsor(s): Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Peripheral stem cell transplantation or bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by donor bone marrow transplantation or peripheral stem cell transplantation in treating patients who have hematologic cancer or genetic disorders. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00008307

176 Hodgkin’s Disease

•

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma Condition(s): adult Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Stanford University; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002715

•

Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Condition(s): adult Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): British National Lymphoma Investigation Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients who have advanced Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two different combination chemotherapy regimens in treating patients who have advanced Hodgkin's lymphoma. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00041210

•

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases Study Status: This study is currently recruiting patients. Sponsor(s): Ireland Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining cytarabine and mitoxantrone in treating patients who have recurrent or refractory leukemia or lymphoma. Phase(s): Phase II

Clinical Trials 177

Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00047021 •

Combination Chemotherapy Plus Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm Study Status: This study is currently recruiting patients. Sponsor(s): Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as alemtuzumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy and monoclonal antibody therapy may kill more cancer cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus alemtuzumab followed by peripheral stem cell transplantation in treating patients who have hematologic cancer. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00027560

•

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Condition(s): stage I adult Hodgkin's lymphoma; stage II adult Hodgkin's lymphoma; adult nodular sclerosis Hodgkin's lymphoma; adult mixed cellularity Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Stanford University Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus low-dose radiation therapy in treating patients who have stage I or stage IIA Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00026208

178 Hodgkin’s Disease

•

Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Children With Hodgkin's Lymphoma Condition(s): stage II childhood Hodgkin's lymphoma; stage I childhood Hodgkin's lymphoma; stage III childhood Hodgkin's lymphoma; stage IV childhood Hodgkin's lymphoma; recurrent/refractory childhood Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): United Kingdom Children's Cancer Study Group Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. PURPOSE: Phase II trial to compare the effectiveness of different combination chemotherapy regimens with or without radiation therapy or peripheral stem cell transplantation in treating children who have Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00025064

•

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Condition(s): adult Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute of Canada; Cancer and Leukemia Group B Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two different combination chemotherapy regimens, with or without radiation therapy, in treating patients who have Hodgkin's lymphoma. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00003389

•

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma Condition(s): adult solid tumor; childhood Hodgkin's lymphoma; childhood nonHodgkin's lymphoma; childhood solid tumor; Lymphoma Study Status: This study is currently recruiting patients.

Clinical Trials 179

Sponsor(s): Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Biological therapies such as interleukin-2 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, peripheral stem cell transplantation, and interleukin-2 in treating patients who have solid tumors or lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00027937 •

Combining Chemotherapy, Tacrolimus, Mycophenolate Mofetil, and Radiation Therapy with Donor Bone Marrow Transplantation in Treating Patients with Hematologic Cancer Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm Study Status: This study is currently recruiting patients. Sponsor(s): Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Tacrolimus and mycophenolate mofetil may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy, tacrolimus, mycophenolate mofetil, and radiation therapy with allogeneic bone marrow transplantation in treating patients who have hematologic cancer. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00049504

•

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma Condition(s): adult lymphocyte depletion Hodgkin's lymphoma; adult mixed cellularity Hodgkin's lymphoma; adult nodular sclerosis Hodgkin's lymphoma; stage III adult Hodgkin's lymphoma; stage IV adult Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): EORTC Lymphoma Cooperative Group; British National Lymphoma Investigation; Groupe d'Etudes de Lymphomes de L'Adulte; Grup per l'Estudi dels Limfomes de Catalunya i Balears; National Cancer Institute of Canada; Australian New Zealand Lymphoma Group; Nordic Lymphoma Group

180 Hodgkin’s Disease

Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have stage III or stage IV Hodgkin's lymphoma. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00049595 •

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm Study Status: This study is currently recruiting patients. Sponsor(s): Sidney Kimmel Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of cyclophosphamide plus bone marrow transplantation in treating patients who have hematologic cancer. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00006042

•

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Condition(s): Cachexia; childhood Hodgkin's lymphoma; childhood brain tumor; childhood non-Hodgkin's lymphoma; childhood solid tumor; hematopoietic and lymphoid cancer Study Status: This study is currently recruiting patients. Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: Clinical trial to study the effectiveness of cyproheptadine and megestrol in improving appetite and preventing weight loss in children who have cachexia caused by cancer or cancer treatment. Study Type: Interventional Contact(s): see Web site below

Clinical Trials 181

Web Site: http://clinicaltrials.gov/ct/show/NCT00066248 •

Donor Stem Cell Transplantation in Treating Patients With Relapsed Hematologic Cancer Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm Study Status: This study is currently recruiting patients. Sponsor(s): Cancer and Leukemia Group B; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Bone marrow or peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. PURPOSE: Phase II trial to study the effectiveness of donor bone marrow or peripheral stem cell transplantation in treating patients who have relapsed hematologic cancer after treatment with chemotherapy and autologous stem cell transplantation. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00053196

•

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; myelodysplastic and myeloproliferative diseases Study Status: This study is currently recruiting patients. Sponsor(s): Roswell Park Cancer Institute; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00055653

•

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Condition(s): Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; NonHodgkin's Lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): University of Minnesota Cancer Center Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy

182 Hodgkin’s Disease

with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of filgrastim and chemotherapy followed by peripheral stem transplantation in treating patients who have Hodgkin's lymphoma or non-Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00005985 •

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated with the Epstein Barr Virus Condition(s): angiocentric immunoproliferative lesions; childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; small intestine cancer Study Status: This study is currently recruiting patients. Sponsor(s): Boston Medical Center Purpose - Excerpt: RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells. PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00006340

•

Gemcitabine, Carboplatin, and Dexamethasone With or Without Rituximab in Treating Patients With Relapsed or Primary Refractory Lymphoma Condition(s): Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; anaplastic large cell lymphoma; angioimmunoblastic T-cell lymphoma; Cutaneous T-Cell Lymphoma; Non-Hodgkin's Lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): University of Washington; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and dexamethasone, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining

Clinical Trials 183

gemcitabine, carboplatin, and dexamethasone with or without rituximab in treating patients who have relapsed or primary refractory lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00072514 •

Gene marked cytotoxic T-cells for patients with relapsed Hodgkin's Lymphoma. Condition(s): Hodgkin Disease Study Status: This study is currently recruiting patients. Sponsor(s): Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital Purpose - Excerpt: The purpose of this study is to find the largest safe dose of LMP-2a specific cytotoxic T cells, to learn what the side effects are and to see whether this therapy might help patients with Hodgkin disease. Gene marking is optional in this study. Eligible patients can participate without the gene marking if they choose. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00062868

•

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm Study Status: This study is currently recruiting patients. Sponsor(s): Ireland Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of transplantation with peripheral stem cells from a brother or sister donor following busulfan, cyclophosphamide, and filgrastim in treating patients with hematologic cancer. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00003116

184 Hodgkin’s Disease

•

Lower-Dose Chemotherapy and Stem Cell Transplantation to Treat Childhood Leukemias and Lymphomas Condition(s): Hodgkin Lymphoma; Lymphocytic Leukemia; Mixed Cell Leukemia; Myelodysplastic Syndrome; Non Hodgkin's Lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): National Cancer Institute (NCI) Purpose - Excerpt: This study will investigate the safety and effectiveness of a new stem cell transplant procedure for treating various leukemias and lymphomas in children. Transplantation of donated stem cells (cells produced by the bone marrow that mature into white and red blood cells and platelets) is a very effective treatment for patients with leukemia, pre-leukemia and lymphoma. However, despite its success in a large number of patients, this procedure has many serious side effects and carries a significant risk of death. These complications result from the intensive chemotherapy and radiation patients receive before the transplant to rid the body of cancer cells. In this study, radiation will not be used and chemotherapy drugs will be given in lower doses to try to reduce the dangers of the procedure. Patients between 5 and 21 years of age with acute lymphocytic leukemia, acute myelogenous leukemia, myelodysplasia, chronic myelogenous leukemia, juvenile chronic myelogenous or myelomonocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood tests (including testing for genetic match with the donor), breathing tests, X-rays, scans and other tests to determine eligibility. They may also undergo bone marrow aspiration, in which the hip area is anesthetized and a small sample of bone marrow is drawn through a needle inserted into the hipbone. A spinal tap may be done to look for cancer cells in the central nervous system. This procedure involves numbing the back and inserting a needle between the bones of the spine to withdraw a small amount of spinal fluid. A central venous catheter (flexible plastic tube placed in a vein) will be put in place before treatment begins. It will be used to draw and transfuse blood, give medications, and infuse the donated stem cells. Before the transplant procedure, patients will receive induction chemotherapy with cyclophosphamide, fludarabine, etoposide, doxorubicin, vincristine and prednisone for 4 days, followed by a 17-day rest period. No more than 3 cycles of this chemotherapy will be given. Following the induction chemotherapy, patients will be admitted to the Clinical Center for 4 days of chemotherapy with cyclophosphamide and fludarabine. The donated stem cells will be infused 3 days later. Patients can leave the hospital when their white cell counts return to near normal and they have no serious complications. After discharge, they will be followed closely (at least once or twice weekly for the first 100 days after transplant) with a physical exam and blood tests. Patients may require immunoglobulin or antibiotics to fight infections and transfusions of red blood cells and platelets. After the 100 days, follow-up visits will continue less frequently for at least 5 years. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00013533

Clinical Trials 185

•

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma Condition(s): recurrent adult Hodgkin's lymphoma; recurrent/refractory childhood Hodgkin's lymphoma; anaplastic large cell lymphoma; recurrent adult diffuse large cell lymphoma; recurrent childhood large cell lymphoma; recurrent cutaneous T-cell lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of MDX-060 monoclonal antibody in treating patients who have refractory or relapsed lymphoma. Phase(s): Phase I; Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00059995

•

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma Condition(s): adult Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; adult non-Hodgkin's lymphoma; adult solid tumor; Cutaneous T-Cell Lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Stanford University; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of gemcitabine by making cancer cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining oblimersen with gemcitabine in treating patients who have metastatic or unresectable solid tumors or lymphoma. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00060112

•

Pegfilgrastim Compared With Filgrastim To Increase Peripheral Stem Cells Before Autologous Stem Cell Transplantation in Treating Patients With Lymphoma Condition(s): adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma; Cutaneous T-Cell Lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Colony-stimulating factors such as filgrastim and pegfilgrastim may increase the number of peripheral stem cells that can be collected during leukapheresis. Autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized

186 Hodgkin’s Disease

phase II trial to compare the effectiveness of pegfilgrastim with that of filgrastim in increasing the number of peripheral stem cells in patients who are undergoing autologous stem cell transplantation for Hodgkin's lymphoma or non-Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00060229 •

Peripheral Stem Cell Transplantation Followed by White Blood Cell Infusion in Treating Patients With Hematologic Cancer Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm Study Status: This study is currently recruiting patients. Sponsor(s): University of Wisconsin Comprehensive Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Donor peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells are rejected by the body's normal tissues. Donor white blood cells that have been treated in the laboratory may prevent this from happening. PURPOSE: Phase I trial to determine the effectiveness of donor peripheral stem cell transplantation followed by infusions of donor white blood cells in treating patients who have hematologic cancer. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00028041

•

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Condition(s): Langerhans cell histiocytosis; childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; hematopoietic and lymphoid cancer Study Status: This study is currently recruiting patients. Sponsor(s): Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of donor peripheral stem cell transplantation in treating patients who have hematologic cancer. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00008216

Clinical Trials 187

•

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Condition(s): Hodgkin Disease Study Status: This study is currently recruiting patients. Sponsor(s): M.D. Anderson Cancer Center Purpose - Excerpt: For patients with Hodgkin's lymphoma receiving ABVD chemotherapy. Phase(s): Phase II; Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00038558

•

Rituximab in Treating Patients With Hodgkin's Lymphoma Condition(s): stage I adult Hodgkin's lymphoma; stage II adult Hodgkin's lymphoma; stage III adult Hodgkin's lymphoma; stage IV adult Hodgkin's lymphoma; recurrent adult Hodgkin's lymphoma; adult lymphocyte predominant Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Stanford University Purpose - Excerpt: RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have Hodgkin's lymphoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00003820

•

Study of @neWorld: A Virtual Community for Children With Cancer Condition(s): childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; childhood solid tumor; Leukemia; psychosocial effects and treatment Study Status: This study is currently recruiting patients. Sponsor(s): Leap of Faith Technologies; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Using an Internet Web site that enables children with cancer to interact online with classmates, participate in classroom activities, get easy-toread medical information, and chat with family members, medical staff, and other children with cancer, may help children cope with isolation, fear, and decreased selfesteem. PURPOSE: Phase I/II trial to study the effectiveness of an Internet Web site in providing social support and education to children who are receiving treatment for cancer. Phase(s): Phase I; Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00070421

188 Hodgkin’s Disease

•

Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Condition(s): Langerhans cell histiocytosis; childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; hematopoietic and lymphoid cancer Study Status: This study is currently recruiting patients. Sponsor(s): Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00008164

•

Vaccine Therapy in Treating Patients With Relapsed Hodgkin's Lymphoma Condition(s): recurrent adult Hodgkin's lymphoma; recurrent/refractory childhood Hodgkin's lymphoma Study Status: This study is currently recruiting patients. Sponsor(s): Baylor College of Medicine Purpose - Excerpt: RATIONALE: Vaccines made from cancer cells that have the EpsteinBarr virus may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of Epstein-Barr virus-specific cytotoxic T cells in treating patients with relapsed Hodgkin's lymphoma. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002821

•

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma Condition(s): recurrent/refractory childhood Hodgkin's lymphoma; childhood lymphocyte predominant Hodgkin's lymphoma; childhood lymphocyte depletion Hodgkin's lymphoma; childhood nodular sclerosis Hodgkin's lymphoma; childhood mixed cellularity Hodgkin's lymphoma Study Status: This study is not yet open for patient recruitment. Sponsor(s): Children's Oncology Group; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and vinorelbine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with vinorelbine in treating young patients who have recurrent or refractory Hodgkin's lymphoma.

Clinical Trials 189

Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00070304 •

Immunotherapy Using Cyclosporine, Interferon gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Condition(s): recurrent adult Hodgkin's lymphoma; recurrent/refractory childhood Hodgkin's lymphoma Study Status: This study is not yet open for patient recruitment. Sponsor(s): Children's Oncology Group; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving immunotherapy using cyclosporine, interferon gamma, and interleukin-2 after stem cell transplantation may help the transplanted cells kill more cancer cells. It is not yet known whether high-dose chemotherapy followed by autologous stem cell transplantation is more effective with or without immunotherapy. PURPOSE: Randomized phase II/III trial to compare the effectiveness of high-dose chemotherapy followed by autologous stem cell transplantation with or without immunotherapy using cyclosporine, interferon gamma, and interleukin-2 in treating patients who have refractory or relapsed Hodgkin's lymphoma. Phase(s): Phase II; Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00070187

•

Reduced-Intensity Regimen Before Bone Marrow Transplantation in Treating Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma Condition(s): adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma Study Status: This study is not yet open for patient recruitment. Sponsor(s): Eastern Cooperative Oncology Group; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet light and drugs outside the body to inactivate T cells. Pentostatin may suppress the immune system and reduce the chance of developing graft-versus-host disease following bone marrow transplantation. Combining photopheresis with pentostatin and total-body irradiation may be effective in killing cancer cells before bone marrow transplantation. PURPOSE: Phase II trial to study the effectiveness of photophoresis, pentostatin, and total-body irradiation as a reducedintensity regimen before allogeneic bone marrow transplantation in treating patients who have relapsed non-Hodgkin's or Hodgkin's lymphoma. Phase(s): Phase II

190 Hodgkin’s Disease

Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00057954 •

Whole-Body Fast MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma Condition(s): Ewing's family of tumors; childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; childhood rhabdomyosarcoma; Neuroblastoma Study Status: This study is not yet open for patient recruitment. Sponsor(s): American College of Radiology Imaging Network; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: New imaging procedures, such as whole-body fast MRI, may improve the ability to detect metastatic cancer and determine the extent of disease. PURPOSE: Diagnostic trial to compare the effectiveness of whole-body fast MRI with that of standard imaging procedures in detecting distant metastases in patients who have solid tumors or lymphoma. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00072488

Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “Hodgkin’s disease” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •

For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/

•

For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html

•

For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/

•

For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm

Clinical Trials 191

•

For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm

•

For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm

•

For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp

•

For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm

•

For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/

•

For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm

•

For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm

•

For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm

•

For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm

•

For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm

•

For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials

193

CHAPTER 6. BOOKS ON HODGKIN’S DISEASE Overview This chapter provides bibliographic book references relating to Hodgkin’s disease. In addition to online booksellers such as www.amazon.com and www.bn.com, excellent sources for book titles on Hodgkin’s disease include the Combined Health Information Database and the National Library of Medicine. Your local medical library also may have these titles available for loan.

Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print®). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for “Hodgkin’s disease” at online booksellers’ Web sites, you may discover non-medical books that use the generic term “Hodgkin’s disease” (or a synonym) in their titles. The following is indicative of the results you might find when searching for “Hodgkin’s disease” (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): •

21st Century Complete Medical Guide to Hodgkin's Disease - Authoritative Government Documents and Clinical References for Patients and Physicians with Practical Information on Diagnosis and Treatment Options by PM Medical Health News; ISBN: 1592480233; http://www.amazon.com/exec/obidos/ASIN/1592480233/icongroupinterna

•

Autologous Bone Marrow Transplantation for Hodgkin's Disease, Non-Hodgkin's Lymphoma and Multiple Myeloma; ISBN: 3540561307; http://www.amazon.com/exec/obidos/ASIN/3540561307/icongroupinterna

•

Autologous Bone Marrow Transplantation for Hodgkin's Disease, Non-Hodgkin's Lymphoma and Multiple Myeloma by A.R. Zander, B. Barlogie (Editor); ISBN: 0387561307; http://www.amazon.com/exec/obidos/ASIN/0387561307/icongroupinterna

194 Hodgkin’s Disease

•

Controversies in the Management of Lymphomas: Including Hodgkin's Disease by John M. Bennett (Editor) (1983); ISBN: 0898385865; http://www.amazon.com/exec/obidos/ASIN/0898385865/icongroupinterna

•

Etiology of Hodgkin's Disease (NATO Asi Series. Series A, Life Sciences , Vol 280) by Ruth F. Jarrett (Editor), et al (1995); ISBN: 0306452057; http://www.amazon.com/exec/obidos/ASIN/0306452057/icongroupinterna

•

Fourth International Symposium on Hodgkin's Lymphoma by ENGERT, A. Engert; ISBN: 905702361X; http://www.amazon.com/exec/obidos/ASIN/905702361X/icongroupinterna

•

Histopathology Non-Hodgkin's Lymphomas by Karl. Lennert; ISBN: 0387104453; http://www.amazon.com/exec/obidos/ASIN/0387104453/icongroupinterna

•

Histopathology of Non-Hodgkin's Lymphomas by Karl Lennert, A. C. Feller; ISBN: 0387512705; http://www.amazon.com/exec/obidos/ASIN/0387512705/icongroupinterna

•

Hodgkin's Disease by Judith Peacock (2001); ISBN: 0736810277; http://www.amazon.com/exec/obidos/ASIN/0736810277/icongroupinterna

•

Hodgkin's Disease by Peter M. Mauch (Editor), et al; ISBN: 0781715024; http://www.amazon.com/exec/obidos/ASIN/0781715024/icongroupinterna

•

Hodgkin's Disease by Henry S., Kaplan; ISBN: 0674404750; http://www.amazon.com/exec/obidos/ASIN/0674404750/icongroupinterna

•

Hodgkin's disease; ISBN: 0842271937; http://www.amazon.com/exec/obidos/ASIN/0842271937/icongroupinterna

•

Hodgkin's Disease by David W. Molander, George T. Pack; ISBN: 0398013225; http://www.amazon.com/exec/obidos/ASIN/0398013225/icongroupinterna

•

Hodgkin's Disease by P. Selby MA MD MRCP (Editor), T.J. McElwain FRCP (Editor); ISBN: 0632013354; http://www.amazon.com/exec/obidos/ASIN/0632013354/icongroupinterna

•

Hodgkin's Disease & Non-Hodgkin's Lymphoma: New Perspectives in Immunopathology, Diagnosis, & Treatment by Richard J. Ford (Editor), Clinical Conference on Cancer (1984); ISBN: 0608006289; http://www.amazon.com/exec/obidos/ASIN/0608006289/icongroupinterna

•

Hodgkin's Disease and Non-Hodgkin's Lymphoma: New Perspectives in Immunopathology, Diagnosis, and Treatment (Ut M. D. Anderson Clinical Conference O) by Richard J. Ford (Editor); ISBN: 0881670391; http://www.amazon.com/exec/obidos/ASIN/0881670391/icongroupinterna

•

Hodgkin's Disease and Non-Hodgkin's Lymphomas in Adults and Children by Lillian M. Fuller (Editor), et al; ISBN: 0890047952; http://www.amazon.com/exec/obidos/ASIN/0890047952/icongroupinterna

•

Hodgkin's Disease and the Lymphomas (ARR) by C R Taylor; ISBN: 0443018014; http://www.amazon.com/exec/obidos/ASIN/0443018014/icongroupinterna

•

Hodgkin's Disease III: Occurrence and Diagnosis (Hodgkin's Disease Series, Vol 3) by M. R. Alderson (1974); ISBN: 0842271953; http://www.amazon.com/exec/obidos/ASIN/0842271953/icongroupinterna

Books

195

•

Hodgkin's Disease in Children: Controversies and Current Practice (Cancer Treatment and Research) by W.A. Kamps, et al (1989); ISBN: 0898383722; http://www.amazon.com/exec/obidos/ASIN/0898383722/icongroupinterna

•

Hodgkin's Disease IV: Therapy and Complications by Daina : Panettiere, Frank Variakojis, George P. Canellos (1974); ISBN: 0685501116; http://www.amazon.com/exec/obidos/ASIN/0685501116/icongroupinterna

•

Hodgkin's Disease: The Consequences of Survival by Mortimer J. Lacher, John R. Redman; ISBN: 0812112040; http://www.amazon.com/exec/obidos/ASIN/0812112040/icongroupinterna

•

Magical Story: A Teenager's Inspiring Battle With Hodgkin's Disease by Leslie Bowden, Brian Bowden (2002); ISBN: 0971331820; http://www.amazon.com/exec/obidos/ASIN/0971331820/icongroupinterna

•

Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances (Developments in Oncology) by Franco Cavalli (Editor), et al (1986); ISBN: 0898387272; http://www.amazon.com/exec/obidos/ASIN/0898387272/icongroupinterna

•

Malignant Lymphomas, Including Hodgkin's Disease: Diagnosis, Management, and Special Problems (Cancer Treatment and Research) by Bruce W. Dana (Editor) (1993); ISBN: 0792321715; http://www.amazon.com/exec/obidos/ASIN/0792321715/icongroupinterna

•

Non-Hodgkin's Lymphomas: Making Sense of Diagnosis, Treatment and Options by Lorraine Johnston; ISBN: 1565924444; http://www.amazon.com/exec/obidos/ASIN/1565924444/icongroupinterna

•

The Non-Hodgkin's Lymphomas by Ian T. Magrath (Editor) (1997); ISBN: 0340557931; http://www.amazon.com/exec/obidos/ASIN/0340557931/icongroupinterna

•

The Official Patient's Sourcebook on Non-Hodgkin's Lymphoma During Pregnancy: A Revised and Updated Directory for the Internet Age by Icon Health Publications (2002); ISBN: 0597834792; http://www.amazon.com/exec/obidos/ASIN/0597834792/icongroupinterna

•

Treatment Strategy in Hodgkin's Disease by R. Somers (1998); ISBN: 2855983983; http://www.amazon.com/exec/obidos/ASIN/2855983983/icongroupinterna

•

Understanding Hodgkin's Disease (1999); ISBN: 1901276295; http://www.amazon.com/exec/obidos/ASIN/1901276295/icongroupinterna

•

What you need to know about Hodgkin's disease (SuDoc HE 20.3152:H 66/2/999) by U.S. Dept of Health and Human Services; ISBN: B000112CTK; http://www.amazon.com/exec/obidos/ASIN/B000112CTK/icongroupinterna

The National Library of Medicine Book Index The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, http://locatorplus.gov/, and then select “Search LOCATORplus.” Once you are in the search area, simply type “Hodgkin’s disease” (or synonyms) into the search box, and select “books

196 Hodgkin’s Disease

only.” From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine:9 •

Borderline cases of Hodgkin's disease. Author: Offerhaus, Leonardus.; Year: 1976; Assen, Van Gorcum, 1957

•

Current studies on standardization problems in clinical pathology, haematology, and radiotherapy in Hodgkin's disease: proceedings of the third international symposium of the Comitato italiano per la standardizzazione dei metodi ematologici e di laboratorio (CISMEL), San Giovanni Rotondo, Italy, 12-14 September 1974 Author: Astaldi, Giovanni.; Year: 1978; Amsterdam: Excerpta Medica; New York: American Elsevier, 1975; ISBN: 0444151621 http://www.amazon.com/exec/obidos/ASIN/0444151621/icongroupinterna

•

Hodgkin's disease Author: Kaplan, Henry S.,; Year: 1979; Cambridge: Harvard Univ. Press, 1980; ISBN: 0674404858 http://www.amazon.com/exec/obidos/ASIN/0674404858/icongroupinterna

•

Hodgkin's disease: histopathology and clinico-pathological correlations Author: Vrede, Martinus Albert.; Year: 1983; Amsterdam: Ronald Meesters, 1981

•

Hodgkin's disease and allied disorders [by] Henry Jackson, Jr. and Frederic Parker, Jr. Author: Jackson, Henry,; Year: 1947; New York, Oxford Univ. Press, 1947

•

Hodgkin's disease and its interrelationships with other disorders. Author: Dawe, Clyde J. (Clyde Johnson),; Year: 1923; [Minneapolis] 1955

•

Hodgkin's disease, compiled and edited by David W. Molander and George T. Pack. Author: Molander, David W.,; Year: 1969; Springfield, Ill., Thomas [c1968]

•

Hodgkin's disease. Author: Bennett, Robert Allan,; Year: 1973; Bristol, Wright, 1923

•

Immunodeficiency in Hodgkin's disease and its relation to prognosis Author: Björkholm, Magnus.; Year: 1980; Copenhagen: Munksgaard, 1978; ISBN: 8716028724

•

Immunological studies in Hodgkin's disease: with special reference to the influence of splenectomy Author: Wagener, Damianus Johannes Theodorus.; Year: 1962; Meppel [Netherlands]: Krips Repro, [1976?]

•

Immunopathology of Hodgkin's disease Author: Poppema, Siebrandes.; Year: 1981; [Groningen, Netherlands: s.n.], 1979

•

Lymphographic polymorphism in Hodgkin's disease; correlation of lymphography to histology and duration. Author: Wiljasalo,kka/Sir.; Year: 1971; Stockholm, 1969

•

Lymphomas other than Hodgkin's disease Author: Stuart, Angus Erskine.; Year: 1983; Oxford; New York: Oxford University Press, 1981; ISBN: 0192612964 http://www.amazon.com/exec/obidos/ASIN/0192612964/icongroupinterna

•

Malignant lymphomas other than Hodgkin's disease: histology, cytology, ultrastructure, immunology Author: Lennert, Karl.; Year: 1978; Berlin; New York: Springer-Verlag, 1977; ISBN: 0387080201

9

In addition to LOCATORPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is currently adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a "Books" button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. Currently, the majority of the links are between the books and PubMed. In the future, more links will be created between the books and other types of information, such as gene and protein sequences and macromolecular structures. See http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.

Books

197

•

Management of Hodgkin's disease and the other lymphomas journal articles; a collection of current published articles related to Hodgkin's disease and the other lymphomas, by Edward S. Greenwald and Warren Zeitlin. Author: Greenwald, Edward S.,; Year: 1955; Flushing, N. Y., Medical Examination Pub. Co., c1971; ISBN: 087488515

•

Monocyte function in Hodgkin's disease Author: Mulder, Pieter Henri Maria de,; Year: 1949; [S.l.: s.n.], 1983

•

Splenectomy in Hodgkin's disease: a clinical and immunological study Author: Askergren, Jutta.; Year: 1976; Stockholm: [s.n.], 1980

•

Splenic dissemination of Hodgkin's Disease Author: Halie, Martin Rudolf.; Year: 1981; Groningen: Veenstra-Visser Offset, 1977

•

Spontaneous lymphocyte transformation in Hodgkin's disease Author: Pauw, Bernardus Emilianus de.; Year: 1977; Meppel, [Netherlands]: Krips Repro, [1980]

•

Symposium on changing concepts in Hodgkin's disease, lymphomas, and leukemias. Philip Rubin, Malcolm A. Bagshaw, guest editors. Author: Rubin, Philip,; Year: 1968; Philadelphia, London, Saunders [c1968]

•

The Natural history, diagnosis and treatment of Hodgkin's disease. Guest editors: G. Mathé & M. Tubiana. Author: Mathé, Georges.; Year: 1973; Copenhagen, Munksgaard [1973]; ISBN: 87013611